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ABSTRACT 
 
 
The cytotoxic activities of proteins from the normally insecticidal Bacillus 
thuringiensis against human cancer cell lines were investigated. Cry41Aa toxin 
derived from the Bacillus thuringiensis strain A1462, which shows activity against 
human cancer cell lines is structurally related to the toxins synthesized by 
commercially produced transgenic insect-resistant plants, with the exception of 
an additional C-terminal beta-trefoil ricin domain. To test whether this putative 
carbohydrate binding domain is responsible for the cytotocidal activity of Cry41Aa 
against cancer cell lines, we developed an efficient expression system for the 
toxin and created a deletion mutant lacking the ricin domain. Both Cry41Aa and 
its deletion mutant were stably expressed and found to have almost identical 
activities against the HepG2 cancer cell line in vitro. Our results suggest that the 
acquisition of the ricin domain was not responsible for Cry41Aa having toxicity to 
human cancer cells and more subtle changes have resulted in the evolution of 
mammalian cancer cell toxicity. We further attempted to identify those differences 
that are responsible for the divergence in activity between the cancer-killing toxins 
and their insecticidal counterparts. We also studied the cell-killing activity of other 
uncharacterized Bacillus thuringiensis crystal toxins including Cry51 and Cry65 
whose targets are not known so far. 
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1. Introduction 
 
1.1 General Introduction 
The toxicity of a naturally occurring organism is a striking phenomenon. As we 
introspect at the history of naturally occurring toxins, be they of bacterial or plant 
origin, we find that once their physical and chemical parameters are understood, 
these substances can be of considerable medical and economic importance 
(Schmitt et al., 1999; Sandvig and Deurs, 2000; Goodsell, 2001). 
 
Bacterial protein toxins have been long employed as biological tools to elucidate 
several mechanisms in agriculture and medicine. Gram-positive 
entomopathogenic bacteria have received substantial attention as biological 
control agents due to their potential to control insect pests in agriculture and 
insect vectors of human diseases. B. thuringiensis δ-endotoxins provide a 
valuable alternative to synthetic insecticides for controlling insect pests. Sprays 
comprising of sporulated Bt have not only been employed for pest control in 
agriculture, sprays of B. thuringiensis subsp. israelensis (Bti) have also been 
used to control disease-carrying vectors such as mosquitoes and blackflies 
(Becker, 2000). Besides sprays, B. thuringiensis genes expressing the 
entomocidal Cry proteins have been engineered into crop plants, rendering them 
resistant to several insect pests (Barton et al., 1987; Vaeck et al., 1987; de Maagd 
et al., 1999; Tabashnik, 2010). B. thuringiensis is safe to the environment, 
humans and non-target organisms owing to its narrow host range alongside its 
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efficacy in controlling varied insect pests (Bulla et al., 1975; Drobniewski, 1994; 
Mendelsohn et al., 2003; Walter et al., 2010; Bravo et al., 2011, 2012). 
Recently B. thuringiensis toxins have been isolated that possess preferential 
activity against human cell lines and in particular cancer cell lines. These toxins 
have been suggested as being non-insecticidal (Mizuki et al., 1999, 2000; Ohba 
et al., 2009). Study of this class of toxin has implications not only in medical 
research as potential therapies for certain cancers or as diagnostic agents but 
also in the risk assessment of Bt toxins being used and developed for insect 
control in agriculture. It is imperative to carry out the risk assessment of food and 
feed derived from genetically engineered Bt plants. Although there have been 
reports of modified Bt on non-target human cells (Mesnage et al., 2012), various 
assessments carried out to check for the safety of commercial Bt toxins as sprays 
or transgenic plants have found them to be environmentally friendly with no 
known adverse effects to non-target species (Kapur et al., 2010; Caquet et al., 
2011). 
 
1.2 Bacillus thuringiensis 
Isolated by the Japanese bacteriologist Ishiwata from diseased silkworm Bombyx 
mori larvae in 1901 and scientifically described by Berliner in 1911 (Heimpel & 
Angus, 1958), B. thuringiensis is currently the leading biorational pesticide which 
is safe to the environment. The bacterium is gram-positive, rod-shaped, aerobic 
endospore-forming and characterised by the presence of protein crystals within 
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the cytoplasm of its sporulating cells that are toxic towards insects. These 
insecticidal  crystal (Cry) proteins produced during the stationary phase of the 
bacterium’s growth cycle have been used as biopesticides against a wide range 
of  agricultural insect  pests belonging to several orders including Lepidoptera 
(butterflies and moths), Diptera (flies and mosquitoes), Coleoptera (beetles and 
weevils), Hymenoptera (wasps and bees)  and Orthoptera (locust) (Hofte & 
Whiteley, 1989; de Maagd et al., 2001). Some of the Cry toxins have been 
reported to show activity against non-insect species particularly the nematodes, 
mites and protozoa (de Maagd et al., 2001; Wei et al., 2003). 
 
     1.3 B. thuringiensis taxonomy and genetics 
B. thuringiensis is closely related to the ubiquitous soil bacterium Bacillus cereus, 
an opportunistic pathogen that causes food poisoning (Gonzalez, 1981; 
Drobniewski, 1993). Molecular characterisation techniques such as 16S and 23S 
rRNA sequence analysis (Ash et al., 1991; Rössler et al., 1991; Akhurst et al., 
1997; te Giffel et al., 1997), AFLP analysis (Keim et al., 1997; Jackson et al., 
1999), multilocus enzyme electrophoresis  (Helgason et al., 2000) have failed to 
discriminate B. thuringiensis isolates from B. cereus, crystal formation being the 
most significant criterion for distinguishing between the two. Thus both B. 
thuringiensis and B. cereus belong to the Bacillus cereus group that also entails 
the mammalian pathogen B. anthracis, B. mycoides, B. pseudomycoides and  a  
psychrotolerant strain B. weihenstephanessis which are able to grow at low 
temperatures of 7⁰C and below (Lechner et al., 1998; Jensen et al., 2003). High 
genetic relatedness has resulted in them being regarded as members of a single 
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species, Bacillus cereus sensu lato (Daffonchio et al., 2000; Helgason et al., 
2000). B. cereus is actually considered as the parental species. The other 
members of the taxa including B. thuringiensis and B. anthracis are in fact the 
derivatives of B. cereus that have acquired large extrachromosomal elements 
that encode for the crystal toxins of B. thuringiensis or the pX01- lethal toxin of 
Bacillus anthracis (Gonzalez et al., 1981; Agaisse et al., 1999; Okinaka et al., 
1999; Read et al., 2003; Hu et al., 2009). It has been reported that transfer of δ-
endotoxin encoding plasmids from B. thuringiensis to B. cereus results in the 
production of crystalline inclusions in the recipient  B. cereus strain rendering it 
indistinguishable from B. thuringiensis (González et al., 1982; Battisti et al., 
1985). Further, it has been reported that B. thuringiensis can incur loss of 
production of δ-endotoxins either due to loss of plasmid or changes in gene 
expression. B. thuringiensis strain thus cured of its cry- encoding plasmid cannot 
be phenotypically distinguished from the B. cereus strain (Aronson, 1993; 
Eilenberg et al., 2000). However, they retain the status of separate species due 
to remarkably different distinct virulence phenotype (Helgason et al., 2000). 
The genome of B. thuringiensis strains range from 2400 to 5700 kb present as 
choromosomal and extrachromosomal elements (Carlson et al., 1994, 1996). The 
crystal toxin genes are found on the extrachromosomal DNA in the form of large 
circular plasmids (Kronstad et al., 1983; Ward & Ellar, 1983), although 
chromosomal homologs have also been identified (Carlson & Kolsto, 1993). 
Plasmids in B. thuringiensis strains range from 4.56 to 228 kb (Gonzalez &  
Carlton, 1980; Lereclus et al., 1982; Baum & Gonzalez, 1992). B. thuringiensis 
harbours a plethora of transposable elements including insertion sequences and 
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transposons, often located in the vicinity of the toxin gene, thus facilitating intra/ 
inter molecular genome mobility (Battisti et al., 1985; Green et al., 1989).  
 
      1.4 Ecology and prevalence 
The search for genetic diversity of B. thuringiensis has led to its isolation 
worldwide from diverse habitats, thus reporting the mesophilic B. thuringiensis to 
be indigenous to many environments having an optimal growth temperature at 
approximately 25-35⁰C (Martin & Travers, 1989; Bernhard et al., 1997). Strains 
have been isolated worldwide from diverse environments including soil (DeLucca 
et al., 1979, 1981; Carozzi et al., 1991; Hastowo et al., 1992; Hossain et al., 
1997), stored grain dusts (DeLucca et al., 1984), mills (Meadows et al., 1992), 
foods (Damgaard et al., 1996; Rosenquist et al., 2005; Frederiksen et al., 2006), 
insect cadavers (Damgaard et al., 1997; Hansen et al., 1998; Eilenberg et al., 
2000), freshwater (Espinasse et al., 2003), phylloplanes of conifer and decidual 
leaves (Collier et al., 2005; Bizzarri & Bishop, 2007), rhizosphere (Manonmani et 
al., 1991), annelids (Hendriksen & Hansen, 2002), crustaceans (Swiecicka & 
Mahillon, 2006) and insectivorous mammals (Swiecicka et al., 2002; Swiecicka & 
De Vos, 2003). Hence with an unclear ecology, this ubiquitous bacterium may be 
best described as an opportunist pathogen. However in spite of such complex 
ecology, it has been suggested the bacterium mainly reproduces in an insect 
cadaver (Raymond et al., 2010). Hence this suggests that the presence of the B. 
thuringiensis in these environments is transient in nature. The persistence of B. 
thuringiensis spores and toxins in various diverse environments have been well 
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researched  (West et al., 1984; Petras & Casida, 1985) reporting the viability of 
spores to be several years. 
An insight into the true ecological roles of B. thuringiensis might prove to be vital 
for improving the reliability of risk assessment and for developing efficient 
methodologies for isolation of novel B. thuringiensis strains harbouring useful δ- 
endotoxin genes. 
 
1.5 Virulence factors 
The bacterium produces a repertoire of virulence factors during vegetative and 
stationary phases of its growth that contribute to its pathogenicity (Hansen & 
Salamitou, 2000). The crystal toxins of B. thuringiensis are considered to be the 
major virulence factors which impart entomopathogenic properties to the 
bacterium. Most of the insecticidal properties of the bacterium are derived from 
the δ-endotoxin present in both the crystalline inclusion and in the spore coat. 
Production of toxin constitutes only one of the factors contributing to the 
pathogenicity of the bacterial strain. The crucial contribution of its spores in its 
pathogenicity has also been noted for instance in case of Galleria mallonella 
larvae (Li et al., 1987). Beside some of the other important non-specific virulence 
factors thought to contribute in its pathogenicity include phospholipases (Henner 
et al., 1988; Lechner et al., 1989; Zhang et al., 1993), bacteriocins (Barboza-
Corona et al., 2009), haemolysins (Pendleton et al., 1973; Heierson et al., 1986; 
Budarina et al., 1994; Bouillaut et al., 2005; Nisnevitch et al., 2010), α-exotoxins 
(Krieg, 1971; Mohd-Salleh et al., 1980), β-exotoxins (Levinson et al., 1990; 
Carlberg et al., 1995; Perani et al., 1998), enterotoxins, inhibitor A (InhA) (Zhang 
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et al., 1993; Fedhila et al., 2002, 2003), proteases (Brar et al., 2009), chitinases 
(Tantimavanich et al., 1997; Kramer & Muthukrishnan, 1998; Sampson & 
Gooday, 1998; Liu et al., 2002; Arora et al., 2003) and antibiotics including 
Zwittermicin A (ZmA) (Stabb et al., 1994; Silo-Suh et al., 1998). Most of the 
virulence factors’ gene expression are regulated by the transcriptional activator, 
phospholipase C regulator (PlcR) which has been thought to activate at least 45 
genes (Agaisse et al., 1999; Gohar et al., 2008). The PlcR regulon is vital for the 
pathogenicity of both B. cereus and B. thuringiensis and is highly reduced or 
abolished by the disruption of PlcR gene (Salamitou et al., 2000).  
In addition to the specific Cry toxins produced during the stationary phase in the 
sporulating cells, the bacterium also produces insecticidal proteins during its 
vegetative growth phase, termed as Vip proteins (vegetative insecticidal proteins) 
which are unrelated and differ remarkably to the Cry toxins (Schnepf et al., 1998). 
Although produced during the different stages of the B. thuringiensis life cycle, 
both Cry and Vip proteins share a common  narrow range of target  insect  pests 
with no significant harmful effects on non-target organisms.  
 
1.6 Vip toxins 
Vip toxins have been classed as Vip1, Vip2, Vip3 and Vip4. One hundred and 
two vip genes have been sequenced so far and have been ranked by percentage 
amino acid sequence identity in accordance to the B. thuringiensis Cry toxin 
nomenclature (Crickmore et al., 2013)  which has resulted in Vip1A (5 members), 
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Vip1B (4), Vip1C (1), Vip1D (1), Vip2A (11), Vip2B (4), Vip3A (66), Vip3B (5), 
Vip3C (4) and Vip4A (1). Vip1A and Vip2A are binary toxins encoded by a single 
operon (Shi et al., 2004) and when used in combination, are highly toxic to the 
agricultural pest the western corn rootworm Diabrotica virgifera infesting corn 
plants (Fang et al., 2007). They demonstrate a typical binary relationship of A+B 
type wherein Vip2 is the cytotoxic A-domain and part of  Vip1 contains the 
receptor-binding B-domain and a possible translocation domain (de Maagd et al., 
2003). Vip3 toxins share no sequence homology to Vip1A and Vip2A toxins. The 
88.5 kDa Vip3 proteins possess insecticidal activity against crucial lepidopteran 
pests of maize and cotton including Spodoptera litura and Helicoverpa zea. They 
have been found to be active against a wide spectrum of lepidopteran larvae. 
Vip1 and Vip4 show homology to Clostridium perfringens iota domain Ib toxins. 
Vip2 is homologous to Ia component of the iota toxin. The Vip proteins are 
secreted during the vegetative stage of the growth commencing at the mid-log 
phase as well as during sporulation  (Estruch et al., 1996).  
 
1.7 Bt δ-endotoxins 
The  Bt δ-endotoxins are the major virulence factors that  have  been known to 
impart pathogenic properties to the bacterium against specific insects (Agaisse 
et al., 1999). The δ-endotoxins of B. thuringiensis can be divided into two major 
families, Cry and Cyt. 
Most B. thuringiensis δ-endotoxin genes reside on plasmids  (Gonzalez et al., 
1981; Kronstad et al., 1983) which appear to be transmissible or conjugative in 
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nature (González et al., 1982). A defining feature of a cry gene is its expression 
during the stationary phase of the growth cycle. Their products generally 
accumulate in the mother cell compartment to form a crystal inclusion accounting 
for 20- 30% of the dry weight of the sporulated cells. The very high level of crystal 
protein synthesis in B. thuringiensis and its co-ordination with the stationary 
phase are controlled by a variety of mechanisms occurring at the transcriptional, 
post-transcriptional and post-translational levels (Schnepf et al., 1998). Although 
a vast number of cry genes for instance cry1Aa, cry1Ab, cry2Aa, cry4Aa, cry15Aa 
studied so far show expression in the mother cell and are dependent on 
sporulation sigma factors σE and/or σK (Brizzard et al., 1991; Brown, 1993; 
Yoshisue et al., 1993a, 1993b; Agaisse & Lereclus, 1995; Dervyn et al., 1995), 
expression of cry genes such as cry3Aa is sporulation independent. Cry3Aa is 
produced during the vegetative growth phase of the bacterium, although at a 
lesser extent than during the stationary phase. The cry3A promoter is weakly 
functional during the vegetative growth phase and is activated at the end of the 
exponential growth. The promoter of the cry3Aa gene resembles the promoter 
recognised by the primary sigma factor σA of the vegetative cells. Cry3A 
expression is increased in Spo0A mutants which are unable to initiate sporulation 
(Agaisse & Lereclus, 1994; Baum & Malvar, 1995; Salamitou et al., 1996). 
As of the start of 2013, there were 290 distinct Cry and Cyt toxins based on amino 
acid sequence identity.  Currently the primary sequence identity among toxin 
sequences forms the basis of nomenclature of Cry and Cyt δ-endotoxins 
(Crickmore et al., 1998). In 1989, Hofte & Whiteley classified the then 14 different 
crystal toxins into 5 groups Cry I, II, III, IV and CytA based on sequence 
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similarities and host specificity. The ever expanding list of B. thuringiensis toxin 
genes rendered it difficult to retain such a form of nomenclature leading to the 
formation of a new revised system of nomenclature which classed toxin genes 
solely on the relatedness between the protein sequences. A committee assigns 
Cry toxins to distinct holotypes based on percentage amino acid sequence 
identity. Each holotype is assigned a primary (Arabic numeral), secondary 
(uppercase letter) and tertiary rank (lowercase letter) representing approximately 
45%, 78% and 95% identity respectively. Quarternary rank (indicated by Arabic 
numeral too) denotes identical sequences which differ only slightly. Hence, those 
toxins differing only in quarternary rank most likely possess identical specificities 
and potencies. The new system removes the need to bioassay each new toxin 
against a series of organisms as the original nomenclature would demand 
(Crickmore et al., 1998). >700 cry genes had been sequenced to date and have 
been assigned to 279 holotypes. 36 cyt genes have been sequenced and have 
been assigned to 11 holotypes (Crickmore et al., 2013).  
1.7.1 Cyt δ-endotoxins 
Cyt toxins from B. thuringiensis are cytolytic to various insects and mammalian 
cells including erythrocytes. Three major classes of Cyt toxins, Cyt1, Cyt2 and 
Cyt3, have been identified. Cytolytic toxins have generally been characterised 
from various strains of B. thuringiensis possessing activity towards mosquitos and 
other dipteran insects. Unlike the B. thuringiensis Cry δ-endotoxins, Cyt toxins 
exhibit a broad cytolytic activity in vitro and are highly specific to dipteran larvae 
in vivo. High hydrophobicity and the ability to bind to certain membrane lipids 
have resulted in the broad cytolytic properties of the Cyt1Aa toxins. The 
mechanism of action is unclear and may be either pore-forming (Promdonkoy & 
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Ellar, 2000, 2003) or detergent-like (Butko, 2003). Like the Cry toxins, the Cyt 
toxins are synthesised as protoxins. Small peptide amino acids are removed from 
the N and C- termini to activate the toxin (Armstrong et al., 1985). For instance in 
case of Cyt2A, 32 amino acid residues and 15 amino acid residues are cleaved 
from N and C-terminal ends respectively by proteinase K treatment yielding a 
monomeric protein with haemolytic activity (Koni & Ellar, 1994). Non-receptor 
mediated binding of Cyt toxins to the synthetic lipid membrane has been 
observed (Thomas & Ellar, 1983b; Gill et al., 1987; Bravo et al., 2007). This is in 
contrast with the receptor mediated activity of Cry toxins. The X-ray structure of 
the Cyt2A toxin depicts a single domain of α/β architecture consisting of six α-
helices and seven β-sheets (Li et al., 1996). The cytolytic toxins possess activity 
against mosquitos with Cyt1Aa and Cyt2Aa possessing the highest activity. The 
presence of a ricin domain (cd00161; pfam 00652) has been detected in the 
inactive Cyt1Ca (Berry et al., 2002). There is evidence of synergism between Cyt 
and Cry toxins for instance Cyt1Aa synergising the mosquitocidal activity of 
Cry11Aa (Wirth et al., 2003; Perez et al., 2005; Oestergaard et al., 2007). 
Synergism was detected between Cyt1A and Cry10Aa toxin of B. thuringiensis 
subsp. israelensis (Hernandez-Soto et al., 2009). Further, co-expression of 
Cyt2Aa2 and Cry4Ba in E. coli resulted in high synergism against Aedes aegypti 
and Culex quinquefasciatus larvae (Promdonkoy et al., 2005).  
1.8 Cry δ-endotoxins 
The 279 distinct crystal toxins of Bacillus thuringiensis can be further divided into 
a number of distinct homology groups (Table 1.1 and Figure 1.1) (de Maagd et 
al., 2003). The three -domain Cry proteins constitute the biggest class comprising 
of 249 Cry toxins. Intriguingly, members of the three-domain Cry proteins are also 
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present in other obligate bacteria for instance Penibacillus popilliae, a causal 
agent of milky disease of scarabaeid larvae, the parasporal crystal protein of 
which contains CryBP1 (Cry18Aa1) which shows 40% sequence identity to Cry2 
polypeptides of B. thuringiensis (Zhang et al., 1997). The three-domain Cry 
protein members, Cry16 and Cry17 are found in Clostridium bifermentans  
(Barloy et al., 1998). The Mtx group of toxins form the second largest class made 
up of 9 members. Members of the Mtx group consists of the conserved domain 
that belongs to Clostridium epsilon toxin ETX / and Bacillus mosquitocidal toxin 
MTX2 superfamily (ETX/MTX2; pfam 03318). The Bin toxins constitute the third 
largest group with three different basic members (primary rank) and seven 
subtypes. Additionally, the other Cry toxins phylogenetically unrelated to above 
include the unique Cry6, Cry22, Cry37, Cry55 and Cry46. The Cry6 toxins were 
isolated from B. thuringiensis strains active on nematodes. Cry6A has been found 
to be active against nematode species (Wei et al., 2003) and on certain 
coleopterans including corn rootworm (Thompson et al., 2001). Cry6 toxin depicts 
homology to the conserved chromosome segregating protein, SMC family of 
proteins (TIGR: 02169). Cry22 proteins were initially isolated from B. thuringiensis 
strains active on ants (Payne et al., 1997). Later the activity of Cry22 was reported 
against coleoptera for instance corn rootworm (Mettus-Light & Baum, 2000) and 
boll weevil (Isaac et al., 2001). X-ray crystallographic studies reveal that the 
protein has an elongated six domain structure consisting of four cadherin-like 
domains flanked by a 242-residue N-terminal domain and a C-terminus of 142 
residues with a fold analogous to the  domain III of the three-domain Cry proteins, 
implicating a binding function (Rydel et al., 2003). Cry55Aa1 is thought to be a 
nematicidal protein (Guo et al., 2008). Cry55Aa2 might possess activity against 
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coleopteran pests (Bradfisch et al., 1999). Cry34 members are not related to 
other Bt crystal proteins; however, they are homologous to binary toxins from B. 
sphaericus with 26-29% sequence identity (de Maagd et al., 2003). Cry46, a 
mammalian cell-killing toxin is a β-pore forming hydralysin-like toxin 
(UniProtKB/Swiss-Prot: Q52SK7.3) (Ito et al., 2004). 
Not all the Cry toxins isolated were insecticidal. Recently a number of non-
insecticidal Cry toxins have been isolated that have been found to possess 
activity against human cancer cell lines. These Cry toxins have been grouped 
into a separate class called parasporins mainly due to their unique cytotoxic 
activity (Mizuki et al., 2000). Parasporins-1 (Cry31), Parasporins-3 (Cry41) and 
Parasporins-6 (Cry63) are the typical 3-domain toxins. Parasporin-2 (Cry46) is a 
hydralysin- like toxin while Parasporin-4 (Cry 45) and Parasporin-5 (Cry64) are 
Mtx-like toxins. 
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Table 1.1 List of Bt toxins and their classification based on homology groups   
Cry1Aa Cry1Ab Cry1Ac Cry1Ad Cry1Ae Cry1Af Cry1Ag Cry1Ah Cry1Ai Cry1Ba Cry1Bb      
Cry1Bc Cry1Bd Cry1Be Cry1Bf Cry1Bg Cry1Bh Cry1Bi Cry1Ca Cry1Cb Cry1Da Cry1Db Cry1Dc Cry1Ea   
Cry1Eb Cry1Fa Cry1Fb Cry1Ga Cry1Gb Cry1Gc Cry1Ha Cry1Hb Cry1Ia Cry1Ib Cry1Ic      
Cry1Id Cry1Ie Cry1If Cry1Ig Cry1Ja Cry1Jb Cry1Jc Cry1Jd Cry1Ka Cry1La Cry1Ma  Cry1Na  Cry1Nb   
Cry2Aa Cry2Ab Cry2Ac Cry2Ad Cry2Ae Cry2Af Cry2Ag Cry2Ah Cry2Ai  Cry2Aj  Cry2Ak  Cry2Ba    
Cry3Aa Cry3Ba Cry3Bb Cry3Ca Cry4Aa Cry4Ba Cry4Ca Cry4Cb Cry4Cc          
Cry5Aa Cry5Ab Cry5Ac Cry5Ad Cry5Ba Cry5Ca Cry5Da Cry5Ea Cry6Aa Cry6Ba Cry7Aa Cry7Ab Cry7Ba Cry7Bb  
Cry7Bb Cry7Ca Cry7Cb Cry7Da Cry7Ea Cry7Fa Cry7Fb Cry7Ga  Cry7Gb  Cry7Gc  Cry7Gd Cry7Ha Cry7Ia  Cry7Ja Cry7Ka 
Cry8Aa Cry8Ab Cry8Ac Cry8Ad Cry8Ba Cry8Bb Cry8Bc Cry8Ca Cry8Da Cry8Db Cry8Ea Cry8Fa Cry8Ga   
Cry8Ha Cry8Ia Cry8Ib Cry8Ja Cry8Ka Cry8Kb Cry8La Cry8Ma Cry8Na  Cry8Pa Cry8Qa  Cry8Ra Cry8Sa Cry8Ta  
Cry9Aa Cry9Ba Cry9Bb Cry9Ca Cry9Da Cry9Db Cry9Dc Cry9Ea Cry9Eb Cry9Ec Cry9Ed Cry9Ee  Cry9Fa Cry9Ga  
Cry10Aa Cry11Aa Cry11Ba Cry11Bb Cry12Aa Cry13Aa Cry14Aa Cry14Ab Cry15Aa Cry16Aa Cry17Aa Cry18Aa Cry18Ba Cry18Ca  
Cry19Aa Cry19Ba Cry20Aa Cry20Ba Cry21Aa Cry21Ba  Cry21Ca  Cry21Da Cry22Aa Cry22Ab Cry22Ba Cry22Bb Cry23Aa Cry24Aa  
Cry24Ba Cry24Ca Cry25Aa Cry26Aa Cry27Aa Cry28Aa  Cry29Aa Cry30Aa Cry30Ba Cry30Ca Cry30Da Cry30Db Cry30Ea Cry30Fa Cry30Ga 
Cry31Aa Cry31Ab Cry31Ac Cry31Ad Cry32Aa Cry32Ab Cry32Ba Cry32Ca Cry32Cb Cry32Da Cry32Ea Cry32Eb Cry32Fa Cry32Ga  
Cry32Ha Cry32Hb Cry32Ia Cry32Ja Cry32Ka Cry32La Cry32Ma Cry32Mb Cry32Na Cry32Oa Cry32Pa Cry32Qa Cry32Ra Cry32Sa Cry32Ta 
Cry32Ua Cry33Aa Cry34Aa Cry34Ab Cry34Ac Cry34Ba Cry35Aa Cry35Ab Cry35Ac Cry35Ba Cry36Aa Cry37Aa Cry38Aa Cry39Aa Cry40Aa 
Cry40Ba Cry40Ca Cry40Da Cry41Aa Cry41Ab Cry41Ba Cry42Aa Cry43Aa Cry43Ba Cry43Ca Cry43Cb Cry43Cc Cry44Aa Cry45Aa  
Cry46Aa Cry46Ab Cry47Aa Cry48Aa Cry48Ab Cry49Aa Cry49Ab Cry50Aa Cry50Ba Cry51Aa Cry52Aa     
Cry53Aa Cry53Ab Cry54Aa Cry54Ab Cry54Ba Cry55Aa Cry56Aa Cry57Aa Cry58Aa Cry59Aa  Cry59Ba       
Cry60Aa Cry60Ba Cry61Aa Cry62Aa Cry63Aa Cry64Aa Cry65Aa Cry66Aa Cry67Aa Cry68Aa Cry69Aa Cry69Ab    
Cry70Aa Cry70Ba Cry70Bb  Cry71Aa  Cry72Aa                  
                           
Cyt1Ab Cyt1Aa Cyt1Ba Cyt1Ca Cyt1Da Cyt2Aa Cyt2Ba Cyt2Bb Cyt2Bc Cyt2Ca Cyt3Aa      
Vip1Ab Vip1Aa Vip1Ac Vip1Ba Vip1Bb Vip1Ca Vip1Da     Sip1        
Vip2Ab Vip2Aa Vip2Ac Vip2Ad Vip2Ae Vip2Af Vip2Ba Vip2Bb            
Vip3Ab Vip3Aa Vip3Ac Vip3Ad Vip3Ae Vip3Af Vip3Ag Vip3Ah Vip3Ba Vip3Bb Vip3Ca Vip4Aa    
The list of Bt toxins has been taken from Bt nomenclature database (http://www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/). Parasporins, a sub-
class of Bt toxins, have been taken from the parasporin nomenclature database (http://parasporin.fitc.pref.fukuoka.jp/list.html). The homology group 
classification is taken from the published paper (de Maagd et al., 2003). The Cry toxins phylogenetically unrelated are highlighted with different 
colours. These toxins are Cry6, Cry22, Cry37, Cry55 and Cry 46. Cry34 members (light green) are not related to other Bt crystal proteins, however 
they are homologous to binary toxins from B. sphaericus (de Maagd et al., 2003). 
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Figure 1.1. Venn diagram depicting homology of Bt proteins to the conserved 
domains and protein families found in a diverse group of organisms. The homology 
group classification is taken from the published paper (de Maagd et al., 2003). The 
conserved domains and protein families have been identified using CD search or BLAST, 
NCBI. The identifiers where applicable are given in the text. 
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1.9 The Mtx Group 
Mtx2 and Mtx3 are widely distributed among mosquitocidal Lysinibacillus 
sphaericus strains. They are related to each other and also to various other 
bacterial toxins such as cytotoxin of Pseudomonas aeruginosa, the epsilon toxin 
of Clostridium perfringens, the alpha toxin of Clostridium septicum and aerolysin 
from Aeromonas hydrophila. B. thuringiensis toxins in this group include 
Cry15Aa, Cry23Aa, Cry33Aa, Cry38Aa, Cry45Aa, Cry51Aa, Cry60Aa, Cry60Ba 
and Cry64Aa. Most of the Bt toxins belonging to this subgroup need further 
characterisation. Cry15Aa protein from B. thuringiensis subsp. thompsoni 
possesses significant homology to Mtx2 and Mtx3 toxins. Cry15Aa requires its 
unrelated helper 40kDa protein for crystallisation and full toxicity against M. sexta 
(Brown & Whiteley, 1992; Rang et al., 2000; Naimov et al., 2008). The 29 kDa 
Cry23 in combination with the 13-14 kDa Cry37 is toxic against certain coleoptera 
for instance boll weevil (Donovan et al., 2000). The sequence of Cry37 bears no 
significant homology to the existing proteins in the public databases. The three 
dimensional structure of the binary Cry23/Cry37 complex resembles that of 
proaerolysin (Figure 1.5, p. 32) (Rydel et al., 2001). cry33Aa and cryNT32 are 
arranged in an apparent operon similar to the Bt subsp thompsoni genes (de 
Maagd et al., 2003). Not much is known about the protein Cry53 from Bacillus 
thuringiensis cameroun strain. Cry38 is isolated from the B. thuringiensis strain 
that produces Cry34/Cry35 (Baum et al., 2004). Cry45 is a parasporin that is a 
mammalian cell killing toxin from Bacillus thuringiensis with no known insecticidal 
activity. Cry51 is related to Cry15A and Cry33A which may possess some 
insecticidal activity (Huang et al., 2007). Cry60s (Cry60Aa/Ba) are putative new 
mosquitocidal toxins (Sun & Park, unpublished). Cry64 is a new parasporin 
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classed as parasporin 5 with no known insecticidal activity (Ekino et al., 
unpublished). The host specificities of the Mtx group of toxins investigated so far 
widely differ ranging from Lepidoptera for Cry15 to Coleoptera for Cry23 and 
Cry38 and in vitro cytotoxicity against mammalian cancer cell lines for the non-
insecticidal Cry45Aa (Lee et al., 2000). Although these proteins demonstrate a 
low sequence similarity yet they share a conserved sequence motif comprising 
of an amphipathic loop region flanked by two Ser/Thr-rich regions with each other 
as well as with protein toxins from a variety of organisms (Naimov et al., 2008). 
 
1.10 The Bin group 
The Bin group toxins comprising of 3 basic members (primary rank) form the third 
largest group of the Bt crystal toxins based on homology groups. Since these Cry 
toxins share sequence similarities to the individual components of the binary toxin 
from mosquitocidal L. sphaericus and are themselves mostly part of a binary 
toxin, they have been classed into Bin group of crystal toxins. The mosquitocidal 
activity of L. sphaericus is due to the presence of ‘Bin’ (binary) toxin produced 
during sporulation. Bin mosquitocidal protein consists of two proteins the toxic 
Bin A of 42 kDa and the binding moiety Bin B of 52 kDa (Charles et al., 1996; 
Wirth et al., 2010). Both components are required for full toxic activity thus 
implicating a binary toxin mode of action (Broadwell et al., 1990). The members 
of the Bin group are Cry35, Cry36 and Cry49. All three Cry35A toxins have a 
carbohydrate binding Ricin-type β-trefoil [cd00161; pfam 00652] domain at the N 
terminus. Cry49Aa is a binary toxin and appears to rely on the presence of a 
second three-domain protein Cry48Aa. Cry36 is toxic on its own. 
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1.10.1 The Binary toxins 
Cry proteins that exerts toxicity together whereas individually they are not toxic 
are grouped as binary toxins. The toxicity appears to rely on the presence of the 
second Cry protein.  For instance such association is observed in case of Bt  
three-domain protein, Cry48Aa with Bin-like protein, Cry49Aa derived from L. 
sphaericus. These are the two component toxins wherein insect toxicity is 
achieved in the presence of the second accessory protein. The necessity for both 
components for pathogenicity has been demonstrated. Other such complexes 
include Cry34/Cry35; Cry23/Cry37 and Vip1/Vip2. Cry35 proteins are only active 
in the presence of the unrelated Cry34 against western corn rootworm (Ellis et 
al., 2002). 29 kDa Cry23 protein functions effectively only in conjunction with 13-
14 kDa Cry37 protein on certain coleopterans (Donovan et al., 2000). The various 
binary toxins studied so far have been illustrated in Figure 1.2. 
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Figure 1.2. The various members of the binary toxins. The Bt toxins which rely on 
each other for toxicity and form complexes with each other are joined by blue lines. ? 
indicates that the associations of Bin Cry36 is not known. The corresponding homology 
groups and conserved domains are also indicated in the diagram. 
 
1.11 The three-domain Cry toxins 
The three-domain Cry toxins have been extensively used as biological 
insecticides for several decades now. They are active against several insect 
orders including Lepidoptera, Diptera, Coleopteran and Hymenoptera. They have 
also been found to be active against nematodes (Figure 1.3). These toxins share 
distinct three dimensional structures comprising of three domains. 
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(de Maagd et al., 2003) 
Figure 1.3. Specificity of the three-domain toxins to various insect orders. 
A common three-domain structure of the activated Cry1Aa (Grochulski et al., 
1995), Cry2Aa (Morse et al., 2001), Cry3A (Li et al., 1991), Cry3Bb (Galitsky et 
al., 2001), Cry4Aa (Boonserm et al., 2006), Cry4Ba (Boonserm et al., 2005) and 
Cry8Ea1(Guo et al., 2009) toxins has been revealed by X-ray crystallography. 
Domain I is comprised of seven α-helices and domains II and III are made up of 
mostly β-sheets (Figure 1.4). While domain I plays a crucial role in pore formation, 
receptor binding and host specificity has been ascribed to domains II and III. Five 
blocks of amino acids are found to be conserved amongst the majority of Cry 
toxins (Hofte & Whiteley, 1989). Amino acid sequence alignment of the Cry toxins 
reveals the presence of three additional blocks outside the active core at the 
carboxyl terminal halves of these sequences (Schnepf et al., 1998). 
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Domain I:  Domain I, corresponding to the N-terminus comprises of seven α-helix 
bundle which is organised into a highly conserved central helix (helix α-5) 
surrounded by six helices which are amphipathic in nature. Helix 5 contains the 
conserved block1. The central location thus implicates its role in maintaining the 
structural integrity of the helix bundle. The helices 4 and 5 are possibly 
responsible for membrane insertion and pore formation (Li et al., 1991). Domain 
I is analogous to other pore forming toxins such as colicin A and diphtheria toxin 
(Parker et al., 1992). An alternative to the above idea that the hydrophobic hairpin 
between α4 and α5 initiates the membrane insertion, is the possibility that helices 
5 and 6 juxtaposed to each other open up in a penknife fashion before inserting 
into the membrane (Hodgman & Ellar, 1990). 
Domain II comprises of three anti parallel β-sheets joined in a Greek Key topology 
forming a β-prism. The first β strand of Domain II and helix 7 of domain I include 
the conserved block 2. Surface-exposed loops of β-sheets bears semblance to 
immunoglobin antigen-binding sites (Schnepf et al., 1998). The β-prism fold is 
similar to that of various plant lectins for instance Jacalin (Bourne et al., 1999; 
Meagher et al., 2005). This suggests the role of domain II in receptor binding.  
Domain III is a β- sandwich structure comprising of two twisted anti parallel β-
sheets displaying a jelly-roll topology. Conserved blocks 3, 4 and 5 lie on one of 
the three buried strands within domain III. The domain III is thought to aid in 
maintaining the integrity of the toxin molecule possibly by masking it from 
proteolysis within the gut of the target insect (Li et al., 1991).  
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(Aronson & Shai, 2001) 
Figure 1.4. Schematic representation of the structure of the three domain toxin 
Cry3A. 
(Bravo & Soberón, 2008) 
Figure 1.5. Structures of various Bt crystal proteins representing the various 
classes of the toxins. Helices are indicated in red, β-sheets are indicated in blue and 
the coils are indicated in purple. 
Domain III 
Receptor binding; 
modulating ion-channel 
activity 
Domain II 
Domain I 
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1.12 Split toxins 
It has been observed in some of the Cry proteins that a pair of adjacent genes 
separated by intergenic region encode the typical N and C terminal regions of Bt 
δ endotoxins as two separate proteins. They are termed as split toxins. These 
split toxins have more than one Open Reading Frame (ORF) separated by an 
intergenic region. One of the ORF’s usually contains homology blocks 1-5 as 
described by Hofte & Whiteley (1989) and is the typical N-terminus present in 
most Bt δ endotoxins. The second ORF usually encode homology blocks 6-8, the 
C-terminal region of longer protoxins. 
Thirteen such cry gene pairs have been found in B. thuringiensis. The first genes 
of these pairs are cry5Ad (Lenane et al., 2008), cry10Aa (Thorne et al., 1986), 
cry19Aa (Rosso & Delecluse, 1997), cry24Ba (Ohgushi et al., 2005), cry30Ba (Ito 
et al., 2006), cry39Aa (GenBank accession BAB72016), cry40Aa (GenBank 
accession BAB72018), cry40Ba (GenBank accession BAC77648), cry41Aa/Ab 
(Yamashita et al., 2005), cry41Ba (GenBank accession HM461871), cry42Aa 
(GenBank accession BAD35166) and cry44Aa (Ito et al., 2006) (Figure 1.6). 
Cry5Ad and orf2-5Ad differ from the other split toxins in that they occur within a 
Cry5A (Cry5Aa, Cry5Ab, Cry5Ac)  family in which the other members encode a 
single open reading frame containing all eight  homology blocks (Lenane et al., 
2008). 
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The carboxy- terminal ends containing homology blocks 6-8 in the longer Cry δ 
endotoxin genes gets cleaved during the proteolytic activation of B. thuringiensis 
protoxins. A possible function as a molecular chaperone helping in the 
crystallization of Cry proteins has been suggested (Bietlot et al., 1990; Park et 
al., 2000; Barboza-Corona et al., 2012). 
The cause of the segmentation of the cry toxin genes into separate open reading 
frames has not been elucidated. Previously such gene configuration was 
observed in mosquitocidal strains. But recently this has been observed in the 
cry41 parasporin genes. Typically, the region separating the open reading frames 
shows no homology to any known transposons or insertion sequences. Possibly 
the segregation into various open reading frames resulted due to recombination 
or transposition event. It would interesting to investigate if such gene structure in 
the split toxins actually confer any advantage to the bacterium or if it’s a mere 
evolutionary process in which the intergenic region was lost in other Bt δ 
endotoxin cry genes and the homology blocks 1-8 were found together on a single 
ORF, or that these split toxins evolved from a full length δ-endotoxin gene. 
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Figure 1.6. Schematic representation of the split toxins. The green boxes denote the 
eight conserved blocks of Cry toxins. The red box denotes homology to the conserved 
ricin domain [cd00161; pfam 00652]. 
 
 
 
 
 
 
Page 36 of 260 
 
1.13 Mode of action 
A multistep process of cell killing has been proposed for the insecticidal three 
domain toxins. Pore formation and signal transduction are two hypotheses being 
put forward, pore formation mode being the most widely accepted and consistent 
with various studies (Vachon et al., 2012). The preliminary steps of toxin 
solubilisation in the midgut lumen, activation by gut proteases and binding to the 
primary receptor cadherin are shared by both the hypotheses. The pore formation 
model further suggests that binding to the primary receptor in the microvilli of the 
midgut cells induces proteolytic cleavage of helix α1 and causes oligomerization 
of the toxin followed by binding to a secondary receptor, for instance 
aminopeptidase (APN) or alkaline phosphatase (ALP). Recently, the possibility 
of a “ping-pong” binding mechanism with cadherin and aminopeptidase N 
receptors has been proposed for toxin action by Paccheco et al. (2009). This 
report suggests that the Cry toxin first binds to the highly abundant but low-affinity 
APN facilitating the concentration of the toxin at the midgut brush border 
membrane for the subsequent binding to cadherin resulting in the oligomerization 
of the toxin which then binds again to the APN with a high affinity leading to the 
insertion of the oligomer and pore formation (Pacheco et al., 2009). The signal 
transduction model which was based on studies conducted on insect cell lines 
proposes that the interaction of the Cry toxin with the primary receptor cadherin 
triggers a cascade pathway mediating the activity of protein G which in-turn 
activates adenylyl cyclase that further augments the cyclic adenosine 
monophosphate levels activating protein kinase A and leading to cell death 
(Zhang et al., 2006). The models are depicted in the Figures 1.7 (p. 43) and 1.8 
(p. 44). The further details of toxin mechanism are given in the following sections. 
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1.13.1 Solubilisation and proteolytic activation 
After ingestion by a susceptible insect, the crystal protoxins are released by 
solubilisation in the gut. For most lepidopterans the alkaline milieu of midgut is 
presumed to be crucial for disruption of intramolecular disulphide bridges formed 
due to 16-18 cysteine residues at the carboxy terminal (Bietlot et al., 1990). 
Differences in the extent of solubilisation possibly result in the variable degree of 
toxicity among Cry proteins. The solubility of crystals containing multiple toxins 
may be affected by the presence of specific Cry toxins as in case of B. 
thuringiensis subsp. aizawai HD-133 which contains Cry1Ab, Cry1Ac and Cry1D. 
HD-133 strain cured of Cry1Ab gene solubilised at higher pH as compared to the 
non-mutated HD-133 crystals (Aronson et al., 1991). In the neutral or slightly 
acidic midguts of coleopteran larvae, proteolytic treatment by a serine protease 
chymotrypsin yields a soluble Cry3A δ-endotoxin product which retains its full 
toxicity (Carroll et al., 1997). 
Solubilisation is followed by activation of the Cry protoxins by trypsin- and 
chymotrypsin-like midgut proteases in insects (Tojo & Aizawa, 1983). The 130 
kDa Cry1A family of protoxins are cleaved at both N and C-termini to yield active 
toxic cores of 55-67 kDa (Schnepf et al., 1998). Only a small peptide <100 amino 
acids are removed from the N terminal. The C terminal half gets cleaved 
sequentially in ~10 kDa fragments resulting in a conformational change within the 
toxic core (Choma et al., 1991). 
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1.13.2 Receptor binding 
The activated crystal toxin binds to the specific membrane protein receptors on 
the gut epithelium of the susceptible insects (Hofmann et al., 1988). The process 
of binding is a two-stage one involving reversible and irreversible steps.  The 
reversible binding involves a low affinity interaction between the toxin and the 
membrane receptor whilst the irreversible binding includes tight binding between 
the receptor and insertion of toxin into the membrane (Hofmann &  Luthy, 1986; 
Van Rie et al., 1989; Ihara & Himeno, 2008). A myriad of such high–affinity toxin 
binding sites in the insect midguts have been reported (Pigott & Ellar, 2007). The 
best characterised amongst the protein receptors identified so far include a 
glycosylphosphatidyl-inositol (GPI) -anchored aminopeptidase-N (APN) (Knight 
et al., 1994; Sangadala et al., 1994; Gill et al., 1995), cadherin-like receptors 
(CADR) in lepidopterans (Nagamatsu et al., 1998, 1999). Glycolipids constitute 
an important class of Cry toxin receptors in nematodes (Griffitts et al., 2005). 
Other Cry toxin receptors include a GPI anchored alkaline phosphatase (ALP) 
(Fernandez et al., 2006), a 270-kDa glycoconjugate  (Valaitis et al., 1997) and a 
252-kDa protein (Hossain et al., 2004). 
The widely accepted view is that the activated toxin inserts into the membrane of 
the susceptible insect and forms pores after toxin-receptor interaction. As 
proposed by Knowles & Ellar (1987), the pore resulted in the death of the insects. 
Bravo et al. (2004) further developed this model of pore formation suggesting that 
a toxin oligomerization precedes the toxic pore formation.  
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1.14 Bravo-Soberon model 
The Bravo-Soberon model is based on experiments with Cry1Ab and the tobacco 
hornworm, Manduca sexta. It predicts the binding of proteolytically activated   
monomeric Cry1Ab toxin to the cadherin receptor BT-R1 followed by cleavage of 
domain I helix α1 by membrane bound proteases. The monomer then 
oligomerises to the tetrameric form  which binds to the receptor APN and forms 
association with lipid rafts further inserting into the membrane forming  pores of 
0.5-1nm in diameter thus resulting in osmotic cell lysis and insect death (Bravo 
et al., 2007). This sequential event in the pore formation pathway was elucidated 
by temporal differences in the immunoprecipitation of BT-R1 and APN by Cry1Ab 
(Bravo et al., 2004). Co-precipitation of Cry1Ab with BT-R1 decreased over time 
whilst 4-fold increase of Cry1Ab-APN precipitation was noted. In addition the 
previous reports suggested a 100-fold greater affinity of the receptor Bt-R1 for 
Cry1Ac as opposed to APN (Vadlamudi et al., 1993; Sangadala et al., 1994). This 
suggests that the binding of Cry1Ab to Bt-R1 and APN is sequential in nature.  
Alternatively, Pigott & Ellar (2007) highlighted that due to the low abundance of 
cadherin as compared to other Cry1Ab receptors, the possibility exists that high 
affinity, low concentration cadherin receptors get rapidly saturated with Cry1Ab 
as compared to APN receptors. The nicking of α-helix 1 upon binding of BT-R1 
and subsequent cleavage was proved by N-terminal sequencing which showed 
its presence in Cry1Ab monomers that were activated by M. sexta gut juice in-
vitro but was absent from Cry1Ab oligomers produced by incubation with BBMV 
(Brush border membrane vesicles) (Gomez et al., 2002). Bravo et al. (2004) 
indicated the presence of BT-R1 in the soluble fraction of iodoxano gradient 
centrifugation of solubilised M. sexta BBMV. APN co-precipitated with lipid rafts. 
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Incubation of BBMV with Cry1Ab prior to solubilisation results in BT-R1 co-
fractionating with lipid rafts if APN is not cleaved of its GPI anchor. This suggests 
the association of BT-R1 –Cry1Ab complex to lipid rafts via APN. 
 
1.15 The “ping-pong” sequential binding model 
Based on the observations on the binding of Cry1Ab mutants to Manduca sexta 
receptors, cadherin and APN, Pacheo et al. (2009) proposed a ping pong binding 
mechanism. The model suggests involvement of domain II loop 3 in the first 
binding event with the high abundance, low affinity, APN receptor which serves 
to locate the monomeric toxin in the vicinity of the microvilli. This interaction is 
followed by a high affinity binding to the cadherin receptor Bt-R1 that involves 
participation of other regions of domain II besides loop 3, such as loops α-8 and 
2. Interaction with Bt-R1 triggers cleavage of helix α-1 and oligomerization of the 
toxin. The oligomeric structure binds with high affinity to APN through other 
regions of the toxin, such as the domain III β16–22 region, whilst remaining 
associated with Bt-R1 through loop 3. This mediates the insertion of the 
oligomeric structure into the membrane suggesting a “ping-pong” binding 
mechanism (Figure 1.8) (Pacheco et al., 2009). 
 
1.16 Zhang-Bulla model 
The Zhang-Bulla model is based upon experiments conducted on 
undifferentiated Trichoplicus ni ovarian cells expressing M. sexta cadherin BT-R1 
and rules out the possibility of dependence of cytotoxicity on pore formation. The 
model proposes that a cell signalling pathway is activated leading to cell death 
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by binding of the receptor Bt-R1 by monomeric Cry1Ab (Zhang et al., 2005, 
2006). The model suggests that the cyclic–AMP (cAMP) pathway is activated by 
Cry toxins. The activated Cry toxins upon binding to BT-R1 stimulate G protein 
which in turn activates AC causing an increase in intracellular cAMP production 
that further activates PKA. PKA activation causes the destabilisation of the 
cytoskeleton and formation of ionic pores leading to cell lysis (Zhang et al., 2008). 
Since the model is based on limited experiments using undifferentiated T. ni 
ovarian cells in vitro, there is no further evidence that Cry1Ab demonstrates 
similar means of toxicity in vivo or in other cell lines. Furthermore, it was noted 
that several Cry toxins which led to the increase of cAMP levels in M. brassicae 
demonstrated no toxicity (Knowles & Farndale, 1988). 
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(Bravo & Soberón, 2008) 
Figure 1.7. The two hypotheses put forth for the mechanism of action for the Bt 
Cry toxins: pore formation model (top) and signal transduction model (bottom). 
The preliminary steps of toxin solubilisation in the midgut lumen (1), activation by gut 
proteases (2) and binding to the primary receptor cadherin (3) are shared by both the 
hypotheses. The pore formation model further suggests that binding to the primary 
receptor in the microvilli of the midgut cells induces proteolytic cleavage of helix α1 (3) 
and induces oligomerization of the toxin (4) followed by binding to a secondary receptor 
(5). The toxin then inserts itself into the membrane, thereby forming a pore (6). The signal 
transduction model proposes that the interaction of the Cry toxin with the primary 
receptor cadherin triggers a cascade pathway mediating  the activity of  G protein (4a) 
which in-turn activates adenylyl cyclase (5a) that further augments the cyclic adenosine 
monophosphate levels activating protein kinase A and leading to cell death.    
 
 
 
Page 43 of 260 
 
 
 
 
(Pardo-López et al., 2013) 
Figure 1.8. Schematic representation of the “ping-pong” binding mechanism as 
suggested by Pacheo et al., 2009. 1. The 3-domain Cry protoxin is solubilised in the 
midgut lumen and activated by the gut protease generating 65kDa toxin fragment. 2.  65-
kDa Cry1Ab monomer binds to low- affinity APN and ALP receptors through domain II 
loop 3. 3. The monomer binds Bt-R1 cadherin receptor through domain II loops α-8, 2, 
and 3 in a high-affinity interaction which induces cleavage of the N-terminal end of the 
toxin including α-1 of domain I. 4. Formation of a 250-kDa oligomer 5. The oligomer binds 
Bt-R1 through loop 3 and to high -affinity APN and ALP through domain III. 6. Membrane 
insertion of the 250-kDa oligomer and pore formation after APN interaction. 
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1.17 Parasporins 
Besides the insecticidal toxins, certain Bt toxins have been isolated from non-
insecticidal strains that are found to be selectively active against human cancer 
cell lines (Kim et al., 2000; Lee et al., 2000b; Mizuki et al., 2000; Yamashita et 
al., 2000). 
The proteins derived from some of these non-insecticidal strains have been 
classed into a new family of Bt endotoxins known as parasporins, toxins that 
exhibit cytocidal activity preferentially killing human cancer cell lines (Mizuki et 
al., 2000). The non-hemolytic and preferential cytotoxic activity distinguishes 
them from the insecticidal Cyt proteins (Mizuki et al., 1999; Schnepf et al., 1998). 
No reports have yet been published indicating the presence of these cytotoxic 
crystal proteins in insecticidal strains. Indiscriminate cytotoxicites of parasporal 
inclusions derived from two mosquitocidal reference strains, israelensis and 
kyushensis to human cells, fish and insect cells has been reported. However, the 
cytotocidal activity has been attributed to the Cyt toxins (Thomas & Ellar, 1983a; 
Mizuki et al., 1999). 
Currently, based on amino acid sequence analysis, these proteins have been 
categorised into 6 families, Parasporin (PS) - 1-6, purified from various Bt strains. 
Differences in molecular weight, structure and target cell specificity set them apart 
from each other. 
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Parasporin-1 (Cry31), parasporin-3 (Cry41) and parasporin-6 (Cry63) are 3-
domain toxins like most insecticidal Cry proteins, with PS-3 being a split-toxin 
containing an additional Ricin-like/β-trefoil domain ((QXW)3 motif). Parasporin-2 
(Cry46) is a hydralysin like toxin while parasporin-4 (Cry 45) and parasporin- 5 
(Cry64) are Mtx-like toxins homologous to Clostridium perfringens ε –toxin whose 
cell- killing mechanism involves oligomerization of the toxin in the lipid rafts and 
formation of pores in the cell membrane (Table 1.2). 
These six different parasporins have been isolated mainly from Japan, Vietnam 
and Canada. There are also reports of occurrence of the parasporins from soils 
in India (Poornima et al., 2010). Recently parasporins have been isolated from a 
Caribbean island indicating the global dispersion of the B. thuringiensis strains 
producing the cancer killing crystal toxin (Gonzalez et al., 2011). 
This class of mammalian cell killing toxins could not only be harnessed as 
potential therapies for certain cancers but also be useful in providing a risk-
assessment of Bt toxins being used for controlling insect pests in agriculture. 
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Table1.2. List of various parasporin toxins isolated so far 
Parasporin Cry toxin Nomenclature Type 
Parasporin 1 
Parasporin 2 
Parasporin 3 
Parasporin-4 
Parasporin 5 
Parasporin 6 
Cry31Aa/b/c/d 
Cry46Aa 
Cry41Aa/b 
Cry45Aa 
Cry64Aa 
Cry63Aa 
Three-domain Cry toxin 
Hydralysin-like toxin 
Three-domain Cry toxin 
Epsilon/Mtx-like toxin 
Epsilon/Mtx-like toxin 
Three-domain Cry toxin 
Parasporins and their corresponding crystal toxin nomenclature have been taken from 
the parasporin nomenclature database (http://parasporin.fitc.pref.fukuoka.jp/list.html), 
the link to which is provided in the Bt nomenclature database. The homology group has 
either been determined using CD search, NCBI or BLAST, NCBI. The identifiers are 
mentioned in the text. 
 
1.17.1 Parasporin-1 (Cry31A) 
Parasporin-1 is a three domain non-insecticidal B. thuringiensis toxin that 
preferentially possesses cytotoxic activity against human cancer cell lines. So far, 
parasporin 1 has been isolated from ten strains of B.  thuringiensis from soils of 
Japan, Vietnam and also from  parasitic dead two-spotted spider mites from 
orchard apples  in Canada  (Jung et al., 2007; Uemori et al., 2008). Parasporin-
1 is produced as an 81 kDa inclusion protein. This three domain toxin exhibited 
a low sequence similarity to existing Cry and Cyt proteins. 
Protease treatment by trypsin yields the active form of parasporin-1 which is a 
heterodimer made up of 15 and 56 kDa subunits.  This proteolytic processing is 
 
 
Page 47 of 260 
 
a pre-requisite for the toxin to be active against the cancer cell lines as observed 
in case of B. thuringiensis Cry toxins (Lightwood et al., 2000). Intriguingly, the 
cytotoxic activity of Parasporin-1Aa1 appeared to be protease specific. 
Parasporin-1Aa1 when treated with trypsin and proteinase K exhibited cytotoxic 
activity. However, cytotoxic activity against HeLa cells, as assessed by MTT 
assay, sharply decreased at concentrations of proteinase K above 60 μg/ml 
possibly due to the broad specificity of the protease used leading to further 
digestion of high molecular weight protein bands of parasporin-1. No cytotoxicity 
was observed when the protein was treated with chymotrypsin (Mizuki et al., 
2000; Katayama et al., 2005) whereas in PS1Aa2 (Cry31Aa2) only trypsin 
generated the cytotoxic fragments. The protein treated with chymotrypsin or 
proteinase K exhibited no cytotoxicity. The trypsin activation occurs by N-terminal 
processing (Jung et al., 2007). The parasporin-1 protein preferentially exerts its 
cytotoxic effects against certain cell lines especially HeLa, MOLT-4 and HL60 cell 
lines. It demonstrates a moderate cytotoxicity to Sawno and HepG2 cells but is 
non-toxic to the cells obtained from normal tissues, peripheral blood T cells and 
MRC-5 cell line (Table 1.3, p. 57). This suggests that a specific receptor is 
required for the parasporin-1 protein. The role of receptors in the insect toxicity 
has been well-documented in the case of B. thuringiensis insecticidal Cry proteins 
which exhibits specific insecticidal activity as opposed to Bt Cyt toxins which are 
toxic to both insects and human cells (Gill & Hornung, 1987; Gill et al., 1992; 
Schnepf et al., 1998). 
Specific cell death as caused by Parasporin-1 differs from the mode of activity   
normally exhibited by pore forming insecticidal Cry or Cyt proteins of B. 
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thuringiensis. This is evident by the absence of lactate dehydrogenase (LDH) 
release and lack of penetration of propidium iodide in HeLa cells as well as no 
alteration in the membrane potential of the cells treated with Parasporin-1Aa1. 
Parasporin-1 treatment is marked by attenuation of cellular protein and DNA 
synthesis and rapid increase in intracellular calcium ions. A large influx of 
extracellular calcium ions was observed in cells which were treated with 
parasporin-1Aa1, resulting in the apoptotic death of the target cell. The apoptotic 
cell death is further strengthened by the fact that a decline of PS1Aa1 cytotoxic 
activity is observed by synthetic caspase inhibitors and the PS1Aa1 treatment 
leads to degradation of apoptosis-related proteins, procaspase-3 and poly (ADP-
ribose) polymerase in HeLa cells. A delayed cytopathy  of 8-10 h is observed in 
case of  sensitive cell lines treated with parasporin-1 unlike that observed in case 
of other parasporin toxins which cause immediate cell death of the sensitive cell 
lines after treatment. Thus, Parasporin-1 appears to cause cell death by a novel 
mechanism by increasing the intracellular calcium ion concentration, not reported 
in any other bacterial cytotoxic protein. Still, the exact mechanisms of its action 
and pathways need further clarification (Katayama et al., 2007). 
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1.17.2 Parasporin-2 (Cry46Aa) 
Parasporin-2 is a hydralysin- like toxin targeting mostly human liver and colon 
cancer cells. PS2Aa1 lacks the conserved blocks of the insecticidal Cry proteins 
and is homologous to hydralysin, a β-pore forming toxin from Hydra, a Cnidaria 
(Sher et al., 2005). PS2 shares no homology to most of the existing B. 
thuringiensis Cry or Cyt toxins. A low homology is seen with Cry15 belonging to 
Mtx-like group  (Brown & Whiteley, 1992). The ~37 kDa protein on proteinase-K 
treatment yields a cytotoxic ~30 kDa fragment that exhibits notable cytotoxicity to 
certain human cancer cell lines. The digestion occurs on both the N and C termini 
of the protein removing 51 and 36 residues from the respective termini (Kitada et 
al., 2006). The active protein is selectively cytotoxic to HepG2 and Jurkat cell 
lines and less toxic to HeLa and normal hepatocyte cells (Ito et al., 2004). The 
cytotoxic effect of parasporin-2 is non-apoptotic causing swelling and 
fragmentation of the susceptible cells possibly altering the ion permeability of the 
cells. The initial step is the specific binding of the activated toxin to a putative 
receptor in the lipid raft of the plasma membrane of the sensitive cells followed 
by the formation of oligomers of PS2Aa in plasma membrane leading to pore 
formation and cell lysis (Abe et al., 2008). Thus the cell killing mechanism is 
similar to various pore forming toxins like hydralysins, aerolysin from Aeromonas 
hydrophila and epsilon toxin from Clostridium perfringens (Kitada et al., 2006). 
The crystal structure of active parasporin-2 has been determined. The active 
protein is mainly composed of long β-strands aligned with its long axis imparting 
it an unusual elongated shape. It exhibits similarity to aerolysin type β –pore 
forming toxin. Three distinct domains can be identified in the molecule. A short α- 
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helix sandwiches a small β-sheet and probably serves as the target binding 
module (Figure 1.9a). Domain 2 and Domain 3 are β sandwiches possibly 
involved in oligomerization and pore formation (Akiba et al., 2009). 
Domain 1 is comprised of four short α-helices (H1-H4) and a small four stranded 
anti-parallel β-sheets (S2-3 and S11-12). H1 helix borders domain 2 whereas H2 
and H3 sandwich the β-sheet. Domain 1 is enriched with aromatic residues 
particularly histidine, phenylalanine, tryptophan and tyrosine.  As put forth for the 
Clostridium perfringens epsilon toxins, these exposed aromatic residues might 
be the putative binding sites for the membrane receptors of the susceptible 
cancer cells (Akiba et al., 2009). 
Domain 2 is a β sandwich domain that contains a β-hairpin (S8-9) and a twisted 
five -stranded β-sheet (S5-6, S7, S10-11 and S13) that are anti- parallel. At the 
interface of domain 2 and domain 3, the five stranded β-sheet is re-organised into 
three-stranded and two-stranded anti-parallel β-sheets. These two β-sheets form 
a β-sandwich which constitutes domain 3. 
Despite the low sequence similarity of circa 26%, parasporin-2 shares a 
remarkable structural similarity with the aerolysin- type β-PFT’s (pore forming 
toxins) (Figure 1.9b, c & d). 
 
 
 
Page 51 of 260 
 
                            
 
Figure 1.9. Ribbon representation of the structural homologues of parasporin-2. 
(a) is the structure of activated parasporin-2 (Akiba et al., 2009). (b) is the epsilon toxin 
from C. perfringens (Cole et al., 2004). (c) is the aerolysin toxin from A. hydrophila 
(Parker et al., 1994). (d) is the Hemolytic lectin from L. sulphurous (Mancheño et al., 
2005). 
(a) 
(Akiba et al., 2009) 
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1.17.3 Parasporin-3 (Cry41Aa and Cry41Ab) 
The 88 kDa proteins classed as parasporin-3 were isolated from the B. 
thuringiensis strain A1462 from soils of Tokyo in Japan and was first reported by 
Yamashita et al. (2005). They reported that the proteinase K activated protein of 
64 kDa was selectively cytotoxic to human cancer cell lines HepG2 (liver) and 
HL60 (myeloid luekemia cells). Amongst all the parasporins isolated so far, 
Parasporin-3 possesses the narrowest cytotoxicity spectrum affecting only the 
above cell lines (Yamashita et al., 2005). Little is known about parasporin-3 which 
is notably similar to the insecticidal Cry proteins of B. thuringiensis in terms of 
amino acid sequence but differs remarkably in its selective cytotoxic activity 
against the human cancer cell lines. 
The amino acid sequences of the parasporin-3 derived from the B. thuringiensis 
strain A1462 exhibit a remarkable similarity to the Bt insecticidal three-domain 
Cry  toxins possessing the conserved domains of the insecticidal Cry1 toxins  as 
described by Schnepf et al. (1998) and are  thus predicted to possess a typical 
three-domain structure. Parasporin-3, found as the second gene (ORF2) in a 
three gene operon, is similar to several B. thuringiensis split toxins as enlisted in 
Section 1.12. The third gene (ORF3) of parasporin-3 resembles the C-terminus 
of the larger Cry1A-type toxins containing the conserved blocks 6-8, the role of 
which still needs investigation. 
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A schematic representation of the parasporin-3 toxin and a B. thuringiensis Cry1 
toxin is shown below in Figure 1.10, depicting the conserved blocks of the two 
proteins. 
 
Figure 1.10. Conserved blocks of Bt insecticidal Cry1 protein and Cry41 
(parasporin-3). The green boxes denote the eight conserved blocks of cry toxins. The 
red box denotes homology to the conserved ricin domain [cd00161; pfam 00652]. 
Additionally ORF2 possesses a conserved domain belonging to Ricin 
superfamily. This is most similar to HA-33 like domain present in Clostridium 
botulinum type C mammalian neurotoxin (Figure 1.11) that causes botulism 
disease characterised by muscular paralysis in humans and animals (Tsuzuki et 
al., 1990). The HA-33 component is responsible for haemagglutination and 
aggregation of erythrocytes caused by the toxin complex from Clostridium 
botulinum. The presence of glutamine-any residue-tryptophan (QxW) pattern is 
observed in the sequence of the ORF2 gene. This is the characteristic feature of 
ricin-like lectin domains, (QxW)3 domains (hereafter referred to as ricin domain) 
and the internal repeats as QxW  repeats (Hazes, 1996).  Whether ricin domain 
has a role to play in the cytotoxicity of the parasporin-3, or is just present as a 
non-functional domain in ORF2 awaits clarification. 
Domains   I              II         III 
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Figure 1.11. Gene organisation of 16S progenitor toxin of Clostridium botulinum 
type C. This comprises of a neurotoxin (turquoise box) in conjunction with non-toxic 
components designated as Nontoxic-non HA (green box) and hemagglutinin. HA is 
composed of subcomponents with molecular masses of 53, 22-23, 17 (yellow box) and 
33 kDa (red box) (Adapted from Fujinaga et al., 1994). 
1.17.4 Parasporin-4 (Cry45Aa) 
Parasporin-4 is a ~30 kDa Epsilon/Mtx-like cytotoxic protein isolated from Bacillus 
thuringiensis strain A1470. The active parasporal protein exhibits strong 
cytotoxicity against human leukemic T cells. As with other parasporins, proteolytic 
processing is indispensable for the toxin activity. The protease treatments yield a 
~27 kDa active form of the toxin selectively cytotoxic against colonic, uterine and 
blood cancer cells. The protein retained its cytolethal activity when processed 
both by alkaline proteinase K and acidic pepsin (Okumura et al., 2005, 2006). 
PS4 treatment causes swelling of the susceptible cells marked with nuclear 
shrinkage causing the bursting of the ballooned cells within 24 hours of its 
administration (Okumura et al., 2011). Circular Dichroism revealed PS4 to be a 
β-sheet dominated protein. Parasporin-4 is homologous with various B. 
thuringiensis Cry toxins including Cry15, Cry33 and Cry14. It also shows 
homology with various pore-forming toxins such as ε-toxin from Clostridium 
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perfringens.  Most of the pore-forming toxins are dependent on cholesterol for 
their activity (Hang'ombe et al., 2004). Insecticidal Cry toxins from B. thuringiensis  
have been reported to be pore forming toxins (Schnepf et al., 1998) with Cry1A  
(Zhuang et al., 2002) and Cry4Ba (Kanintronkul et al., 2005) believed  to be 
cholesterol- dependent. Parasporin-2 also needs cholesterol for its cytotoxic 
activity (Kitada et al., 2009). However parasporin-4 activity seemed independent 
of cholesterol. Cytotoxicity of parasporin-4 was not altered in case of cholesterol-
depleted CACO-2 cells. Thus parasporin-4 seems to be a pore forming toxin 
whose activity is independent of cholesterol that thus differs from aerolysin-type 
and cholesterol dependent toxins (CDC) such as streptolysin O of S. pyogenes, 
pnemolysin of streptococcus pneumonia (Tilley et al., 2005) and perfringolysin of 
C. perfringens. Parasporin-4  binds non-specifically to the plasma membrane of 
the susceptible cells and oligomerises to form pores only in the target cells 
causing cell death (Okumura et al., 2011). 
 
1.17.5 Parasporin-5 (Cry64Aa)  
Parasporin-5 has been isolated in 2009 by Ekino & Shin (unpublished) from the 
Bt strain A1100. Not much has been reported for PS5. Sequence analysis reveals 
that PS-5 is an Epsilon/Mtx like toxin. 
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1.17.6 Parasporin-6 (Cry63Aa) 
Parasporin-6 (Cry63Aa) has been isolated from B. thuringiensis strains M109 and 
CP84 (Nagamatsu et al., 2010). Sequence analysis suggests that it is a three-
domain Cry toxin. The proteolytically active toxin was cytotoxic towards human 
hepatocyte cancer HepG2 cells and uterus cervix cancer HeLa cells (Table 1.3). 
The treatment was accompanied by swelling of the cells and formation of 
vacuoles in the cytoplasm of the sensitive cells (Nagamatsu et al., 2010). Not 
much work has been reported on this mammalian Cry toxin. 
 
Each parasporin studied so far is endowed with its own mechanism for inducing 
cell death. PS1 activates apoptotic signalling due to increased levels of calcium 
ions. PS2 acts as a cytolysin which causes permeabilization of the plasma 
membrane with target cell specificity. PS4 is a cholesterol independent pore-
forming toxin. The mode of action of PS3, PS5 and PS6 still needs investigation. 
The cytotoxicity spectrum of the parasporins isolated and investigated so far is 
summarised in Table 1.3. Although each of the parasporins differed in their 
specificity to different cell types, human HepG2 liver carcinoma cell line is 
susceptible to all of them (Table 1.3). 
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Table 1.3 Cytotoxicity spectrums of parasporins 
CELL LINE ORIGIN PS1 PS2 PS3 PS4 PS5 PS6 
HUMAN 
MOLT 4 
JURKAT 
HL60 
HeLa 
TCS 
Sawano 
HepG2 
A549 
CACO-2 
T cell 
UtSMC 
HC 
MRC-5 
MONKEY 
Vero 
RODENT 
PC12 
 
Leukemic T cell 
Leukemic T cell 
Myeloid Leukemia 
Uterus cervix cancer 
Uterus cervix cancer 
Uterus cancer 
Hepatocyte cancer 
Lung cancer 
Colon cancer 
Normal T cell 
Normal uterus 
Normal Hepatocyte 
Normal Lung 
 
Kidney 
 
Pheochromocytoma 
 
++ 
- 
+++ 
+++ 
- 
- 
++ 
- 
- 
- 
- 
- 
- 
 
- 
 
?? 
 
++++  
++++ 
++++ 
- 
- 
++++ 
++++ 
+++ 
+ 
+++ 
++ 
- 
+ 
 
?? 
 
?? 
 
- 
- 
++ 
- 
- 
- 
++ 
- 
- 
- 
- 
- 
- 
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?? 
 
- 
- 
+++ 
- 
- 
- 
++ 
- 
- 
- 
- 
- 
- 
 
- 
 
++ 
  
 
 
 
+ 
 
 
++++ 
 
+ 
 
(Adapted from Ohba et al., 2009) 
The levels of cytotoxicity, based on EC50 calculated using cell proliferation assays were 
denoted as follows:  extremely high, ++++; high, +++, moderate, ++, low, + and non- toxic, 
-.? indicates not tested 
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1.18 Present work 
Chapter three studies the cytotoxic effect of various Cry proteins from native 
strains of B. thuringiensis on human cancer cell lines. Chapter four describes the 
attempted heterologous expression of cry41Aa (Parasporin-3) gene and its 
various mutants in E. coli. Chapter five summarises the creation of homologous 
expression systems for parasporin-3. It also investigates whether the putative 
carbohydrate binding beta-trefoil ricin domain domain present at the C-terminal 
of cry41Aa gene is responsible for the cytotocidal activity of Cry41Aa against 
cancer cell lines. Chapter six analyses the Mtx-type Cry51 and three-domain 
Cry65 toxins and evaluates their activities against cancer cell lines. 
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2. Materials and Experimental protocols 
 
2.1 General materials 
 
2.1.1 Bacterial strains 
 
2.1.1.1 E. coli 
2.1.1.1.1 JM109 procured from Promega was used for T-vector cloning, 
subcloning, transformation, and in some instances for protoxin expression. 
Genotype: end A1, rec A1, gyr A96, thi, hsd R17, rel A1, sup E44, [ lac-pro AB 
], [F’ traD36 , proAB, lacIqZM15]. 
2.1.1.1.2 BL21(DE3) 
An E. coli strain with DE3, a λ prophage carrying the T7 RNA polymerase gene 
under the control of lac UV5 promoter. BL21(DE3) permits high-efficiency protein 
expression of a gene cloned  with its own ribosome binding site under the control 
of a T7 promoter. 
Genotype: F– ompT gal dcm lon hsdSB (rB- mB-) λ(DE3 [lacI lacUV5-T7 gene 1 
ind1 sam7 nin5]). 
 
2.1.1.1.3 GM2163 
This is Dam- Dcm-    strain which does not methylate DNA and is resistant to 
chloramphenicol. E. coli GM2163 was used to obtain unmethylated DNA for ease 
of transformation in B. thuringiensis since it was observed by Macaluso & Mettus 
(1991) that some B. thuringiensis strains restrict uptake of methylated DNA and 
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hence unmethylated plasmid DNA is a requisite for efficient transformation of B. 
thuringiensis. 
 
Genotype: ara14, leuB6, thi, fhuA31, lacY1, tsx78, galK2, supE44, hisG4, 
rpsL136 (Strr), xyl5, mtl1, dam13:Tn9 (Cmr), dcm6, mcrB1, hsdR2, mcrA. 
 
 2.1.1.2   Bacillus thuringiensis 
2.1.1.2.1 Bacillus thuringiensis native strain A1462 donated by BFRI, JAPAN. 
2.1.1.2.2 Bacillus thuringiensis strain Sbt012 isolated from China. 
2.1.1.2.3 Bacillus thuringiensis subspecies kurstaki HD73 that produces 
insecticidal Cry1Ac toxin. 
2.1.1.2.4 IPS 78/11, a crystal free (acrystalliferous) strain of Bacillus thuringiensis 
subsp israelensis. 
2.1.1.2.5 Bacillus thuringiensis strain 4D7, a crystal free derivative of Bacillus 
thuringiensis subspecies kurstaki, was obtained from Bacillus Genetic Stock 
Center, Department of Biochemistry, Ohio State University. 
2.1.1.2.6 Bacillus thuringiensis strain 4Q7, a crystal free plasmid-cured strain of 
Bacillus thuringiensis subsp israelensis, was obtained from Bacillus Genetic 
Stock Center, Department of Biochemistry, Ohio State University. 
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2.1.2 Plasmids 
2.1.2.1 Plasmid vectors 
2.1.2.1.1 pSVP27A, an E. coli –Bt expression vector: This is an  E. coli / B. 
thuringiensis shuttle vector with the Cyt1A promoter from the cyt1A toxin gene of 
B. thuringiensis subsp. israelensis upstream of the cloned target gene (Crickmore 
& Ellar, 1992; Crickmore et al., 1994). The vector, pSVP27 possesses attributes 
of the E. coli / B. thuringiensis shuttle vector, pSV2 which is used in cloning genes 
in E. coli via the multiple cloning site for expression in B. thuringiensis. The vector 
possesses origin of replication for both E. coli and B. thuringiensis. The vector 
carries chloramphenicol and ampicillin resistance genes. 
2.1.2.1.2 pGEM-T vector procured from Promega was employed for cloning PCR 
products amplified using Taq DNA polymerase which adds adenine (A) to the 3’ 
end of its PCR products. It possesses an origin of replication in E. coli and an 
ampicillin resistance gene. 
2.1.2.1.3 pET3a Expression vector procured from Novagen which possesses an 
origin of replication in E. coli, ampicillin resistance gene, T7 IPTG inducible 
promoter and a multiple cloning site. 
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2.1.2.2 Recombinant plasmids 
2.1.2.2.1 Plasmid pGC-I harbouring the gene that encodes Cry41Aa1 (PS3Aa1) 
toxin from BFRI, JAPAN. 
2.1.2.2.2 Recombinant cry51Aa1 cloned into the shuttle vector pHT304 with its 
own promoter and conferring resistance to erythromycin from the collaborators 
(Ming Sun’s lab, Huazhong Agricultural University, Wuhan) in China. 
2.1.2.2.3 Recombinant Cry65Aa: Cry65Aa1 was isolated from B. thuringiensis 
strain SBt003 by Sun et al., 2010 (unpublished). Recombinant cry65 cloned and 
expressed in the Bt recombinant strain BMB1281 and conferring resistance to 
chloramphenicol was sent by the collaborators from China. 
2.1.2.2.4 pGEMCry1Ac: Insecticidal cry1Ac gene cloned into pGEM-T vector and 
expressed in E. coli JM109.  
 
2.1.3 Insect populations 
 
2.1.3.1 Plutella  xylostella strains 
2.1.3.1.1 NO-QA: Cry1Ac resistant population. The field-collected insecticidal 
Cry1Ac resistant population was obtained from the Max Planck Institute for 
Chemical Ecology (Thuringia, Germany) and maintained in the laboratory on a 
diet of six-week-old Chinese cabbage (Brassica pekinensis) at 25°C under a 16 
h photophase. 
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2.1.3.1.2 G-88: Cry1Ac susceptible population. A subpopulation of Gen-88 
adapted to artificial diet (Gen-88 D) was obtained from Dr. Ben Raymond, Centre 
for Ecology and Hydrology (Oxford, UK) and maintained in the lab on a sterile 
artificial Hoffman’s diet at 25°C under a 16 h photophase. 
2.1.3.1.3 LAB-UK:  Cry1Ac susceptible population maintained in the laboratory 
on a diet of six-week-old Chinese cabbage (Brassica pekinensis) at 25°C under 
a 16 h photophase. 
2.1.4 Human cancer cell lines 
2.1.4.1 A549 (human lung carcinoma), an anchorage dependant (adherent) cell 
line was kindly provided by Dr. Lynne Mayne, University of Sussex, UK. 
2.1.4.2 HepG2 (human Caucasian hepatocyte carcinoma), an adherent cell line 
was purchased from ECACC, Salisbury, UK. 
2.1.4.3 HeLa (human cervical cancer), an adherent cancer cell line was kindly 
provided by Dr. Michelle West, University of Sussex, UK. 
2.1.5 Culture media 
The cell lines mentioned above were routinely maintained in the medium DMEM 
(Dulbecco's modified Eagle media) supplemented with 10% FBS (Fetal Bovine 
Serum) and  2% PSG (Penicillin, Streptomycin, and Glutamine) as recommended 
by the supplier. 
2.1.5.1 Sub-culture Routine 
The cells were kept in sterile polystyrene 80 cm2 flasks (Nunc)  with filter cap and 
sub-confluent cultures (70-80%) were trypsinised (Trypsin/EDTA 1X containing 
0.05% Trypsin and 0.53 mM EDTA) and split bi-weekly in case of HeLa and A549 
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cells and weekly in case of HepG2 cells depending on the seeding ratio. The cells 
were grown in a standard, cell culture incubator at 37°C/5%CO2 humidified air. 
2.1.6 Miscellaneous reagents and kits used for cell assays 
2.1.6.1 Etoposide (Sigma), a derivative of podophyllotoxin and topoisomerase II 
inhibitor was prepared as 10 mg/ml stock solution in DMSO and diluted to the 
appropriate concentration in tissue culture medium. 
2.1.6.2 Trypan Blue Solution (Gibco®), 0.4%. 
2.1.6.3 CellTiter-Blue cell viabillity assay kit from Promega. 
2.1.6.4 CellTiter-Glo luminescent cell viability assay kit from Promega. 
 
2.1.7 Bacterial culture media 
2.1.7.1 LB (Luria –Bertani) media 
Tryptone: 10 g 
Yeast Extract: 5 g 
NaCl: 10 g 
Water to 1 litre. The pH was adjusted to 7.5 with 5 M NaOH. 
2.1.7.2 LB agarose plates:  Luria –Bertani media solidified with 15 g/l agar. 
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2.2 Experimental protocols 
2.2.1 Design of PCR primers for amplification of DNA fragments 
The primers were designed by analysing the specific target sequence and their 
properties and suitability assessed by using PCR Primer Stats (SMS on 
www.bioinformatics.org). The primers were further crosschecked using the 
programme PRIMER SELECT from the DNASTAR software package. The 
appropriate primers are listed in the relevant chapters. 
2.2.2 PCR amplification of DNA 
The open reading frames and the DNA fragments of the crystal genes under 
investigation were amplified using the appropriate primers as listed in the relevant 
chapters. The PCR amplification reactions were performed using either Taq or 
Pfu DNA polymerase as mentioned in the relevant chapters. High fidelity Expand 
long range PCR kit from Roche was used according to the manufacturer’s 
instructions for generation of PCR products with 3’A- overhangs to enable cloning 
into the pGEM-T vector possessing 3’ T- overhangs. High Fidelity pfu DNA 
polymerase-based PCR amplification system from Stratagene, Pfu Ultra Hotstart 
Master mix was used in many instances for amplification of DNA fragments. High 
fidelity PCR master mix from Roche was also employed in certain instances as 
mentioned in the relevant chapters. 
PCR contents for a 50 µl volume whilst employing High fidelity Expand long range 
PCR kit from Roche were 1 pmol/μl (1 μM) of Forward and Reverse primers each, 
10 µl of 5X Expand Long Range Buffer (Roche), 10-500 ng of template DNA, 2.5 
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µl of nucleotide mix, 0.7 µl of Expand Long Range Enzyme mix and 35.3 µl of 
water.  In case of using Pfu Ultra Hotstart Master mix from Stratagene or High 
Fidelity Master mix from Roche, the contents were as follows: 0.5 µl of 100 
pmol/µl Forward and Reverse primers each, 0.5 µl of template DNA, 25 µl of the 
master mix (2.5 U per 50 µl reaction) and 23.5 µl of sterile distilled water. The 
initial denaturation was set up at 95°C for 2 min. The annealing temperature used 
for amplification usually varied between 55-60°C. The extension time was based 
on the size of the target DNA, set up as 30 seconds per kb of DNA to be amplified 
for targets which were more than 10kb. PCR reactions were generally run for 30 
cycles. PCR amplicons were analysed and visualised by electrophoresis on a 1% 
(w/v) agarose gels and staining with a fluorescent nucleic acid dye GelRed. 
 
2.2.3 Purification of PCR amplicons 
 
2.2.3.1 Column purification of the PCR amplicons  
The PCR amplified products were purified using QIAquick PCR Purification kit 
(Qiagen) according to the manufacturer’s instructions.  
2.2.3.2 Gel isolation of the DNA fragments  
In some instances the PCR amplicons and the desired DNA fragments were 
isolated from the agarose gel and purified using a simple bind-wash-elute 
protocol based QIAquick Gel Extraction kit (Qiagen) according to the 
manufacturer’s instructions.  
 
 
 
Page 67 of 260 
 
2.2.4 Ligation of the purified PCR amplicons 
The purified PCR products were either self- ligated or ligated to the desired vector 
for the formation of the desired construct using either 2X Rapid Ligation buffer 
(Promega) or T4 DNA Ligase buffer 10X (Promega). 
Purified PCR amplicons were ligated into pGEM-T or pGEM-T easy vectors 
vector using 2X Rapid Ligation buffer (Promega). For ligation of other purified 
PCR amplicons, T4DNA Ligase buffer 10X (Promega) was used. Ligation 
reactions were typically assembled as follows: 0.1-1 weiss units of T4 DNA ligase, 
1 µl of Ligation Buffer and 3:1 Molar ratio of vector: insert DNA. Sterile distilled 
water was added to make the volume to 10 µl. The reaction mix was incubated 
2-3 h at room temperature and further kept on ice. 
1 µl of the above ligation mix was used for transformation into 50 µl of competent 
E. coli cells by electroporation.  
 
2.2.5 Transformation of bacterial strains with plasmids 
 
2.2.5.1 Transformation of E. coli strains by electroporation 
A fresh colony of E. coli strain was used to inoculate 100 ml of L. Broth. Cells 
were grown with vigorous aeration at 37°C to mid-log phase, until they reached 
an OD600 of 0.4-0.8. The cells were harvested by centrifugation at 15,000 g for 10 
min in sterile centrifuge bottles in SLA-1500 rotor. The cells were then washed 
extensively to eliminate all salts. The cell pellet was washed in 100 ml cold 
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distilled water and further centrifuged at 15,000 g for 10 min in SLA-1500 rotor. 
The pellet was resuspended in 1 ml of cold distilled water and transferred to an 
Eppendorf tube. The cells were centrifuged for a further 2 min at 16,000 g rpm 
and resuspended in 200 µl of cold water. 50 µl of the competent E. coli cells, thus 
prepared were mixed with 1 µl of the DNA to be transformed and then pipetted 
into a sterile electroporation cuvette containing electrodes. A short electric pulse 
of 1.8 kV, 200 Ω, 25 µF is applied to the cells for the uptake of DNA. The cells 
were then incubated with broth and allowed to express the antibiotic resistance 
gene for 30-60 min prior to plating. Transformed cells were plated out on LB-agar 
plates containing the antibiotic ampicillin at a concentration of 100 µg/ml and 
incubated at 37°C overnight to obtain the colonies with the desired DNA. 
2.2.5.2 Transformation of Bacillus thuringiensis strains 
Plasmids were transformed into various strains of B. thuringiensis by 
electroporation. The Bt cells were rendered electrocompetent using the same 
methodology as that used for competent E. coli cells with few modifications. The 
fresh Bt cultures were grown at 30°C in a shaking incubator until they reached an 
OD600 of 0.4-0.8. The cells were harvested and competent Bt cells were prepared 
as described above. Electroporation was carried out using the same protocol as 
outlined in Section 2.2.5.1. However following electroporation, the cells were 
incubated with broth at 30°C without shaking and allowed to express the antibiotic 
resistance gene for 60 min prior to plating. Transformed cells were plated out on 
LB-agar plates containing the antibiotic chloramphenicol at a concentration of 5 
µg/ml and incubated at 30°C overnight to obtain the colonies with the desired 
DNA. 
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2.2.6 Rapid size screen of the E. coli transformants 
To identify the desired clone, rapid size screening was performed. The rapid size 
150 µl of 10% SDS, 2.5 ml of 0.5 M NaOH, 600 µl of 1.4 M KCl and 6.5 ml  of 
water. The dye Bromophenol blue was added to the solution. 
25 µl of the above RSS solution (pre-warmed) was added to the Eppendorf tubes. 
Individual bacterial colonies were picked by a sterile toothpick and resuspended 
in the solution. The tube was incubated in water bath at 37°C for 5 min followed 
by incubation in ice for 5 min. The samples were centrifuged at 11,000 g for 5 
min. 10 µl of the sample was loaded on to a 1% agarose gel. Plasmids with insert 
ran slower than the plasmids carrying no insert and were chosen for further 
analyses. 
 
 
2.2.7 Extraction of plasmid DNA from transformed bacterial strains 
 
2.2.7.1 Extraction of plasmid from E. coli transformants  
Small scale plasmid preparations were carried out using QIAprep Spin Miniprep 
kit (Qiagen) that follows a simple bind-wash-elute protocol as per the 
manufacturer's recommendations.  
 
screen (RSS) solution consisted of 100 µl of 500 mM EDTA, 1 g of 10% sucrose, 
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2.2.7.2 Extraction of plasmid from B. thuringiensis transformants  
Plasmid DNA was extracted from B. thuringiensis by using QIAprep Spin Miniprep 
Kit from Qiagen. Freshly grown transformed Bt cells were resuspended in 250 μl 
of Buffer P1 containing 10 mg/ml lysozyme and incubated in water bath at 37°C 
for 30 min to 1 h to enhance the lysis of the cell wall. 250 μl of lysis Buffer P2 was 
added to the tube and gently inverted 4-6 times and the rest of the protocol as 
mentioned above in case of E. coli (Section 2.2.7.1) was carried out according to 
the manufacturer’s instructions. 
2.2.8 Analyses of extracted plasmids 
 
The sequence integrity of all the plasmid constructs was verified by restriction 
analysis and sequencing. 
2.2.8.1 Restriction analysis of extracted plasmids 
The extracted plasmids were subjected to restriction analysis. All digestions in 
this study were performed using restriction enzymes and their associated buffers 
purchased from NEB (New England Biolabs). Digestions were carried out 
according to manufacturer’s recommendations for the optimal temperature and 
buffer conditions for each enzyme used. Restriction digestion was performed on 
the plasmids thus extracted to verify the correct size of the insert. Typically, 1 μg 
of plasmid DNA was digested with 0.5 µl of restriction enzyme (10 U/µl) and 1 µl 
of corresponding buffer (10X) in which the enzyme shows maximum activity. The 
total volume was made up to 10 µl by adding water. The reaction was incubated 
in water bath at 37°C for 1 h and the digest verified on a 1% agarose gel. 
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2.2.8.2 DNA sequence analysis 
The plasmid DNA products were sequenced to confirm the integrity or presence 
of desired inserts or deletions at the junctions by dideoxy chain termination 
method (MWG, Germany). 
 
2.2.9 Expression and harvesting of the protein 
 
2.2.9.1 Expression and harvesting of the protein from E. coli JM109  
Fresh transformed colony of desired plasmid in E. coli JM109 was grown in LB 
medium supplemented with the appropriate antibiotic. 100 ml of L-broth was 
inoculated with the culture of interest and appropriate antibiotic usually 100 μg/ml 
of ampicillin for JM109 and grown for three days at 37°C. After three days of 
growth, the resultant inclusion bodies of the recombinant crystal gene were 
harvested. The culture thus grown was centrifuged at 20,000 g for 10 minutes. 
The pellet was resuspended in 30 ml of sterile distilled water, sonicated for 1 min 
4 times and then re-centrifuged and finally resuspended in 5 ml of water. The 
protein was checked on the 7.5% SDS-PAGE as described in Section 2.2.10. 
2.2.9.2 Expression and harvesting of protein from E. coli BL21(DE3) 
Expression plasmids were transformed into E. coli BL21(DE3) cells and the 
transformant of interest was grown in LB medium supplemented with ampicillin 
(100 µg/ml) until optical density of 0.5 was obtained at 600 nm. Protein expression 
was then induced by the addition of 0.5 mM IPTG. The induced culture was grown 
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for 24 h at 37°C in a shaker at 175 rpm. The protein was harvested after 24 hours 
of growth as discussed above. Protein samples were analysed by SDS-PAGE. 
 
2.2.9.3 Expression and harvesting of protein from Bacillus thuringiensis 
The wild type-Bt isolates and the Bt transformants harbouring the plasmid of 
interest were grown on LB agar plates supplemented with appropriate antibiotic,   
when necessary for 3-5 days at 30°C. Sporulated cells were scrapped off the 
plates and suspended in 30 ml of sterile distilled water. The cells were then 
harvested and subjected to extensive washing procedure as described above in 
Section 2.2.9.1. The protein was analysed by SDS-PAGE. 
 
2.2.10 Analysis of harvested proteins by SDS-polyacrylamide gel 
electrophoresis 
The harvested proteins were resolved on a SDS-PAGE (sodium dodecyl 
polyacrylamide gel electrophoresis). The size of the crystal toxin was assessed 
using either 7.5% or 12% SDS-PAGE based on the method described by 
Laemmli (1970). Smaller molecular weight proteins were resolved on 12% SDS 
gels. Polyacrylamide gels were prepared from materials supplied by Bio-Rad.  
For 7.5% gel, Resolving gel solution consisted of 2 ml of water, 1 ml of Resolving 
Gel Buffer (18.18 g Tris, 0.4 g SDS, distilled water to 100 ml, pH 8.8), 1 ml 
Acrylamide/bis-Acrylamide mixture, 30% solution (Sigma), 8 µl of 400 mg/ml 
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ammonium per sulphate solution (freshly made) and 4 µl of TEMED. For 12% 
SDS-PAGE gel, the volume of distilled water used was 1400 µl and the volume 
of acrylamide/bis-Acrylamide used was 1600 µl, the volumes of remaining 
ingredients being the same. 
Stacking gel solution remained same for both 7.5 and 12% gels and consisted of 
1ml of distilled water, 500 µl of Stacking gel Buffer (6.06 g Tris, 0.4 g SDS, Water 
to100 ml, pH 6.8), 333 µl Acrylamide/bis-Acrylamide mixture, 4 µl of and 2 µl of 
TEMED. 
Protein samples were mixed with 2X sample buffer (1:1) (2 g SDS, 6 mg EDTA, 
20 mg Bromophenol blue, 5 ml Resolving gel buffer, 50% (v/v) glycerol, 5% β- 
mercaptoethanol) and boiled for 3-5 min before loading on the SDS gel. 
Electrophoresis was performed at 200V for approximately 30 min using 1X Tris-
glycine-SDS Buffer (0.76 g Tris, 3.6 g Glycine, 0.25 g SDS and water to 25 ml) 
followed by 30 min staining using Coomassie Brilliant Blue R dye (Sigma). The 
samples were then destained using the solution comprising of methanol, water 
and glacial acetic acid (10:9:1). 
 
2.2.11 Estimation of protein concentration 
The Bio-Rad protein assay kit based on the method described by Bradford (1976) 
was employed to estimate the concentration of the solubilised and the trypsin-
treated protein samples with BSA (bovine serum albumin) as the standard. The 
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assay involves the addition of the acidic dye, Coomassie Brilliant Blue G-250 to 
the protein solution and subsequent measurement of the absorbance at 595 nm 
with spectrophotometer. Briefly, 1 part of the dye reagent, Coomassie Brilliant 
Blue G-250 (Bio-Rad) was diluted with 4 parts of sterile distilled water and filtered 
through Whatman filter to get rid of the particulates. Five dilutions of the protein 
standard, BSA at 10mg/ml ranging from 0.2 to 1mg/ml was prepared in order to 
get a linear range. 20 μl of each standard and protein sample solutions were 
pipetted to the disposable polystyrene cuvettes. 980 μl of the diluted dye reagent 
was added to each cuvettes and vortexed. The reaction mix was incubated for at 
least 5 min before measuring the absorbance at 595 nm. A curve of protein 
concentration (mg/ml) of the standard versus the OD595 was plotted and the 
concentration of the unknown protein samples deduced based on their 
absorbance. 
 
2.2.12 Characterisation of the expressed proteins 
Solubilisation and activation of crystal proteins 
The protein samples were dispensed in an Eppendorf tube and centrifuged for 5 
min at 11,000 g. The supernatant was discarded and the pellet resuspended in 
50mM sodium carbonate buffers at various pH ranging from 8.0 to 11.0. In some 
instances, as mentioned in the relevant chapter, an acidic buffer was also used 
to solubilise the proteins. DTT at the final concentration of 1mM was added to the 
samples to carry out solubilisation in a reducing environment. The sample was 
incubated at 37°C, water bath for 1 h. After incubation, the reaction mix was 
centrifuged and the supernatants were analysed by SDS-PAGE. Similarly, either 
the solubilised proteins or protein extracts were processed by varied 
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concentrations of various proteases including proteinase K (Sigma), trypsin 
(Sigma), chymotrypsin (Sigma) and gut extracts from Plutella xylostella 
populations prepared in the corresponding solubilising buffer.  
 
 
2.2.13 Purification of the protein samples 
 
2.2.13.1 Purification of proteins by sucrose density gradient 
 
To separate the crystalline inclusions from the spores, a differential 
ultracentrifugation through a discontinuous sucrose gradient was performed 
based on the method described by Thomas & Ellar (1983a). The sucrose gradient 
comprised of three layers of 10 ml each with concentrations in the ascending 
order of 1.97 M (67.4 g of sucrose in 100 ml of water), 2.1 M (71.8 g of sucrose 
in 100 ml water), and 2.3 M (78.7 g in 100 ml water) sucrose added slowly to the 
sides of a 38 ml polycarbonate round centrifuge tubes (Nalgene). 1 ml of the 
washed and sonicated crystal-spore mixture was applied to each tube band the 
centrifugation was set up at 72,000 g at 40C for 16 h in an SW28 rotor using an 
Optima LE-80K Ultracentrifuge (Beckman). 
The layer of interest approximately 1-5 ml (present in the bottom part of the middle 
sucrose layer) was removed, diluted 10-fold in ice-cold distilled water and was 
centrifuged at 25,000 g at 40C for 15 min in a SS-34 rotor. The pelleted crystalline 
inclusions were resuspended in 0.5 ml of sterile distilled water for further 
solubilisation and trypsin activation.  
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2.2.13.2 Dialysis 
 
The protein samples containing DTT were dialysed using a 25 kDa MWCO Micro 
DispoDialyzer (Sigma) against 50 mM Tris buffer pH 8 overnight on a magnetic 
stirrer at 4°C to remove DTT and low molecular weight contaminants.  Briefly, 
100 μl of the sample was placed into the dialyzer and immersed in approximately 
500 ml of 50 mM Tris buffer, pH 8. Dialysis was carried out at 40C overnight with 
constant stirring. The dialysed samples were analysed on the 7.5% SDS-PAGE 
and their concentration was determined and further frozen at -200C for cell 
assays. 
 
2.2.13.3 Anion exchange chromatography-FPLC 
Purification of the solubilised crystal toxins were performed using AKTA FPLC 
(GE Healthcare). The solubilised protein samples were applied to an anion-
exchange column, Resource Q (Amersham Pharmacia Biotech, UK) at a flow rate 
of 1 ml/min at 4°C in 50 mM sodium carbonate buffer, pH10.5 and were eluted 
with an increasing linear gradient of 1 M sodium chloride. 1 ml fractions were 
collected and analysed on SDS-PAGE. 
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2.2.14 Feeding regimens for artificial rearing of Plutella xylostella G-88 
population 
G-88 was maintained on an aseptic artificial Hoffman’s diet at 250C under a 16 h 
photophase. The artificial diet comprised of the following ingredients: 32 g wheat 
germ, 15 g casein, 13 g sucrose, 6.4 g yeast, 4.3 g Wesson’s salt mix, 0.4 g 
cholesterol, 0.4 g methyl paraben and 0.7 g sorbic acid measured and blended 
in 357 ml of boiling sterile distilled water containing 5.4 g agar. The blended 
mixture was then rendered sterile by autoclaving. The autoclaved mix was then 
allowed to cool down to 400C. 0.1 g vanderzant vitamin mixture (Sigma), 2.0 g of 
ascorbic acid and 0.4 g choline chloride aseptically measured and dissolved in 
50ml of sterile distilled water were then added to the above cooled autoclaved 
mix. The diet was supplemented with 1 ml of the antibiotic rifampicin (25 mg/ml 
stock prepared in methanol).  
The diet thus prepared was then dispensed 20 ml each into 50 ml of sterile plastic 
cups and covered with cling film and stored at 40C for further rearing and 
bioassays. 
2.2.15 Toxicity assays 
The toxic activity of the protein samples were evaluated on the insects and 
human cancer cells. 
2.2.15.1 Assay of insecticidal activity 
The toxicity of protein samples to the cabbage pest, Plutella xylostella were 
evaluated using leaf-dip and diet-based bioassays based on the method 
described by Sayyed et al. (2000). 
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2.2.15.1.1 Leaf-dip bioassay 
The protein samples to be assayed for the insecticidal activity were diluted in a 
sterile distilled water-triton (50 μg/ml triton X-100) solution. Chinese cabbage leaf 
discs (were dipped for 10 s into the resulting protein solutions and allowed to air 
dry at ambient temperature for 1-2 hours. The discs were placed in sterile 
petridishes (5 cm diameter) containing filter paper moistened with distilled water. 
Five second-instar larvae were introduced into each disc and incubated at 250C 
for 3 days after which the mortality was assessed. Larvae which failed to exhibit 
any coordinated movement upon prodding with blunt ended sterile forceps, were 
considered dead.  Larvae fed on Leaf discs dipped in just sterile distilled water-
triton (50 μg/ml triton X-100) solution was used as a negative control. Larvae fed 
on Leaf discs dipped in insecticidal Cry1Ac at 3 mg/ml was used as a positive 
control. 
2.2.15.1.2 Diet-based assays 
20 ml of sterile artificial diet were poured aseptically into a 50 ml autoclaved cup 
and allowed to set. The cups were treated with 100 μl of protein samples which 
were surface-spread and allowed to air dry at ambient temperature. Five second-
instar larvae were introduced into each cups and incubated at 250C for 5 days. 
The mortality was assessed after 3 days as well as 5 days. Larvae which failed 
to exhibit any coordinated movement upon prodding with blunt-ended sterile 
forceps, were considered dead. Negative control larvae were fed on diet treated 
with sterile distilled water-triton (50 μg/ml triton X-100) solution. Positive control 
larvae were fed on diet treated with insecticidal Cry1Ac at 1 mg/ml. 
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2.2.15.2 Assay of cytocidal activity 
 
2.2.15.2.1 Dye-exclusion cell viability assay 
In order to measure the percentage of cell suspension that was viable, the dye 
trypan blue (0.4%) was used which stains the dead cells blue and leaves the 
viable cells unstained due to their intact cell membrane which excludes dyes like 
trypan blue, eosin or propidium. The assay was performed in 96 -well flat 
bottomed plate (Costar). 90 µl of cell suspension was dispensed in each well. 5 
x 103 cells of A549 and HepG2 were used. The plate was then incubated at 
37°C/5%CO2 humidified air for 48 hours. After 48 hours incubation, each well 
received 10 µl of treatments which included Control i.e the sodium carbonate 
buffer, protein samples to be tested at a concentration of 1 µg per well and 
Etoposide, a topoisomerase II inhibitor at a concentration of 50 µM. The medium 
in the well was changed and the plate was incubated at 37°C/5%CO2 humidified 
air for 48 hours to check for cytopathic effects. After 48 hours, the media was 
sucked out of the wells by the aid of a sterile Pasteur pipette. The cells were 
trypsinised with 100 µl of trypsin for 5 min at 37°C/5%CO2 humidified air and 
dispensed into the universal flasks containing 100 µl of medium. The flasks were 
then centrifuged at 800 rpm for 5 min. The supernatant was discarded and pellets 
were resuspended in the culture medium and trypan blue (1:1). The cells were 
counted after 1 min using hemacytometer. The dead cells appeared blue. 
Percentage viability was calculated by dividing the total number of viable cells per 
ml of the aliquot by total number of cells per ml of aliquot multiplied by 100. 
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2.2.15.2.2 CellTiter-Blue cell viability assay 
The levels of cytotoxicity of the proteins were assessed by using the CellTIter-
Blue cell viability assay (Promega) to determine the number of viable cells in 
culture. The test methodology for cytotoxicity evaluation was adopted from 
previously published journal papers and manufacturer’s instructions (Ahmed et 
al., 1994; Squatrito et al., 1995; Slaughter et al., 1999; O'Brien et al., 2000; 
Gonzalez & Tarloff, 2001; Promega, 2009). Briefly, serial dilutions of cells were 
made in triplicates. 90 µl of the cells were dispensed in the 96-well flat bottomed 
plate (Costar or nunc). The  various dilutions of the cells used per well were:   1.0 
x 104 , 5 x 103 cells, 2.5 x 103 cells,1.25 x 103 cells, 6.25 x 102 cells. Each 
experimental condition was set-up in triplicate to ensure well-to well consistency 
and for quantitating interwell variability. Cytopathic effects were observed under 
a phase-contrast microscopy. The assay was performed in 96 -well flat bottomed 
plate (black plates from Costar or clear plates from Nunc). 90 µl of cell suspension 
was dispensed in each well. The plate was then incubated at 37°C/5%CO2 
humidified air for 24 hours. After 24 hours incubation, each well received 10 µl of 
treatments. 
After 24 hours of treatment, the wells were incubated with CellTiter-Blue 
(resazurin) reagent (Promega). 20 µl of CellTiter-Blue reagent was added 
aseptically to each well with 100ml of medium. The plates were placed back into 
the incubator. Plates were removed and reading taken after every hour for 1 h, 2 
h and 4 h. 
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Cell cytotoxicity was measured using fluorescence by a fluorescent plate reader 
(GloMax –Multi Microplate Multimode reader from Promega). 
Fluorescence was measured with a green filter with excitation wavelength at 
525nm and emission wavelength ranging between 580-640 nm. Triplicate 
readings were averaged and Fluorescence reading was plotted against the cell 
number plated. Treatment was carried out on various cell lines including HepG2 
and HeLa. 
 
 
 
2.2.15.2.3 CellTiter-Glo luminscent cell viability assay 
 
Cytotoxicity of the proteins was further corroborated by bioluminescent detection 
of ATP using CellTiter-Glo luminscent cell viability kit from Promega. This is 
based on quantitation of ATP which plays an important role in energy exchange 
processes in biological systems and hence serves as a reliable biomarker of cell 
viability (Crouch et al., 1993). The assay was set up according to the 
manufacturer’s instructions. 
Briefly, serial dilutions of cells were made in triplicates. 90 µl of the cells were 
dispensed in the recommended opaque- walled white 96-well flat and clear 
bottomed plate (Costar). The  various dilutions of the cells used per well were:   
1.0 x 104 , 5 x 103 cells, 2.5 x 103 cells,1.25 x 103 cells, 6.25x 102 cells. Each 
experimental condition was set-up in triplicates to ensure well-to-well consistency 
and for quantitating inter-well variability. Cytopathic effects were observed under 
a phase-contrast microscopy. 90 µl of cell suspension was dispensed in each 
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well. The plate was then incubated at 37°C/5%CO2 humidified air for 24 hours. 
After 24 hours incubation, each well received 10 µl of treatments. After 24 hours 
of treatment, the experimental plate was equilibrated at room temperature for 30 
min before adding equal volume of CellTIter- Glo reagent to the volume of cell 
culture medium in each well. The CellTiter-Glo reagent was prepared according 
to the supplier’s instructions. Briefly, the CellTiter-Glo buffer was thawed and 
equilibrated to room temperature prior to use. CellTiter-Glo substrate was 
equilibrated to room temperature prior to use. The thawed buffer was transferred 
to the amber bottle containing the CellTiter-Glo substrate and gently vortexed to 
reconstitute the CellTiter-Glo Reagent. The reagent was then added to the plate 
containing the cell culture medium as discussed above. The contents were mixed 
for 2 min on an orbital shaker to induce cell lysis. The experimental plate was 
further incubated at room temperature for 10 min to stabilise luminescent signal. 
The luminescence was recorded using Promega’s GloMax –Multi Microplate 
Multimode reader. An integration time of 0.5 s per well was used. The 
luminescence measured was plotted against the number of cells in culture. 
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3. In vitro evaluation of anticancer activity against human cancer 
cells, and pathogenicity against an insect pest, of toxins derived 
from native B. thuringiensis strains 
 
3.1 Introduction 
The parasporins studied thus far have been found to possess specific cytotoxicity 
to different cell lines. However, a human hepatocellular carcinoma cell line, 
HepG2 is noted as being susceptible to all the parasporins so far investigated for 
their cytocidal activity (Ohba et al., 2009; Nagamatsu et al., 2010). 
The present work examined two native B. thuringiensis strains isolated from soils 
of Japan and China. The work evaluates the toxic activities of the insecticidal B 
thuringiensis subspecies kurstaki HD-73 and E. coli expressed insecticidal 
Cry1Ac toxin. The toxicity of a crystal free B. thuringiensis strain 4D7 normally 
employed for expression of B. thuringensis cry genes was also investigated.  
It was reported in a previous study in Japan that the B. thuringiensis strain A1462 
(previously designated as 89-T-26-17) exhibits preferential activity against 
human cancer cells upon proteolytic activation (Yamashita et al., 2000). The 
strain transferred to us for further investigation. This work explores the proteins 
of the native strain A1462 from Japan, tests the cytotoxic activity of the native 
strain and further characterises the gene involved in the cytocidal activity. 
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We intended to investigate if the cytotoxic activity towards mammalian cells is 
explicit to the parasporins or whether it is also present in the insecticidal Cry 
proteins. This would also provide a valuable asset to the risk assessment on 
fauna of food derived from crops in which B. thuringiensis Cry toxins have been 
used either as crude microbial preparations or genetically engineered in plants.  
It has been reported that the parasporin-3 toxin exhibited strong cytocidal activity 
against the liver cancer cell line (HepG2) and no toxicities against several other 
cancer cell lines for instance A549 (lung carcinoma). Hence we aimed to further 
clarify if the cell killing activity is attributed to the sensitivity of the cell lines used 
or if it is a specific toxin-mediated action. 
The present work further examines the toxicity of a soil isolate from China Sbt021, 
sequencing of which had identified a putative candidate toxin gene homologous 
and similar to the one present in B. thuringiensis strain A1462. The objective was 
to study the biological activity of the native strain Sbt021 against insect crop pests 
and human cancer cell lines and to characterise the genes encoding the toxin 
proteins. Cell viability assays and bioassays were conducted to assess the 
toxicity of the proteins derived from B. thuringiensis native strains. 
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3.2 Results 
 
3.2.1 Preparation of inclusion proteins from the native strains, 
solubilisation, proteolytic processing and activation of the toxins 
 
The soil isolates of Bacillus thuringiensis A1462 from Japan, Sbt021 from China, 
wild type HD73 and acrystalliferous 4D7 strains were colony purified several 
times before use. The strains were grown on sterile nutrient agar plates at 30°C 
for 4 days. Sporulation was checked under the microscope and the sporulated 
cells were harvested as described in Section 2.2.9.3. The proteins were analysed 
on a 7.5% SDS-PAGE gel. E. coli expressed recombinant insecticidal Cry1Ac 
protoxin at 4 mg/ml previously prepared in the lab was used for assays. 
Parasporal inclusions of the strain B. thuringiensis  A1462 contained protein 
bands of sizes 180, 150, 100, 90 and 80 kDa (Figure 3.1) as previously reported  
(Yamashita et al., 2005). Sbt021 inclusions contained a major protein band at 
140 kDa and a minor band at 80 kDa (Figure 3.2). Btk HD-73 yielded a major 
protein band of 130 kDa (Figure 3.2). As expected the SDS-profile of crystal free 
strain 4D7 did not show any protein bands (data not shown).   
Various buffers at different pH were used to solubilise the proteins as described 
in Section 2.2.12. The proteins were also subjected to trypsin treatment as 
described in Section 2.2.12. These assays were carried out in a reducing 
environment or a non-reducing one (data not shown). The solubilisation assays 
suggested that 50 mM carbonate buffer at pH 10.9 optimally solubilised the 80 
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kDa protein from A1462 strain in the presence of 1 mM DTT. The 80 kDa protein 
was detected in the supernatant (Lane 3, Figure 3.1). The other proteins of higher 
molecular mass were either not solubilised or were degraded. Trypsin in 
presence of 1 mM DTT resulted in the partial digestion of the protein bands of the 
native strain A1462 generating a band slightly lower than 80 kDa and a band of 
circa 60 kDa (Figure 3.1, lane 2). Solubilisation of protein inclusions from Sbt021 
in the presence of DTT resulted in obtaining the major band of 140 kDa and minor 
band of 80 kDa in the soluble fraction (Figure 3.3, lane 1). Trypsin treatment in 
the presence of DTT yielded multiple protein bands of varying molecular masses 
(Figure 3.3, lane 2). The trypsin digestion of protein inclusions from HD-73 yielded 
two bands of circa 58 kDa (Figure 3.4). No protein bands were observed in case 
of crystal free 4D7 which was used as a negative control (data not shown). 
The solubilised and the trypsin treated samples containing DTT were dialysed 
against 50 mM carbonate buffer pH 10.9 (Section 2.2.13.2). The Bradford method 
was employed to estimate the concentration of the protein samples with BSA as 
the standard (Section 2.2.11). The dialysed samples were frozen at -20 °C for 
further cell assays. 
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Figure 3.1. Protein analysis of the B. thuringiensis isolate A1462. Lane1, protein 
inclusions from the strain A1462; lane 2, protein treated with trypsin (1 mg/ml); lane 3, 
solubilised protein in sodium carbonate buffer, pH 10.9; lane M, protein marker. 
Solubilisation and trypsin treatment were carried out in presence of 1 mM DTT. 
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Figure 3.2. SDS-PAGE profile of B. thuringiensis native strains Sbt021 and HD-73. 
Lanes 1-5, Various dilutions of Sbt021 protein inclusions; lane M, protein marker; lanes 
6-9, Various dilutions of HD-73 protein inclusions. 5, 4, 3, 2 and 1μl of the protein samples 
were run on the gel. The samples were diluted with sterile distilled water to make up to 
a total volume of 5 μl. 
 
                                                                      
Figure 3.3. Solubilisation and proteolytic processing of protein inclusions from 
Sbt021.The sample was solubilised in 50 mM carbonate buffer, pH 10.9 (Lane 1) and 
treated with 1 mg/ml trypsin in presence of 5 mM DTT (Lane 2). Lane M represents 
protein marker. 
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Figure 3.4. Proteolytic processing of Btk HD-73. 1 mg/ml trypsin with 5 mM DTT was 
used to activate the δ-endotoxin (Lane 1); protein marker (Lane M). 
3.2.2 Activation and purification of recombinant Cry1Ac toxin 
Recombinant Cry1Ac protoxin was activated using trypsin (1 mg/ml). A 65 kDa 
band was observed on the gel (Figure 3.5). AKTA FPLC was used for purifying 
the activated toxin fragment. The fractions were analysed on 7.5% SDS-PAGE. 
The activated protein was present in fractions A 8, A9, A10, A11 and A12 as 
evident from the SDS-PAGE gel (Figure 3.7). 
 
 
                           
Figure 3.5. Solubilisation and proteolytic processing of the recombinant 
insecticidal Cry1Ac toxin. A. Lane1, recombinant Cry1Ac toxin. B. Lane M, protein 
marker; lane 2, solubilised Cry1Ac toxin; lane 3, proteolytically processed Cry1Ac toxin.  
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Figure 3.6. Purification of activated insecticidal Cry1Ac protein. Elution profile of 
activated toxin on anion exchange chromatography. 
 
 
Figure 3.7. SDS-PAGE (7.5%) analysis of purified fractions of activated Cry1Ac 
protein. Lanes A8-A12 contain the purified activated Cry1Ac toxin. Lane U contains the 
un-purified trypsin activated Cry1Ac toxin. 
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3.2.3 Toxicity evaluation of B. thuringiensis proteins 
 
3.2.3.1 Assessment of insecticidal activity 
 
Toxicity was tested against Cry1Ac susceptible G88 populations of Plutella 
xylostella using leaf-dip and diet based assays as described in Section 2.2.15.1. 
No mortality was observed in the case of G88 populations treated with solubilised 
or trypsin treated A1462 or Sbt021 protein inclusions even at high concentrations 
of 0.5 mg/ml. Whereas, the insecticidal Cry1Ac and HD-73 solubilised crystals 
caused high larval mortality when used at concentration of 1-2 μg/ml. 
 
 
3.2.3.2 In vitro cytocidal activity  
 
The solubilised and the trypsin activated proteins were tested on human cancer 
cell lines, HepG2 and HeLa. Serial dilutions of cells were made in triplicate. 90 µl 
of the cells were dispensed in a 96-well flat bottomed plate (Nunc or Costar). The  
various dilutions of the cells used per well were: 1.0 x 104 , 5 x 103 cells, 2.5 x 103 
cells,1.25 x 103 cells and 6.25 x 102 cells. Cytopathic effects were observed with 
an inverted phase-contrast microscope. The degree of cytotoxicity was assessed 
using cell viability assay techniques (CellTiter-Blue and CellTiter-Glo luminescent 
cell viability assays) as described in Sections 2.2.15.2.2 and 2.2.15.2.3.  
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Trypsin- treated B. thuringiensis acrystalliferous strains 4D7, HD-73 and purified 
trypsin-treated recombinant Cy1Ac did not elicit any morphological changes in 
HepG2 cells or HeLa cells as observed under the inverted phase contrast 
microscope (data not shown). No cytotocidal activity was observed upon 
treatment with these proteins as evidenced by cell viability assays. However, 
trypsin- treated A1462 protein caused marked morphological changes in HepG2 
cells when used at a concentration of <10 μg/ml. The treatment resulted in 
spillage of the intracellular contents into the extracellular milieu. HeLa cells 
however did not exhibit any detectable morphological changes upon incubation 
with the same concentration of trypsin-treated A1462 protein (data not shown). 
Figure 3.8 shows the cell viability curves obtained for trypsin-treated Bt strain 4D7 
and trypsin-treated A1462 strain in HepG2 cells with CellTiter-Blue assay. No 
cell-killing activity was observed when HepG2 cells were treated with the negative 
control, trypsin-treated 4D7. The trypsin-treated protein from B. thuringiensis 
strain A1462 induced cytotoxicity in HepG2 cells. The positive control, etoposide 
brought about significant cell-killing when used at a final concentration of 100 
μg/ml. The cytotoxicity of trypsin-treated A1462 against HepG2 cells was further 
corroborated using CellTiter-Glo (Promega) (Section 2.2.15.2.3), the results of 
which obtained are shown in Figure 3.9. The results further substantiated that 
trypsin-treated A1462 is significantly cytotoxic to HepG2 cells. No cell-killing 
activity was observed when HepG2 and HeLa cells were administered with the 
trypsin-treated HD-73 used at a final concentration of 10 μg/ml. HD-73 did not 
affect viability of HepG2 cells (Figure 3.9). Figure 3.10 shows the cell viability of 
the Bt proteins on A) HepG2 cells B) HeLa cells as measured by CellTiter- Blue 
assay. The purified trypsin-treated recombinant Cry1Ac toxin did not affect the 
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cell viabilities in case of HepG2 (Figure 3.10A) and HeLa cells (Figure 3.10B). 
The trypsin-treated protein from B. thuringiensis strain A1462 induced cytotoxicity 
in HepG2 cells affecting the cell viability  (Figures 3.10A) but failed to exhibit a 
comparable cytotoxicity against HeLa cells as seen by the CellTiter-blue assay 
when used at the same concentration of 50 μg/ml (Figure 3.10B). Trypsin-treated 
Sbt021 exhibited cytocidal activity against HepG2 as indicated by the CellTiter-
blue assay. A comparison with trypsin-treated A1462 suggested that the degree 
of susceptibility of HepG2 cells to trypsin- treated Sbt021 is weak (Figure 3.10A). 
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Figure 3.8. Effect of Bt proteins on viability of HepG2 cells. X-axis represents the 
cell number and Y- axis represents Relative Fluorescence Unit (RFU). Fluorescence was 
measured using a green filter with an excitation wavelength at 525 nm and emission 
wavelength 580-640 nm. Error bars denote SD of the mean of triplicate wells. 
Experiments are representative of at least five independent assays with each treatment. 
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Effect of Bt proteins on HepG2 cells: CellTiter-Glo assay 
 
Figure 3.9. Effect of trypsin-treated A1462 and HD-73 on HepG2 cells: CellTiter-Glo 
Assay. Cytotoxicity of trypsin treated Bt A1462 was further corroborated by 
bioluminescent detection of ATP. X-axis represents the cell number and Y- axis 
represents Relative Luminescence Unit (RLU). Error bars denote SD for the data derived 
from the individual wells (triplicates). An integration time of 0.5 s was used. Experiments 
are representative of at least three independent assays with each treatment. 
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A.  Effect of Bt proteins on HepG2 cells: 2h incubation with CellTiter- Blue  
  
B. Effect of Bt proteins on HeLa cells: 2h incubation with CellTiter- Blue  
 
Figure 3.10. Effect of Bt proteins on (A) HepG2 (B) HeLa cells. X-axis represents the 
cell number and Y-axis represents Relative Fluorescence Unit (RFU). Data presented 
here is for 5000 cells/well. Error bars denote SD of the mean of triplicate wells. 
Experiments are representative of at least five independent assays with each treatment. 
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Dose response studies were conducted to assess if the proteins exhibited dose-
dependent cytotoxicity. Figure 3.11 shows the concentration-response graphs 
obtained for the trypsin-treated A1462 samples on HepG2 cells with CellTiter-
Blue assay. Serial dilutions of trypsin-treated inclusion proteins were prepared in 
50 mm sodium carbonate buffer pH 10.9 and administered to HepG2 cells. The 
cytotoxicity was monitored with CellTiter -Blue as described earlier (Section 
2.2.15.2.2). Maximal cell killing activity was obtained with the undiluted highest 
concentration of the trypsin- treated proteins. Progressive decrease in cell-killing 
activity was observed with decreasing concentration. Similar results were seen 
with trypsin-treated Sbt021 (data not shown). 
Dose-response effect of trypsin-treated A1462 protein on HepG2 cells: 2h 
incubation with CellTiter- Blue 
 
Figure 3.11. CellTiter-Blue assay indicating a dose-response analysis of trypsin- 
treated A1462 on viability of HepG2 cells. Y-axis represents Relative Fluorescence 
Unit (RFU). Data presented here is for 5000 cells/well. Error bars denote SD of the mean 
of triplicate wells. Experiments are representative of at least three independent assays 
with each treatment. 
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3.3 Discussion 
 
An initial screen of B. thuringiensis wild type strains for in vitro cytotoxic activity 
ascertained that some of the B. thuringiensis strains possess activity against 
human cancer cells. The present studies confirmed that some of the B. 
thuringiensis inclusion proteins possess cytocidal activity against human 
carcinoma cell lines. The results confirm that the B. thuringiensis wild type  strain 
A1462 from Japan demonstrates cytotoxic activity against human cancer cells as 
reported earlier  (Yamashita et al., 2005). Limited cytotoxic activity was also seen 
for the native strain Sbt021 from China. The soils isolate A1462 exhibited 
cytotoxicity against human liver cancer cells (HepG2) whereas no such 
comparable cytotoxic activity was demonstrated against human cervical cancer 
(HeLa) cells. The data thus suggests varying preferential susceptibility of certain 
human cancer cell lines to the B. thuringiensis protein. HepG2 was weakly 
susceptible to the trypsin-treated proteins from Sbt021. No cytotoxicity was 
detected in case of the Lepidopteran insecticidal HD-73 strain and insecticidal 
Cry1Ac protein. The B. thuringiensis strain 4D7 did not exhibit any cytocidal 
activity.  
 
Solubilised non-proteolytically treated proteins of A1462 or Sbt021 retained very 
low levels of cytotoxicity against HepG2 cells, this low level possibly owing to the 
proteolysis products generated by the action of endogenous protease. This is in 
agreement with the low-level of cytotoxicity observed by Lee et al. (2000a) 
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against MOLT-4 cells by alkali-solubilised parasporin-4 producing 89-T-34-22 
strains. The proteins from the B. thuringiensis isolates A1462 and Sbt021 
exhibited significant in vitro cytotoxicity to HepG2 cells only when treated with 
trypsin. This result can account for previously reported several findings that 
trypsinisation results in the cytocidal activity of B. thuringiensis parasporins. For 
instance Mizuki et al. (2000) observed that proteolytic processing is indispensable 
for imparting cytocidal properties to the Bt isolate 84-HS-1-11 that produces 
Cry31Aa1, an 81 kDa protein demonstrating preferential activity against leukemic 
cells. Similarly, Katayama et al. (2005) observed that parasporin-1 produced by 
the strain A1190 exhibits toxicity when cleaved by trypsin at two sites generating 
a heterodimer of 15 and 56 kDa subunits. Further, A1547 which is a parasporin-
2 producer exhibits no cytotoxicity without protease digestion (Ito et al., 2004). 
The parasporin-4 toxin from B. thuringiensis strain 89-T-34-22 exhibited high 
cytotoxic activity against MOLT-4 cells only upon protease treatment (Lee et al., 
2000a).  
 
The cytotoxic activity thus exhibited by the inclusion proteins is selectively 
affecting certain types of cancer cell lines. This is in agreement with other studies 
that have showed cytotoxic activity associated with some B. thuringiensis strains. 
The preferential cell–killing activity of the parasporins from B. thuringiensis strains 
is similar to that demonstrated by the insecticidal Cry proteins of B. thuringiensis 
which recognise specific receptors on the susceptible insect cells. This renders 
them active against specific insect pests (Schnepf et al., 1998). 
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SDS-PAGE profiles of B. thuringiensis A1462 inclusions contained protein bands 
with molecular weight ranging from 180 to 80 kDa. This concurs with the previous 
study (Yamashita et al., 2005). Alkali solubilisation resulted in the obtaining of an 
80 kDa band in the soluble fraction. The higher molecular mass proteins were 
either degraded or traces of them remained insoluble. Similar results were 
obtained by Kim et al. (2000) whilst investigating the cytotoxic properties of the 
wild type strain 90-F-45-14 which consisted of five major protein bands of 
molecular masses 170, 103, 73, 40 and 32 kDa. Upon alkali solubilisation of the 
inclusion, the higher molecular mass proteins of 170, 103 and 73 kDa could not 
be recovered possibly subjected to proteolytic degradation by the endogenous 
protease (Kim et al., 2000).  
 
As opposed to the indiscriminate toxicity demonstrated by B. thuringiensis 
serovar israelensis owing to a broad-spectrum cytolysin, the Cyt1 toxin (Thomas 
& Ellar, 1983a; Mizuki et al., 1999), protein inclusions from the A1462 strain 
exhibit a selective activity against certain human cancer cell lines (Yamashita et 
al., 2000). There have been reports of the B. thuringiensis isolates being able to 
discriminate normal T cells from the leukaemic ones (Mizuki et al., 2000; 
Okumura et al., 2005). 
 
It was observed with other B. thuringiensis native strains that the alkali-solubilised 
inclusions possess no cytotoxic activity. Proteolytic treatment of the inclusions 
resulted in the degradation of the protein to a lower molecular mass band which 
exhibited cytocidal activity against cancer cell lines (Mizuki et al., 1999; Lee et 
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al., 2000a; Ito et al., 2004; Yamashita et al., 2005). Our results suggested that 
the trypsin-treated A1462 demonstrated significant cytotoxic activity against 
HepG2. The solubilised A1462 lacks such significant activity thus further 
corroborating that proteolytic processing is indispensable for a significant 
cytotoxic activity. 
 
Our results coupled with previous observations prompted us to further delve into 
characterisation of the protein inclusions cytotoxic to mammalian cell lines in 
order to assess the risk associated with the B. thuringiensis toxins being used in 
agriculture. Risk assessment being the vital aspect, it would also enable us to 
assess their suitability for clinical and diagnostic purposes. 
In the next few chapters we aimed at analysing and determining the virulence 
factors that contribute to in vitro cytotoxicity observed in some of the B. 
thuringiensis strains. 
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4. Heterologous expression and characterisation of Parasporin-
3 (cry41A) genes 
 
4.1 Introduction 
Cry41Aa and Cry41Ab parasporal inclusion proteins derived from non-
insecticidal  Bacillus thuringiensis strain A1462 have been reported to possess 
preferential cytotoxicity towards human cancer cell lines (Yamashita et al., 2005). 
These cytotoxic proteins belong to the parasporin-3 family. Amino acid analysis 
of the Cry41Aa and Cry41Ab responsible for the reported cytocidal activity of 
A1462 revealed only slight differences in their sequences thus showing a high 
degree of similarity. 
 
Cry41Aa and Cry41Ab are ‘split’ toxins found as the second gene i.e. ORF2 in a 
three-gene operon. Sequence analysis of cry41Aa and cry41Ab genes detected 
three open reading frames in close proximity to each other and in the same 
orientation. Analysis of the ORFs of this operon shows that the upstream region 
of all the ORFs contained the putative translational signals, ribosome binding 
sites. The parasporin-3 cry41Aa1 gene is found as part of a three-gene operon 
in which nonoverlapping reading frames are separated by short intergenic 
sequences. ORF1 consists of 543 base pairs encoding 180 amino acid residues 
with a predicted molecular weight of 19.5kDa. ORF1 has no conserved domains 
or blocks. ORF2 consists of 2478 base pairs encoding 825 amino acid residues 
with predicted molecular weight of 95.7 kDa. ORF2 contains the five conserved 
blocks found in many of the three-domain insecticidal Cry1A-type toxins. ORF2 
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is further characterised by the presence of tandem repeats of QXW/F motif in the 
conserved ricin domain. The ricin domain contained at the end of ORF2 is 
comprised of 110 amino acid residues. ORF3 consists of 2214 base pairs 
encoding 737 amino acid residues with a predicted molecular weight of 82 kDa. 
ORF3 possesses the conserved blocks 6, 7 and 8 of the larger Cry toxins (Figure 
4.1). 
Cry41Ab possess a similar gene organisation to Cry41Aa. ORF1 of Cry41Ab 
consists of 543 base pairs encoding for 180 amino acid residues depicting a high 
degree of percentage identity of 87.2% with ORF1 of Cry41Aa. ORF2 of Cry41Ab 
possesses 820 residues encoded by 2490 base pairs, showing a high degree of 
percentage identity of 82.7% with Cry41Aa ORF2. 735 residues of Cry41Ab 
ORF3 as well as 737 residues of Cry41Aa ORF3 shared a greater degree of 
percentage identity of 99.3% with the three conserved boxes 6, 7 and block 8 of 
insecticidal Cry1Ac. 
 
Conserved domain analysis in the protein sequences of ORF2 Cry41Aa and 
Cry41Ab by Conserved Domain (CD) search, NCBI (Marchler-Bauer & Bryant, 
2004; Marchler-Bauer et al., 2009; Marchler-Bauer et al., 2011) identified the 
presence of ricin-like lectin domains [cd00161; pfam 00652] in their carboxy 
termini, referred to as ricin domain (RD) in this and subsequent chapters. The  
amino acid sequence of  Cry41Aa and Cry41Ab contained multiple short 
consensus of “Gly -X-X-X-Gln -X- Trp/Phe ” possessing the signature Q-X-W/F 
motifs (underlined in Figure 4.2) which form the defining characteristics of a 
member of the “Ricin Superfamily” (Hirabayashi et al., 1998). No function of this 
domain has yet been established in parasporins.  
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Figure 4.1. Diagrammatic representation of the domains of Cry41A (parasporin-3) 
and insecticidal Cry1. RD (red box) denotes the ricin-like domain at the end of ORF2 
which most closely resembles that from HA-33 from Clostridium botulinum. 
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                              α1                  α2a                     α2b 
                          .:  *:.::.:***  .* **.. *::. : *:: *:     *:**:  :* **** 
     
Cry41Aa(PS3)          KLDEYARSKAISELNGLKNVLELYQDAADDWNENPGDLRNKNRVLTEFRNVNGHFENSMP 180 
Cry1Ac                RIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNPALREEMRIQFNDMNSALTTAIP 146 
                                    α3                           α4 
                      :::*:**.:***.*:**.*: ::* ::  :*: :* :   ::.:  :*.::*. : .::* 
                                      
                                  BLOCK1 
Cry41Aa(PS3)          SFAVRNFEVNLLPVYAEAANLHLLLLRDAVKFGEGWGMSTDPGAERDDMYRRLRSRTEIY 240 
Cry1Ac                LFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDAATINSR---YNDLTRLIGNY 203 
                                 α5                            α6 
                       ***:*::* **.**.:****** :***.  **: **:.: .  .*   *. *      * 
                                                                      
Cry41Aa(PS3)          TDHCVNTYNQGLQQAKSLQANVSDYSRYPWTQYNQSGGFSYREAKGEYRGTENWNLYNAF 300 
Cry1Ac                TDYAVRWYNTGLERVWGPDS-------------------------------RDWVRYNQF 232 
                                                                              α7 
                      **:.*. ** **::. . ::                               .:*  ** * 
                                 BLOCK2                                       
Cry41Aa(PS3)          RRDMTILVLDIIAQFPTYDPGLYSRPVKSELTREVYTDIRGTTWRSDANLNTIDAIENRM 360 
Cry1Ac                RRELTLTVLDIVALFPNYDSRRYPIRTVSQLTREIYTNPVLENFDGSFRG-SAQGIERSI 291 
                                               β1a     β1b   α8a            α8 
                      **::*: ****:* **.**.  *.  . *:****:**:    .: .. .  : :.**. : 
                                                                             
Cry41Aa(PS3)          VGSRQLQLFTWLTEMKFYIRNTGSITSYTHGDLMVGLEKKIRKTNDNDQWLPLEGQNTSY 420 
Cry1Ac                RSPHLMDILNSITIYTDAHRGYYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIV 351 
                                 β2        β3r     β3           β4               β5 
                       ..: ::::. :*  .   *.    :.:      **:.    .    .       *:    
 
Cry41Aa(PS3)          TRIDRPGIELGKNYWYYARTQQWFETRLLQLWANTDVLSLNAGTVGNEFWVRDVPDYRNI 480 
Cry1Ac                AQLGQGVYRTLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLD 411 
                                β6                β7r     β7         β8      β9 
                      :::.:   .  ..  *    :  ::.: *.:  .*:.   .:..: . .: :. .      
                                                                    BLOCK3 
Cry41Aa(PS3)          YARSTRNHFIENHRLSWIKFEPVRDNCPFAWPGYKQLSALLFGWTHNSVDLNNIISQYRI 540 
Cry1Ac                EIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSI 471 
Conserved blocks 
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                                           β10              β11           β12 
                         . .*:.  .: :*    .    .. *: .. . : * :*.* *.*.::****:.  * 
 
Cry41Aa(PS3)          TQIPAVKAYWNRGAFSVIRGPGSTGGNLVQLGTGG-------EVSVKVRPEQTGSDWYRV 593 
Cry1Ac                TQIPAVKGNFLFNG-SVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPST-STRYRV 529 
                      β13            β14          β15       β16 
                      *******. :  .. *** *** ***:**:*.:.*        :.* ::  .* *  *** 
                       BLOCK4 
Cry41Aa(PS3)          RIRYAAGSRGRLNVKKYVSSIHASVTYDYNMTMSSSTQGTYNSFQYLDVYNFRLAEPEFE 653 
Cry1Ac                RVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFESANAFTSSLGNIVGV 589 
                       β17     β18       β19                 β20    β21     β22 
                      *:***: :  :***:   ***.:...     ::..  .. :. *:  :.:.  *.:     
                                  BLOCK5 
Cry41Aa(PS3)          VWLTNESGGPIWIDKIEFIPLSPIPELPVYPGTYQIVTALNNSSVVTSEEFCMGIGLTTR 713 
Cry1Ac                RNFSGTAG--VIIDRFEFIPVTATLEA--------------------------------- 614 
                                 β23 
                        ::. :*  : **::****::.  *                                   
                                         HA-33 OR RICIN –LIKE DOMAIN 
Cry41Aa(PS3)          CGVNLWSNNGNTLQKWRFVYNGDQNAFQIKSTPNEDLVLSGSNSGTSVTAETNQNRPNQY 773 
Cry1Ac                ------------------------------------------------------------ 
                                                                                   
 
Cry41Aa(PS3)          WLIEEAGNGYVYLRSKGNPNLVLDVAGTSTANGTNIILWNYNGSTNQKFKLS-------- 832 
Cry1Ac                ------------------------------------------------------------ 
                                                                                                                                                                                            
 
 
 
BLOCK6 
Cry41Aa(PS3)          ------------------MNYNVTKAREAVQALFSNPTTLQLK--VTDHHVNQVARLVEC 888 
Cry1Ac                -------------------EYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTY 655 
                                         :**: :*::**:***:... * **  ***:*::**:.**   
 
Cry41Aa(PS3)          IADQIHPKEKMCLLDQVKLAKRLSRERNLLNYGDFESSDWVGTDGWNVSTNVYTVADNPI 948 
Cry1Ac                LSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDV 715 
                      ::*::  .**  * ::** ***** *****: .:*:. :     **. **.:   ..: : 
                                                    BLOCK7 
Cry41Aa(PS3)          FKDHYLNMPSANNPILSDKIFPTYAYQKVEESRLKPYTRYIVRGFVGSSKDLEILVARYD 1008 
Cry1Ac                FKENYVTLSGT-----FDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYLIRYN 770 
                      **::*:.:..:      *: :*** ***::**:**.:*** :**:: .*:**** : **: 
 
Cry41Aa(PS3)          KEVHKRMNVPNDIIPTSPCTGEPVSQPTPYPVMPSNTMPQDMWCNPCGNGYQTAAGMMVQ 1068 
Cry1Ac                -AKHETVNVPGTGSLWPLSAQSPIGKCG----EPNRCAPHLEWN--------PDLDCSCR 817 
                         *: :***.     . .: .*:.:       *..  *:  *         .  .   : 
                                          BLOCK8 
Cry41Aa(PS3)          STGMMCQDPHEFKFHIDIGELDMERNLGIWIGFKVGTTEGMATLDNIEVVEVGPLTGDAL 1128 
Cry1Ac                DGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEAL 877 
                      .    .:..*.*.:.**:*  *::.:**:*: **: * :* * *.*:*.:*  **.*:** 
 
Cry41Aa(PS3)          TRMQKRETKWKQKLTEKRMKIEKAVQIARDAIQTLFTCPNQSCLQSAITLQNILRAEKLV 1188 
Cry1Ac                ARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRV 937 
                      :*::: *.**::*  : . : : . : *::::::**. .: . **:  .:  *  *:* * 
 
Cry41Aa(PS3)          QKIPYVYNQFLQGVLSAVPGEAYAYDIFQQLSDAVATARALYNQRNVLNNGDFSAGLSNW 1248 
Cry1Ac                HSIREAYLPELS-VIPGVN-----AAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCW 991 
                      :.*  .*   *. *:..*        **::*.. : ** :**: ***::****. *** * 
 
Cry41Aa(PS3)          NGTEGADVQQIGN-ASVLVISDWSASLSQHVYVKPEHSYLLRVTARKEGSGEGYVTISDG 1307 
Cry1Ac                NVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHE- 1050 
                      * .  .**:: .*  ****:.:*.*.:**.* * * :.*:***** *** *** *** :  
 
Cry41Aa(PS3)          TEENTETLKFMVGEETTGATMSTIRSNIRERYNERNMATPDPDAYGGTNGYASNQNMVNY 1367 
Cry1Ac                IENNTDELKFSNCVEEEIYPNNTVT----------------------------------- 1075 
                       *:**: ***    *    . .*:                                     
 
Cry41Aa(PS3)          SSENYGMSAHSGNNNMNYQSESFGSKPYGDGNSMINGSSNNYEANGYPGNNNINDQSENY 1427 
Cry1Ac                --------------------------------------CNDYTVN-----------QEEY 1086 
                                                            .*:* .*           .*:* 
 
Cry41Aa(PS3)          GANAYSSNNMNYQSESSGFTPYGDENNMTNYPSNNYEMNPYSSDMNMSMNRGSDCGCGCS 1487 
Cry1Ac                GG-AYTSRNRGYNEAPSVPADYASVYEEKSYTDGRREN-------PCEFNRG-------- 1130 
                      *. **:*.* .*:. .*  : *..  : ..*.... *          .:***         
 
Cry41Aa(PS3)          ANAYPGGNMMMNNYSSSTYEMNTYPSSTNMTNHQGMGCGCHYSTNEYPMIEENIPDFSGY 1547 
Cry1Ac                -------------------------------------------------YRDYTPLPVGY 1141 
 
                                                                        .:  *   ** 
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Cry41Aa(PS3)          VTKTVEIFPETNRVCIEIGETAGTFMVESIELIRMDCE 1585 
Cry1Ac                VTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE- 1178 
 
                      *** :* ****::* *****  ***:*:*:**: *: 
 
Figure 4.2.  ClustalW multiple sequence alignments of parasporin Cry41Aa and 
insecticidal Cry1Ac. Conserved blocks of Cry41Aa are highlighted in green and those 
of Cry1Ac are highlighted in yellow. The ricin domain (RD) of Cry41Aa is highlighted in 
pink. The signature Q-X-W/F motifs in the RD are underlined. Amino acid residues of 
Cry1Ac in bold red letters represent the α-helices of domain I (α1-7) and domain II (α8a 
and 8) and those in light blue letters represent the β-strands of domain II (β1a-β11) and 
domain III (β12-23). These secondary elements are mentioned under the alignment. In 
order to predict the secondary structure elements, Cry1Ac was aligned with homologous 
Cry1Aa whose three-dimensional structure has been resolved by x-ray crystallography 
(Appendix 1). 
 
The prediction of secondary structure was facilitated using Jpred server 
(http://www.compbio.dundee.ac.uk/www-jpred/) in conjunction with the alignment 
program, Clustal W (Figure 4.3). Clustal W, revealed a few differences between 
the parasporin-3 and insecticidal Cry1Ac (Figure 4.3), the notable ones being the 
ricin domain, a 31 amino acid long region forming a loop like configuration 
preceding the predicted α-7 helix  in Domain II from residues 261-291 in Cry41Aa 
and the differences at the C-terminus. Domain II loops have been well 
characterised in various Cry toxins including Cry3A, Cry1C and Cry1Ab (Figure 
4.4). Three apical loops in Domain II of insecticidal Cry1 toxins have been 
implicated in receptor binding thus affecting toxicity. These three loops involved 
in receptor binding in insecticidal Cry vary considerably in length, sequence and 
confirmation (Schnepf et al., 1998; Pigott & Ellar, 2007). The predicted tertiary 
structures of Cry41Aa and Cry1Ac were compared using Swiss Model, a protein 
homology-modelling server (Guex & Peitsch, 1997; Schwede et al., 2003; Arnold 
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et al., 2006). The PDB file for Cry41Aa was compiled by the Swiss Model program 
based on the known structure of Cry1Aa (PDB code: 1ciy). Residues between 61 
and 675 were modelled. The PDB file for Cry1Ac was also generated based upon 
the known structure of Cry1Aa (PDB code: 1ciy). Modelled residues were in the 
34-611 range (Figure 4.5 and 4.6). The predicted three-dimensional structures of 
Cry1Ac and Cry41Aa were also visualised using FirstGlance in Jmol by uploading 
the PDB co-ordinate files generated by Swiss Model. No apparent equivalent of 
residues 261-291 in Cry41Aa is present in Cry1Ac. Note that the 31 residue insert 
cannot be accurately predicted by Swiss Model. 
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Cry41Aa(PS3)          MNQNCNNNGYEVLNSGKGYCQPRYPFAQAPGSELQNMGYKEWMNMCTSGDPTVLGEGYSA 60 
Cry1Ac                MDNNPNINECIPYN------------------------------CLSNPEVEVLGGERIE 30 
                      *::* * *     *                                :. :  ***      
Cry41Aa(jpred)        --------------------------------H--------------------------- 
Cry1Ac(jpred)         --------------###############################-------------EEE 
 
Cry41Aa(PS3)          DVRDAVITSINIASYLLSVPFPPAGVAAGILGALLGLLWPTNTQAVWEAFMNTVEALINQ 120 
Cry1Ac                TGYTPIDISLSLTQFLLSEFVPGAGFVLGLVDIIWGIFGPS----QWDAFLVQIEQLINQ 86 
                          .:  *:.::.:***  .* **.. *::. : *:: *:     *:**:  :* **** 
 
Cry41Aa(jpred)        HHHHHHHHHHHHHHHHHHH-HHHHHHHHHHHHHHHHH------HHHHHHHHHHHHHHHHH 
Cry1Ac(jpred)         --HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH--------####HHHHHHHHHHHHHHH 
 
Cry41Aa(PS3)          KLDEYARSKAISELNGLKNVLELYQDAADDWNENPGDLRNKNRVLTEFRNVNGHFENSMP 180 
Cry1Ac                RIEEFARNQAISRLEGLSNLYQIYAESFREWEADPTNPALREEMRIQFNDMNSALTTAIP 146 
                      :::*:**.:***.*:**.*: ::* ::  :*: :* :   ::.:  :*.::*. : .::* 
 
Cry41Aa(jpred)        HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-----HHHHHHHHHHHHHHHHHHHHHHH 
Cry1Ac(jpred)         HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH------HHHHHHHHHHHHHHHHHHHHHH 
 
                                 BLOCK 1 
Cry41Aa(PS3)          SFAVRNFEVNLLPVYAEAANLHLLLLRDAVKFGEGWGMSTDPGAERDDMYRRLRSRTEIY 240 
Cry1Ac                LFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQRWGFDAATINSR---YNDLTRLIGNY 203 
                       ***:*::* **.**.:****** :***.  **: **:.: .  .*   *. *      * 
 
Cry41Aa(jpred)        HH---------HHHHHHHHHHHHHHHHHHHHHHH------------HHHHHHHHHHHHHH 
Cry1Ac(jpred)         H----------HHHHHHHHHHHHHHHHHHHHHHHH-----HHHHHH###HHHHHHHHHHH 
 
 
Cry41Aa(PS3)          TDHCVNTYNQGLQQAKSLQANVSDYSRYPWTQYNQSGGFSYREAKGEYRGTENWNLYNAF 300 
Cry1Ac                TDYAVRWYNTGLERVWGPDS-------------------------------RDWVRYNQF 232 
                      **:.*. ** **::. . ::                               .:*  ** * 
 
Cry41Aa(jpred)        HHHHHHHHHHHHHHHH------------------------------------HHHHHHHH 
Cry1Ac(jpred)         HHHHHHHHHHHHH-------###############################HHHHHHHHH 
 
                           BLOCK 2 
Cry41Aa(PS3)          RRDMTILVLDIIAQFPTYDPGLYSRPVKSELTREVYTDIRGTTWRSDANLNTIDAIENRM 360 
Cry1Ac                RRELTLTVLDIVALFPNYDSRRYPIRTVSQLTREIYTNPVLENFDGSFRG-SAQGIERSI 291 
                      **::*: ****:* **.**.  *.  . *:****:**:    .: .. .  : :.**. : 
 
                      
Cry41Aa(jpred)        HHHHHHHHHHHHHH--------------EEEEEEEE-----------------HHHHHH- 
Cry1Ac(jpred)         HHHHHHHHHHHHHH--------------EEEEEEEEE-------------#-HHHHHH-- 
  
 
Cry41Aa(PS3)          VGSRQLQLFTWLTEMKFYIRNTGSITSYTHGDLMVGLEKKIRKTNDNDQWLPLEGQNTSY 420 
Cry1Ac                RSPHLMDILNSITIYTDAHRGYYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIV 351 
                       ..: ::::. :*  .   *.    :.:      **:.    .    .       *:    
 
Cry41Aa(jpred)        -------HHHHH---EEEEEE-----------EEEEEEEEEEE-----EEE--------- 
Cry1Ac(jpred)         -----------EEEEE-------EEE--EEEEEE------EEEEE--------------- 
 
 
 
Cry41Aa(PS3)          TRIDRPGIELGKNYWYYARTQQWFETRLLQLWANTDVLSLNAGTVGNEFWVRDVPDYRNI 480 
Cry1Ac                AQLGQGVYRTLSSTLYRRPFNIGINNQQLSVLDGTEFAYGTSSNLPSAVYRKSGTVDSLD 411 
                      :::.:   .  ..  *    :  ::.: *.:  .*:.   .:..: . .: :. . Cry41Aa(jpred)        
-------------EEEEEEEE---------------EEE--------------------- 
Cry1Ac(jpred)         -------EEEEEE-------------EEEEEEE-----------------------EEEE 
                                                                   
                                                                  BLOCK 3 
Cry41Aa(PS3)          YARSTRNHFIENHRLSWIKFEPVRDNCPFAWPGYKQLSALLFGWTHNSVDLNNIISQYRI 540 
Cry1Ac                EIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSI 471 
                         . .*:.  .: :*    .    .. *: .. . : * :*.* *.*.::****:.  * 
 
Cry41Aa(jpred)        -------------EEEEEEEEE---------------EEEEEEEEE-------EE----- 
Cry1Ac(jpred)         -----------------EEEEEEE--------------EEEEEEEE-------EE----- 
 
 
 
Cry41Aa(PS3)          TQIPAVKAYWNRGAFSVIRGPGSTGGNLVQLGTGG-------EVSVKVRPEQTGSDWYRV 593 
Cry1Ac                TQIPAVKGNFLFNG-SVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPST-STRYRV 529 
                      *******. :  .. *** *** ***:**:*.:.*        :.* ::  .* *  *** 
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Cry41Aa(jpred)        ----EEEE-------EEEEE-------EEEE----#######EEEEEEEE------EEEE 
Cry1Ac(jpred)         EEEEEEEEEE----#EEEE--------EEEE----------EEEEEEE-----#--EEEE 
 
                      BLOCK 4 
Cry41Aa(PS3)          RIRYAAGSRGRLNVKKYVSSIHASVTYDYNMTMSSSTQGTYNSFQYLDVYNFRLAEPEFE 653 
Cry1Ac                RVRYASVTPIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFESANAFTSSLGNIVGV 589 
                      *:***: :  :***:   ***.:...     ::..  .. :. *:  :.:.  *.:     
 
Cry41Aa(jpred)        EEEEE----EEEEEEE--------EEEEE----------EEEEEEEE---EEE-----EE 
Cry1Ac(jpred)         EEEEEE---EEEEEEE----EEEEEE--------------EEEEEEEEE------EEEEE 
 
                                 BLOCK 5 
Cry41Aa(PS3)          VWLTNESGGPIWIDKIEFIPLSPIPELPVYPGTYQIVTALNNSSVVTSEEFCMGIGLTTR 713 
Cry1Ac                RNFSGTAG--VIIDRFEFIPVTATLEA--------------------------------- 614 
                        ::. :*  : **::****::.  *            
 
Cry41Aa(jpred)        EEEEE-----EEEEEEEE---------------EEEEEE-----EEEE------------ 
Cry1Ac(jpred)         EEE-------EEEEEEEEEE-------################################# 
   
                                       RD 
Cry41Aa(PS3)          CGVNLWSNNGNTLQKWRFVYNGDQNAFQIKSTPNEDLVLSGSNSGTSVTAETNQNRPNQY 773 
Cry1Ac                ------------------------------------------------------------ 
 
Cry41Aa(jpred)        --EEEE--------EEEEEE---EEEEEEE----EEEE--------EEEEEE------EE 
                      ############################################################ 
 
 
Cry41Aa(PS3)          WLIEEAGNGYVYLRSKGNPNLVLDVAGTSTANGTNIILWNYNGSTNQKFKLS-------- 832 
Cry1Ac                ------------------------------------------------------------ 
 
Cry41Aa(jpred)        EEEEE----EEEEEEE-----EEEE---------EEEEEE-------EEEEEE####### 
Cry1Ac(jpred)         ############################################################ 
                                                                                   
 
 
Cry41Aa(PS3)          ------------------MNYNVTKAREAVQALFSNPTTLQLK--VTDHHVNQVARLVEC 888 
Cry1Ac                -------------------EYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVTY 655 
                                         :**: :*::**:***:... * **  ***:*::**:.**  
  
Cry41Aa(jpred)        ##################---EEEEEE----EEE------EEE##E---H------HHH- 
Cry1Ac(jpred)         ###################---HHHHHHHHH------------------HHHHHHHHHH- 
 
 
                             BLOCK 6 
Cry41Aa(PS3)          IADQIHPKEKMCLLDQVKLAKRLSRERNLLNYGDFESSDWVGTDGWNVSTNVYTVADNPI 948 
Cry1Ac                LSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDDV 715 
                      ::*::  .**  * ::** ***** *****: .:*:. :     **. **.:   ..: : 
 
Cry41Aa(jpred)        -------HHHHHHHHHHHHHHHHHHHH-------------------EE--EEEEEE---- 
Cry1Ac(jpred)         -------HHHHHHHHHHHHHHHHHHHH-------------------E----EEEEE---- 
 
 
                                               BLOCK 7 
Cry41Aa(PS3)          FKDHYLNMPSANNPILSDKIFPTYAYQKVEESRLKPYTRYIVRGFVGSSKDLEILVARYD 1008 
Cry1Ac                FKENYVTLSGT-----FDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYLIRYN 770 
                      **::*:.:..:      *: :*** ***::**:**.:*** :**:: .*:**** : **: 
 
Cry41Aa(jpred)        ----EEE------------------EE-------------EEEEEE-----EEEEEEE-- 
Cry1Ac (jpred)        ----EEE----#####-------HHHH-------------EEEEEE-----EEEEEEE-- 
 
 
Cry41Aa(PS3)          KEVHKRMNVPNDIIPTSPCTGEPVSQPTPYPVMPSNTMPQDMWCNPCGNGYQTAAGMMVQ 1068 
Cry1Ac                -AKHETVNVPGTGSLWPLSAQSPIGKCG----EPNRCAPHLEWN--------PDLDCSCR 817 
                         *: :***.     . .: .*:.:       *..  *:  *         .  .   : 
 
Cry41Aa(jpred)        --EEEEEE-------------------------------------------EE------- 
Cry1Ac(jpred)         #-EEEEEE--------------------####------------########-------- 
 
                                             BLOCK 8 
Cry41Aa(PS3)          STGMMCQDPHEFKFHIDIGELDMERNLGIWIGFKVGTTEGMATLDNIEVVEVGPLTGDAL 1128 
Cry1Ac                DGEKCAHHSHHFSLDIDVGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEAL 877 
                      .    .:..*.*.:.**:*  *::.:**:*: **: * :* * *.*:*.:*  **.*:** 
 
Cry41Aa(jpred)        ----------EEEEE-EEEE--------EEEEEEEE----EEEE--EEEEE-----HHHH 
Cry1Ac (jpred)        ----------EEEEEEEEEE--------EEEEEEE-----EEEE--EEEEE-----HHHH 
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Cry41Aa(PS3)          TRMQKRETKWKQKLTEKRMKIEKAVQIARDAIQTLFTCPNQSCLQSAITLQNILRAEKLV 1188 
Cry1Ac                ARVKRAEKKWRDKREKLEWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRV 937 
                      :*::: *.**::*  : . : : . : *::::::**. .: . **:  .:  *  *:* * 
 
Cry41Aa(jpred)        HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH--------------HHHHHHHHHH 
Cry1Ac (jpred)        HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH----------------HHHHHHHHH 
 
Cry41Aa(PS3)          QKIPYVYNQFLQGVLSAVPGEAYAYDIFQQLSDAVATARALYNQRNVLNNGDFSAGLSNW 1248 
Cry1Ac                HSIREAYLPELS-VIPGVN-----AAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCW 991 
                      :.*  .*   *. *:..*        **::*.. : ** :**: ***::****. *** * 
 
Cry41Aa(jpred)        H--H----HH---------------HHHHHHHHHHHHHHHHHHHH--------------- 
Cry1Ac(jpred)         ------------#------#####HHHHHHHHHHHHHHHHHHHHH--------------- 
 
Cry41Aa(PS3)          NGTEGADVQQIGN-ASVLVISDWSASLSQHVYVKPEHSYLLRVTARKEGSGEGYVTISDG 1307 
Cry1Ac                NVKGHVDVEEQNNQRSVLVVPEWEAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHE- 1050 
                      * .  .**:: .*  ****:.:*.*.:**.* * * :.*:***** *** *** *** :  
 
Cry41Aa(jpred)        -----EEEEEE--#--EEEEE-----EEEEEEE-----EEEEEEEEEE----EEEEEE-- 
Cry1Ac(jpred)         EE---EEEEEE----EEEEE------EEEEEEE-----EEEEEEEEE-----EEEEEE-# 
 
 
Cry41Aa(PS3)          TEENTETLKFMVGEETTGATMSTIRSNIRERYNERNMATPDPDAYGGTNGYASNQNMVNY 1367 
Cry1Ac                IENNTDELKFSNCVEEEIYPNNTVT----------------------------------- 1075 
                       *:**: ***    *    . .*:        
 
 
Cry41Aa(jpred)        ----EEEEEEE---------EEEEEE-----EEEEEEEE------------------EE- 
Cry1Ac(jpred)         -----EEEEE-------EEEE--EE################################### 
 
 
 
 
Cry41Aa(PS3)          SSENYGMSAHSGNNNMNYQSESFGSKPYGDGNSMINGSSNNYEANGYPGNNNINDQSENY 1427 
Cry1Ac                --------------------------------------CNDYTVN-----------QEEY 1086 
                                                            .*:* .*           .*:* 
 
Cry41Aa(jpred)        ------------------------------------------------------------- 
Cry1Ac(jpred)         #######################################E-EEEEE###########E--- 
 
 
 
Cry41Aa(PS3)          GANAYSSNNMNYQSESSGFTPYGDENNMTNYPSNNYEMNPYSSDMNMSMNRGSDCGCGCS 1487 
Cry1Ac                GG-AYTSRNRGYNEAPSVPADYASVYEEKSYTDGRREN-------PCEFNRG-------- 1130 
                      *. **:*.* .*:. .*  : *..  : ..*.... *          .:***    
 
Cry41Aa(jpred)        ----------------------------------------EEE-----EE---------- 
Cry1Ac(jpred)         --#EEEEE-EEEE------------E------------#######------E######## 
 
 
 
Cry41Aa(PS3)          ANAYPGGNMMMNNYSSSTYEMNTYPSSTNMTNHQGMGCGCHYSTNEYPMIEENIPDFSGY 1547 
Cry1Ac                -------------------------------------------------YRDYTPLPVGY 1141 
 
                                                                        .:  *   ** 
Cry41Aa(jpred)        ------------------------------------------EE---------------- 
Cry1Ac(jpred)         #################################################EE--------- 
 
 
Cry41Aa(PS3)          VTKTVEIFPETNRVCIEIGETAGTFMVESIELIRMDCE 1585 
Cry1Ac                VTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE- 1178 
                      *** :* ****::* ****** ***:*:*:**: *:   
Cry41Aa(jpred)        EEEEEEEE-----EEEEE-----EEEEEEEEEEEEE-- 
Cry1Ac(jpred)         EEEEEEEEE---EEEEEEE---EEEEEEEEEEEEE--# 
Figure 4.3. Clustal W alignments of Cry41Aa and Cry1Ac with superimposed Jpred 
secondary structure predictions. H represents helix. E represents sheet. – represents 
coil. # indicates lack of amino acid residue at a particular position upon alignment. The 
conserved blocks of Cry1Ac and Cry41Aa are highlighted in yellow and green 
respectively. Ricin domain of Cry41Aa is highlighted in red. 
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Figure 4.4. Predicted three-dimensional structure of Cry1Ab. The three domains: I 
(white), II (blue), III (red) and portions of domain II loops 1,2 ,3 and α-8 loops in standard 
(left) and rotated formats (right) are shown (Schnepf et al., 1998).   
                  
Figure 4.5. Swiss-model output of Cry1Ac (A) and Cry41Aa (B) predicted 
structures shown in a ribbon model. 261-291 residues of Cry41Aa form a loop-like 
configuration (indicated by red arrow), with no apparent equivalence in insecticidal 
Cry1Ac. Note this is just a representation as the 31 amino acid insert of Cry41Aa cannot 
be predicted accurately. 
A B 
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Figure 4.6.Three-dimensional predicted structures of Cry41Aa (A) and Cry1Ac (B) 
generated using FirstGlance in Jmol. Residues from 261-291 are marked by yellow 
dot- halos in case of Cry41Aa. The equivalent region (223-224) obtained by ClustalW 
alignment in Cry1Ac is also depicted by yellow halos. 
 
We intended to identify the source of cytotoxicity induced by Cry41Aa and 
Cry41Ab parasporin inclusion proteins derived from the Bt isolate A1462. We 
aimed to study the roles played by various ORFs in crystal formation and toxin 
production, the toxicity of the domains on common agricultural pests as well as 
on human cancer cell lines and attempt the identification of the individual factors 
responsible for inducing in vitro cytotoxicity towards cultured mammalian cells. 
 
This chapter describes how we attempted to develop a system for the 
heterologous expression of the parasporin-3 toxins from B. thuringiensis A1462 
in E. coli. This system enabled us to generate mutants through deletions, domain 
swaps and fusion constructs. We further aimed at investigating the roles of the 
three open reading frames in crystal formation and expression of the parasporin 
B A 
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toxin. The role of parasporin Domain II was examined by creating a hybrid 
between the parasporin-3 and insecticidal Cry1Ac. Our next objective was to 
investigate the role of the ricin domain by deleting it from Cry41A thus generating 
the mutant Cry41AΔRD and also by fusing the RD domain to the B. thuringiensis 
insecticidal Cry1Ac toxin thus generating the recombinant Cry1AcIg. We further 
aimed at investigating the role of the loop-like region (residues between 261and 
291) in imparting cytotoxicity to Cry41Aa by deletion. These constructs are 
depicted in Figure 4.7. 
 
 
Figure 4.7. Diagrammatic representation of some of the deletions and fusion 
constructs attempted. The conserved blocks of Cry1Ac are indicated by blue boxes 
and the conserved blocks of Cry41Aa are indicated by green boxes. The red boxes 
indicate the ricin domain. The purple omega represents the protruding loop region. 
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4.2 Results 
4.2.1 Expression of cry41Aa1 gene in E. coli JM109 
An attempt was made to express cry41Aa gene using its own promoter and 
ribosome binding site in E. coli strain JM109. The cry41Aa1 gene region 
containing the three open reading frames was amplified by PCR using genomic 
DNA from B. thuringiensis strain A1462. The forward primer and the reverse 
primer were deduced from the whole genome sequence of A1462. The upstream 
regions of ORF1 were searched for the consensus sequences matching core 
promoter elements of Bt. Although a Shine-Dalgarno ribosome-binding site was 
found, the -10 and -35 regions of the cry41A gene bear no semblance to either 
the σE (-35, KMATATT; -10,  CATACA-T) or σK (-35, GKMACA; -10, CATANNNT) 
consensus Bt promoter where K= G or T and M= C or A (Wong et al., 1983; 
Moran, 1993; Dervyn et al., 1995). Hence, the primers were designed to amplify 
405 base pairs upstream of the ATG start codon of ORF1 to include any promoter 
site upstream of the ORF1 ATG start codon, the ribosome binding site and the 
terminator sequence downstream of ORF3. The transcriptional terminators were 
identified using TransTerm program (www.tigr.org now updated to 
http://www.jcvi.org/) (Ermolaeva et al., 2000). High fidelity Expand long range 
PCR kit (Roche) was used for generation of PCR products from the genomic DNA 
with 3’A-overhangs to enable cloning into the pGEM-T vector possessing 3’ T-
overhangs. Amplification of cry41Aa gene was also attempted with High Fidelity 
pfu DNA polymerase-based PCR amplification system from Stratagene. All PCR 
amplification reactions, whether performed using Taq or Pfu DNA polymerase, 
yielded a product consistent with the expected size of 6.1 kb. We opted for the 
PCR products generated by Roche for further studies due to higher yield and also 
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because it generates PCR amplicons with 3’A-overhangs. PCR amplicons were 
further purified using Qiagen kit (Section 2.2.3.1) and ligated into pGEM-T 
(Promega) according to the manufacturer’s instructions (Section 2.2.4). The 
reaction-mix was used to transform competent E. coli JM109 cells by 
electroporation (Section 2.2.5.1). The transformants were selected on LB-agar-
ampicillin plates (100 µg/ml) at 37°C. To confirm the successful formation and 
introduction of the plasmid into JM109 cells, the single colonies obtained were 
randomly selected from ampicillin containing LB agar plates and were further 
streaked on to LB-agar-ampicillin plates (100 µg/ml) at 37°C for increased 
plasmid yield. Small -scale plasmid preparations were carried using QIAprep Spin 
Miniprep Kit (Qiagen) (Section 2.2.7.1) and extracted plasmids were subjected to 
restriction analysis (Section 2.2.8) to check for colonies harbouring the desired 
cry41Aa gene operon cloned into pGEM-T vector, designated as pGEMCry41Aa 
(Figure 4.8). The identity of the plasmid was verified with restriction digestion and 
sequencing. Sequencing results obtained with the universal T7 sequencing 
primer confirmed the pGEMCry41Aa cassette to be as desired i.e. having 
cry41Aa gene operon with its own promoter. E. coli JM109 cells containing the 
plasmid pGEMCry41Aa were cultured in 100 ml of LB medium containing 
ampicillin (100 μg/ml) at 37°C for 72 h. Cells were then harvested as described 
in Section 2.2.9.1 and total protein extracts were analysed on a 7.5 % SDS-
PAGE. A major band of ~88 kDa was observed on the gel (Figure 4.9A). 
Parasporal proteins thus expressed in E. coli strain JM109 resulted in formation 
of inclusion bodies as observed under phase contrast microscope (data not 
shown). 
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Inclusion bodies of recombinant Cry41Aa parasporal proteins expressed in E. coli 
JM109 were solubilised at alkaline pH under reducing milieu in presence of 1 mM 
DTT. The crystals were solubilised in 50 mM Na2CO3 (pH 9.5)/1 mM DTT at 37°C, 
water bath for 1 h. A major protein band of ~88 kDa was apparent on the gel 
(Figure 4.9B). Usually, after solubilisation protoxins must undergo proteolytic 
processing in order to become active toxins (Lecadet & Dedonder, 1967, Tojo & 
Aizawa, 1983). The crystal proteins were then digested by varied concentrations 
of proteinase K, trypsin, chymotrypsin and gut extracts from Plutella xylostella 
LAB-UK susceptible populations. The proteins generated by proteolytic 
processing with proteinase K, trypsin and gut extract from the cabbage pest, 
Plutella had a molecular mass of ~64 kDa (Figure 4.10). Although, unlike in case 
of the insecticidal Cry toxins wherein protease treatment generates an 
approximately 60 kDa protease-resistant biologically active core (de Maagd et 
al., 2001), higher concentrations of chymotrypsin above 2 mg/ml digested the 
solubilised recombinant Cry41Aa inclusions (Figure 4.10C). Similar results were 
obtained upon treatment with other proteinases at a high concentration (data not 
shown). 
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Figure 4.8. Schematic representation of the plasmid pGEMCry41Aa depicting the 
location of genes of the cry41Aa operon. 
 
A                              B 
                  
Figure 4.9. 7.5% SDS-PAGE analysis of Cry41A proteins. A. Lane 1, native 
parasporal inclusion proteins of Bt strain A1462; lane 2, E. coli JM109 expressed 
recombinant Cry41Aa protein inclusions. B. Lane 1, ~88kDa alkali-solubilised E. coli 
expressed recombinant Cry41Aa; lane M; molecular mass marker. 
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Figure 4.10. SDS-PAGE analysis of the proteolytic processing of the 88 kDa protein 
expressed in E. coli. Varied dilutions of (A) trypsin, (B) gut extract of P. xylostella and 
(C) chymotrypsin were used. The processed toxin fragments are indicated by the arrow. 
The concentrations of the proteolytic enzymes used are indicated above their respective 
lanes. Lane A represents alkali solubilised protein inclusions; lane M represents protein 
marker and lane S is the untreated total sample. 
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4.2.2 Domain Analysis 
 
4.2.2.1 Investigating the roles of ORF1 and ORF3 
To further investigate the involvement of various open reading frames in crystal 
formation and protein production, these were individually deleted from the 
operon. The deletions were PCR mediated as depicted schematically in Figures 
4.11 and 4.12, by using primers that flanked the deleted regions and PfuUltra 
Hotstart from Stratagene. pGEMCry41Aa was used as the template DNA. 
Following amplification, PCR amplicons were self-ligated resulting in the creation 
of mutants, pGEMCry41ΔORF1 of 8518 base pairs with deleted ORF1 and 
pGEMCry41ΔORF3 of 6878 base pairs with deleted ORF3. 
Deleting ORF1 had no effects either on crystal formation as observed under the 
phase contrast microscope (data not shown) or protein production. ~88kDa 
protein band was still detected on the gel and was further obtained in the soluble 
fraction upon alkaline treatment (Figure 4.13, lane 2). However, the resulting 
transformants produced smaller crystalline inclusions when cry41Aa gene was 
expressed without ORF3 as seen using the phase contrast microscope (data not 
shown). Upon ORF3 deletion, a major protein band at approximately 84 kDa was 
obtained (Figure 4.13, lane 5). However, ORF3 deletion resulted in production of 
proteins which were not recovered in the soluble fraction upon alkaline treatment 
(Figure 4.13, lane 6). The samples were further subjected to trypsin treatment as 
described in Section 2.2.12 and analysed on 7.5% SDS-PAGE. The samples 
were treated with concentrations of trypsin ranging from 2 mg/ml to 0.08 mg/ml. 
Trypsin at a final concentration 0.4 mg/ml and 0.08 mg/ml partially digested 
recombinant Cry41AaΔORF1 protein inclusions yielding a band of ~60 kDa 
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(Figure 4.13, lanes 3 & 4). No 60 kDa protein band was detected when 
recombinant Cry41AaΔORF3 inclusions were treated with trypsin (Figure 4.13, 
lanes 7, 8 & 9). 
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Figure 4.11. Schematic representation of the construct pGEMCry41AaΔORF1. 
 
 
    Self -Ligation 
   PCR amplicon 
pGEMCry41AaΔORF1 
            8.5 kb 
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Figure 4.12. Schematic representation of the construct pGEMCry41AaΔORF3. 
  
pGEMCry41AaΔORF3 
                6.9kb 
 
 
PCR Amplicon 
  Self-Ligation 
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Figure 4.13. 7.5% SDS-PAGE profile depicting the effect of ORF deletions on 
protein production. Lanes 1-4, analysis of Cry41AaΔORF1 expressed from 
pGEMCry41AaΔORF1 in E. coli JM109 and lanes 5-9, analysis of Cry41AaΔORF3 
expressed from pGEMCry41AaΔORF3 in E. coli JM109. Lane 1, E. coli 
pGEMCry41AaΔORF1 protein inclusions; lane 2, alkali solubilised E. coli expressed 
Cry41AaΔORF1. Lanes 3 and 4 are trypsin- treated samples. Samples were treated with 
0.4 mg/ml (Lane 3) or 0.08 mg/ml (Lane 4). Lane 5, Cry41AaΔORF3 protein inclusions; 
lane 6, alkali solubilised sample. Lanes 7-9 are trypsin-treated Cry41AaΔORF3. Samples 
were treated with 2 mg/ml (Lane 7) or 0.4 mg/ml (Lane 8) or 0.08 mg/ml (Lane 9). Lane 
M is the protein marker in kDa. 
 
4.2.2.2 Functional analysis of the conserved blocks of ORF3 
ORF3 of parasporin-3 resembles the C-terminal half of the larger Cry toxins, a 
region that is believed to be important for the expression and crystallization of B. 
thuringiensis toxins. To identify regions in ORF3 which are imperative for crystal 
formation and protein production, deletions in ORF3 were planned.  
To investigate the role of C-terminal region including block 8, the conserved 
region was deleted using the reverse primer from the construct 
pGEMCry41AaΔORF1 as diagrammatically represented in Figure 4.14. Further, 
in order to verify if the regions after block 8 were dispensable for crystal formation 
  1    2    3    4   M   5   6     7   8   9 
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 62 
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or protein production, they were deleted as schematically demonstrated in Figure 
4.15. Deleting block 8 and C-terminal residues resulted in a PCR amplicon of 
6978 base pairs. Deleting residues after block 8 resulted in a PCR product of 
7128 base pairs. However, these two deletions in ORF3 resulted in complete 
abrogation of expression. No protein band was detected on the SDS gel (data not 
shown). 
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Figure 4.14. Schematic illustration of C-terminal deletion including block 8 of 
Cry41AaORF3  using the template pGEMCry41AaΔORF1. 
PCR Amplicon 
SELF -LIGATION 
pGEMCry41AaΔORF1 
pGEMCry41AaORF2    
ORF3ΔBL8 
                7kb 
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Figure 4.15. Schematic illustration of C-terminal deletion (excluding block 8) of Cry 
41AaORF3. 
PCR Amplicon 
SELF-LIGATION 
pGEMCry41AaΔORF1 
pGEMCry41AAORF2ORF3ΔR 
                  7.1kb 
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4.2.2.4 Role of Domain II: Hybrids with insecticidal Cry1Ac  
Since Domain II in insecticidal Cry proteins has been ascribed a role in the 
specificity of the toxin (Schnepf et al., 1998), an attempt was made to exchange 
and replace the domain II of insecticidal Cry1Ac with Cry41Aa domain II to create 
the hybrid construct designated as pGEMCry1AcDI/41AaDII/1AcDIII as 
schematically represented in Figure 4.16. The expression vector pGEMCry1Ac 
designed to express Cry1Ac in E. coli hosts which had native cry1Ac promoter, 
its ribosome binding site and pGEM-T vector backbone was used. The suitable 
junction was decided by comparing the known 3D structures of insecticidal Cry 
toxins including Cry1A, Cry3A. In absence of 3D structure for Cry41Aa, the 
suitable junction was extrapolated by aligning it with the insecticidal Cry1 toxins 
whose structure are known. Primers were designed to delete domain II of Cry1Ac 
gene contained in the plasmid pGEMCry1Ac. The primers used amplified the 
domains I and III resulting in the deletion of domain II as schematically illustrated 
in Figure 4.17 yielding a fragment of 6509 base pairs. The primers used to for 
amplify the domain II of Cry41Aa1 as schematically illustrated in Figure 4.17, 
yielded a PCR product of 519 bp. The amplified domain II from Cry41Aa was then 
ligated to pGEM1Ac and used to transform E. coli 109 to form a construct of 7106 
base pairs. No expression of the hybrid could be obtained on SDS gel. The 
recombinant Cry1Ac is approximately 120 kDa. However, replacement of its 
domain II with Cry41Aa domain II, abolished its expression. No recombinant 
protein of desired 130 kDa was observed on the gel though crystal inclusions 
were observed with the phase contrast microscope (data not shown). 
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                                               Figure 
4.16. Schematic representation of construction of the hybrid 
pGEMCry1AcDI/41AaDII/1AcDIII.
DII 
DII 
pGEMCry1AcDI/
41AaDII/1AcDIII 
PCR Amplicons 
      Ligation 
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A 
The primers used for amplifying the domain II of Cry41Aa1  
Forward Primer 
5’-CTCACGCGAGAAGTTTATACAGATATAC-3’  
Reverse Primer 
5’-TACACTGTTATGAGTCCAACCAAATAAC-3’ 
 
Primers annealing to pGEMCry41Aa ORF2  
158th amino acid residue of ORF2                                                           529th amino acid  
L      T     R     E     V   Y   T    D     I       R   G     T     T    W                                K      Q       L     S     A        L       L       F      G    W     T        H      N      S    V ( part of block 3) 
ctc acg cga gaa gtt tat aca gat ata cga ggt aca aca tgg………………….aaa caa tta agt gct ttg tta ttt ggt tgg act cat aac agt gta 
(Part of Block 2) 
 
 
The PCR amplified 199 amino acid residues of Cry41Aa domain II 
 
LTREVYTDIRGTTWRSDANLNTIDAIENRMVGSRQLQLFTWLTEMKFYIRNTGSITSYTHGDLMVGLEKKIRKTNDNDQWLPLEGQNTSYTRIDRPGIELGKNYWYYARTQQWFETRLLQLWANTDVLS
LNAGTVGNEFWVRDVPDYRNIYARSTRNHFIENHRLSWIKFEPVRDNCPFAWPGYKQLSALLFGWTHNSV 
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B 
Primers designed to delete domain II of cry1Ac gene from the plasmid pGEMCry1Ac.  
Forward Primer 
5’GAATTTAATAATATAATTGCATCGGATAG 3’  
Reverse Primer                            
5’ TTGGGAAACTGTTCGAATTGG 3’ 
Primers annealing to pGEMCry1Ac DNA 
 
BLOCK2                                263rd amino acid residue                 460th amino acid residue 
 
     R Y    P  I    R   T  V  S    Q   L   T   R   E   I            H  R   S   A   E   F   N   N  I   I    A  S   D    S  I 
 
GA-AGA-TAT-CCA-ATT-CGA-ACA-GTT-TCC-CAA-TTA-ACA-AGA-GAA-ATT-........ CAT-CGT-AGT-GCT-GAA-TTT-AAT-AAT-ATA-ATT-GCA-TCG-GAT-AGT-ATT 
 
 
Deleted 198 amino acid residues of Cry1Ac 
 
LTREIYTNPVLENFDGSFRGSAQGIERSIRSPHLMDILNSITIYTDAHRGYYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYRTLSSTLYRRPFNIGINNQQLSVLDGTEFAYG
TSSNLPSAVYRKSGTVDSLDEIPPQNNNVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSA 
 
Replacement of 198 amino acid of Cry1Ac with 199 amino acid residues of Cry41Aa 
 
     P      I          R      T        V     S        Q       L      T     R     E     V   Y   T    D     I       R   G     T     T    W      K      Q       L     S     A        L  L       F      G    W T  H  N        S        V   E     F      N    
 
-CCA-ATT-CGA-ACA-GTT-TCC-CAA- ctc acg cga gaa gtt tat aca gat ata cga ….aaacaa tta agt gct ttg tta ttt ggt tgg act cat aac agt gtaGAA-TTT-AAT 
 
 
 
Figure 4.17. Schematic depiction of creation of the hybrid pGEMCry1AcDI/41AaDII/1AcDIII. A. Amplification of DII from pGEMCry41Aa. B. 
Replacement of DII of pGEMCry1Ac with the amplified Cry41Aa Domain II thus resulting in the desired hybrid construct.
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4.2.3 Investigating the role of ricin domain 
To test whether the beta-trefoil ricin domain present at the C-terminus of ORF2 
of Cry41Aa is responsible for its cytotoxic activity against cancer cell lines, we 
carried out deletion of this domain from ORF2. Additionally, we intended to 
transfer this domain on to the insecticidal Cry1Ac toxin to investigate if it alters 
the specificity of the insecticidal Cry1Ac. 
4.2.3.1 Deleting ricin region from ORF2 of cry41 gene 
 A Cry41Aa mutant designated as pGEMCry41AaΔRD from which the ricin 
domain was deleted was constructed as schematically represented in Figure 
4.18. Ricin domain was identified using CD search, NCBI and Motifscan 
(http://myhits.isb-sib.ch/cgi-bin/motif_scan). SDS-PAGE analysis detected a 
recombinant protein of same molecular mass i.e. 88 kDa as that of Cry41Aa 
expressed in E. coli (Figure 4.19A & B). Crystal inclusions were observed under 
the microscope. The mutant recombinant protein yielded a similar band of 64 kDa 
on proteinase K treatment as the non-mutant pGEMCry41Aa with intact ricin 
domain (Figure 4.19C). Trypsin-treatment too resulted in the generation of 64 
kDa band (data not shown).  
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Forward primer: 
41rddelF 5’ TAAAGGTGTGCAACTATCCCTTGAC 3’  
 Reverse primer:         
41rddelR 5’ TCGAGTGGTTAAGCCAATACCC 3’   
Primers annealing to pGEMCry41Aa/ORF2ORF3 : 
 
+2113 bases downstream of the ORF2 start codon    
                                                      
 ATG GGT ATT GGC TTA ACC ACT CGA TGT GGG-RD-TAA aggtgtgcaactatcccttgactaa catatacatttaacaggcatcttaaagcaaagctcatacgaaggaggataatgaATG 
 M    G   I    G   L   T   T    R   C    G 
                                                                                                                                                                       Intergenic region                                                          Start of ORF3 
                                                                                                                                      
Ligation of amplified pGEMCry41Aa with deleted ricin domain region  
ATG GGT ATT GGC TTA ACC ACT CGA TAAaggtgtgcaactatccctgactaacatatacatttaacaggcatcttaaagcaaagctcatacgaaggaggataatgaATG 
 M    G   I    G   L   T   T    R    
 
  
Figure 4.18. Schematic depiction of binding of the primers to pGEMCry41Aa/ORF2ORF3 for deletion of the ricin domain. RD represents 
ricin domain. The region highlighted in grey was deleted. The intergenic region is depicted by small purple letters.
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A                       B                                  C 
                         
Figure 4.19. SDS-PAGE profile of the expression of Cry41AaΔRD in E. coli JM109. 
A. Cry41AaΔRD inclusions (Lane 1). B. Comparison of the inclusions of the mutant 
Cry41AaΔRD (Lane 1) with the non-mutant Cry41Aa (Lane 2). C. Protease-treated E. 
coli expressed Cry41AaΔRD. The solubilised samples were treated with 0.002 mg/ml 
(Lane 1), 0.002 mg/ml (Lane 2), 0.02 mg/ml (Lane 3), 0.2 mg/ml (Lane 4) or 0.4 mg/ml 
(Lane 5) proteinase K; solubilised sample (Lane 6); total protein sample (Lane 7); protein 
marker (Lane M). 
 
4.2.3.2 Fusion of ricin domain on to insecticidal pGEMCry1Ac 
The  ricin domain was amplified from cry41AaORF2 gene and fused into the 
insecticidal cry1Ac after the conserved block 5 to assess if this particular domain 
confers any cytotoxic properties or changes the specificity of the insecticidal 
Cry1Ac thus verifying the involvement of  HA-33 like domain in cytotoxicity. The 
formation of the desired chimeric construct referred to as pGEMCry1AcIg is 
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schematically represented in Figure 4.20. 519 base pairs of ricin region which 
encompasses the conserved ricin domain of Cry41AaORF2 including 105 base 
pairs before the start of the ricin domain (+2041 nucleotides downstream of the 
start codon of ORF2), 78 base pairs of the intergenic region and the start codon 
of ORF3 was amplified from pGEMCry41Aa using the forward primer 41IGF 5’ 
CCAGTATATCCTGGTACCTATC 3’ and the reverse primer 41IGR 5’ 
CATTCATTATCCTCCTTCG 3’ which includes the start codon ATG at its 5’end 
indicated in red letters (Figure 4.21A). 7103 base pairs of pGEMCry1Ac was 
amplified by using the forward primer which binds to the region before the 
conserved block 6 1AcIGF 5’GAATATAATCTGGAAAGAGCG 3’ and the reverse 
primer which binds to regions in and around block 5 1ACIGR 5’ 
AGCCTCGAGTGTTGCAG 3’. This is in order to accommodate the ricin region 
amplified from Cry41Aa after the block 5 of the insecticidal Cry1Ac and render it 
as a split toxin by incorporating the start codon before its block 6 (Figure 4.21B).  
The expression of the Cry1AcIg was analysed in E. coli strain JM109. An 
approximately 75 kDa band was detected on the gel (Figure 4.22, lane 2), the 
predicted molecular weight being 84 kDa. The recombinant toxin was expressed 
as inclusion bodies in E. coli JM109 as visible under the phase contrast 
microscope. However attempts to solubilise inclusion bodies were not met with 
success (data not shown).  
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Figure 4.20. Schematic representation of the construction of pGEMCry1AcIg. 
   PCR Amplicons 
Ligation 
pGEMCry1Ac 
        7.1kb 
 
 
RD 
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A 
Forward primer 
5’-CCA-GTA-TAT-ATC-CTG-GTA-CCT-ATC -3’ 
Reverse primer (includes a start codon)  
Start codon  
           
5’-CAT-TCA-TTA-TCC-TGG-TAC-CTA-TC -3’ 
Primers annealing to Cry41Aa ORF2 DNA (Part of Cry41Aa ORF2 sequence): 
 
     Forward Primer 
  +2,041 bases downstream of ORF2 start codon 
                                 Amplified region 
  P  V  Y P G  T  Y Q  I  V  T A  L  N  N  S S V  V --RD- 
5’-cca gta tat cct ggt acc tat caa atcg tga cag ctt taa ata ata gta gtg ttg taa- - -RD- TAA-3’- intergenic sequence-5’-ATGORF3-3’ 
                                                                                                                                          Reverse primer
Amplified PCR amplicon (highlighted in grey): 
                                             Start codon which was included in the reverse primer 
                                                  
5' CCA-RD –intergenic region-ATG 3' 
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B 
Forward primer 
5’ GAATATAATCTGGAAAGAGCG 3’ 
Reverse primer          
5’- AGCCTCGAGTGTTGCAG-3’ 
Primers annealing to pGEMCry1Ac 
                                                             21amino acids before the start of Block 6 
      Block 5                       Reverse Primer        E         Y    N          L       E      R      A 
5’-CA-GTT-ACT-GCA-ACA-CTC-GAG-GCTGAA TAT AAT CTG GAA AGA GCGCAGAAGGCGGT-3’  
              V   T        A        T        L       E    A           Forward Primer 
 
Fusion of amplified Cry41Aa ricin domain region onto pGEMCry1Ac DNA in between the conserved blocks 5 and 6 which includes addition of the 
start codon before block 6 : 
         V      T       A         T     L     E                                              M       E         Y    N      L          E      R     A 
5' –GTT ACT-GCA-ACA-CTC-GAG-CCA-RDintergenicregionATGGAA TAT AAT CTG GAA AGA GCGCAGAAGGCGGT-3’ 
 
 
Figure 4.21. Creation of fusion construct pGEMCry1AcIg. (A) Schematic representation of the strategy to amplify ricin domain from ORF2 of 
Cry41Aa. (B) Schematic depiction of the binding of primers to pGEMCry1Ac and intended fusion of Cry41Aa ricin domain region onto 
pGEMCry1Ac DNA in between the conserved blocks 5 and 6.  The fused region from cry41Aa is highlighted  in grey.
 
 
Page 138 of 260 
 
 
                                          
Figure 4.22. 7.5% SDS-PAGE analysis of the expression of the recombinant fusion 
protein in E. coli JM109. Lane 1, recombinant Cry1Ac inclusions; lane 2, fusion 
recombinant Cry1AcIg inclusions; lane 3, recombinant Cry41Aa inclusions; lane 4, 
protein marker. 
 
 
4.2.4 Purification and biological activity of Cry41Aa protein expressed in E. 
coli JM109 
Recombinant Cry41Aa toxin devoid of ORF1 was solubilised in 50 mM carbonate 
buffer, pH 9.5 and purified using AKTA FPLC. The fractions were analysed on 
7.5% SDS-PAGE. The solubilised protein was present in fractions B9, B10 and 
B11 (Figure 4.23). After purification, the samples were treated with various 
concentrations of trypsin which processed the toxin to ~64 kDa (Figure 4.24). 
  
1          2        3        M  
kDa
175 
83 
62 
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                                 FLOWTHROUGH            ELUTION (1ml/min) 
Figure 4.23. Purification of recombinant Cry41Aa toxin expressed in E.coli JM109. 
Elution profile of the recombinant toxin on anion exchange chromatography. 
 
Figure 4.24. 7.5% SDS-PAGE depicting trypsin treatment of Cry41AaΔORF1 
expressed in E. coli JM109. Lane 1, untreated Cry41AaΔORF1 sample; lanes 2, 3 and 
4, B10 fraction of purified Cry41AaΔORF1 samples treated with 0.5, 1 and 2 µl of trypsin 
(2mg/ml) respectively; lanes 5, 6, 7, B11 fraction of purified Cry41AaΔORF1 sample 
treated with 2, 1 and 0.5 µl of trypsin (2 mg/ml) respectively; lane M, protein marker. 
Arrows indicate the activated 64 kDa band. 
1       2     3        4      M       5       6      7 
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4.2.4.1 Assessment of biological activity 
 
The toxicity of the pGEMCry41 protein was tested against insecticidal Cry1Ac 
susceptible G88 and resistant populations KARAK and NO-QA of Plutella 
xylostella using leaf–dip and diet based assays according to the protocols 
described in Section 2.2.15.1. No mortality was observed in case of G88 or 
KARAK or NO-QA populations treated with solubilised or trypsin treated protein 
inclusions. Trypsin-treated Cry1Ac toxic to the cabbage pest, Plutella xylostella 
was used as a positive control. 
Dye Exclusion viability assay using Trypan blue (0.4%) was used to assess the 
cytotoxic activity of solubilised and trypsin treated recombinant Cry41Aa (Section 
2.2.15.2.1). The soluble and the trypsin treated proteins at 10 μg/ml failed to 
demonstrate toxicity against human liver cancer, HepG2 cells and A549 (Human 
lung cancer cell) (data not shown). Cry41Aa at this concentration has shown to 
be cytocidal against HepG2 cells (Yamashita et al., 2005). 
 
4.2.4.2 Mass spectrometry analysis 
Since the recombinant Cry41A expressed in E. coli failed to demonstrate any 
cytocidal effects against cancer cells and since the deletions made in ORF2 
resulted in no change in the size of the proteins on the SDS-PAGE and any 
mutagenesis in ORF3 resulted in the disruption of the protein produced in E. coli 
JM109, the protein sample was analysed by mass spectrometry to confirm its 
identity. The data revealed that pGEMCry41Aa resulted in the expression of 
ORF3 in E. coli JM109. 
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Expressing the ORFs in E. coli JM109 resulted in production of ORF3 as the 
dominant protein which is similar in size to the desired 88 kDa ORF2 protein. The 
required ORF2 was not expressed as a major protein in E. coli JM109. 
We then attempted to develop an alternative method for over-expressing Cry41A 
proteins. We attempted to express Cry41AORF2 with/without ORF3 in E. coli by 
using T7RNA polymerase/T7 promoter expression systems.  
 
4.2.5 Expression of Cry41Aa ORF2 with/without ORF3 using T7 RNA 
polymerase promoter 
cry41AaORF2 and cry41AaORF2ORF3 genes were amplified from the genomic 
DNA to yield PCR amplicons of 2.7 kb and 4.9 kb respectively. High Fidelity PCR 
master mix (Roche) was used. Purified amplicons were ligated into pGEM-T Easy 
vector to form the plasmids referred to as pGEMCry41Aa/ORF2 and 
pGEMCry41Aa/ORF2ORF3. The expression of the proteins were analysed in E. 
coli strain BL21(DE3). 
An attempt to express cry41Aa gene in E. coli BL21(DE3) under T7 promoter 
resulted in overproduction of β-galactosidase (Figure 4.25), a product of Lac Z 
gene upon induction with IPTG as identified by mass spectrometry. No 
expression of cry41Aa gene was obtained in spite of varying various conditions 
including media, IPTG concentration, growth- time. 
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Figure 4.25. SDS-PAGE analysis of Cry41Aa/ORF2ORF3 protein expression in E. 
coli BL21(DE3). Lanes 1-3, No IPTG added; lane 1, total protein sample; lane 2, 
supernatant; lane 3, pellet resuspended in water; lane M, protein marker. Lanes 4-6; 
protein harvested after 24 hours of addition of IPTG; lane 5, supernatant fraction; lane 4, 
pellet resuspended in water; lane 6, total protein. The β-galactosidase over expressed is 
shown by arrow. 
  
   1           2       3         M         4         5           6 
 
 
Page 143 of 260 
 
4.2.6 Development of pET Expression systems 
4.2.6.1 Expression of Cry41Aa ORF2 with/without ORF3 
Since attempts to express cry41Aa gene using T7 promoter of pGEM-T in E. coli 
strain BL21(DE3) met with little success, we attempted to express the target gene 
in a tightly regulated T7 RNA polymerase-based pET vector expression system 
as diagrammatically represented in Figure 4.26 and Figure 4.27. 
cry41AaORF2ORF3 gene was PCR amplified to be ligated in-frame at the BamHI 
site of pET3a vector. Similarly, cry41AaORF2 gene was amplified by PCR and 
ligated in-frame at the NdeI-BamHI sites of pET3 vector allowing fusion of the 
leader peptide to the gene of interest. Using High fidelity PCR master mix from 
Roche according to the manufacturer’s instructions, ORF2 and ORF3 of cry41Aa 
gene were amplified by PCR using genomic DNA from the Bt strain A1462 with 
the primers incorporating BamHI restriction sites to the PCR amplicons to be 
ligated at the BamHI site of pET3a expression plasmid. The forward or 5’ PCR 
primers BamF  5’ AATGGAGGATCCTCAATGAATCAAAATTG 3’and  the  3’ 
reverse 3BamR 5’ GCTTCGGGGATCCTGCTACC 3’ were used to generate 
PCR amplicon of 5 kb. Both the primers contained BamHI restriction site, letters 
shown in red. Similarly ORF2 of cry41Aa gene was amplified by PCR to be ligated 
in-frame at the NdeI and BamHI sites of pET3a expression plasmid. The forward 
5’ PCR primer 5’AATGGAGGATTGCATATGAATCAAAATTG 3’ containing NdeI 
site (coloured green) and the 3’ reverse primer 2BamR 5’ 
TTAGTCAGGGATCCTTGCACACC 3’ containing the BamHI site (coloured red) 
were employed to yield a PCR product of 2.5 kb. The PCR amplicons were 
column purified and subjected to restriction digestion. The PCR product of 
Cry41Aa containing ORF2 and ORF3 was digested with BamHI whereas 
Cry41Aa containing ORF2 without ORF3 was digested with NdeI and BamHI and 
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gel purified (Section 2.2.3.2). The 4640 bp expression plasmid, pET3a was 
digested with the respective enzymes and gel purified as described in Section 
2.2.3.2. The genes and the vectors were ligated according to the manufacturer’s 
instructions and used to transform competent E. coli JM109 cells by 
electroporation. The colony containing the correct inserts were identified by rapid 
size screen (Section 2.2.6) and further verified by restriction digestion and 
sequencing. The expression of the proteins were analysed in E. coli strain 
BL21(DE3). However, no proteins of interest were obtained on the 7.5% SDS-
PAGE (data not shown). Varying several culture conditions did not further aid in 
obtaining the expression of the desired recombinant proteins, thus suggesting 
that the cloning of cry41AaORF2 and cry41AaORF2ORF3 genes in pET 
expression system resulted in no expression.
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      RBS        NdeI                     Leader   peptide 
GAAGGAGATATAcatatgGCTAGCATGACTGGTGGACAGCAAATGGGTCGCggatcctcaATGAATCAA.. ATGAATTAC…TGAtgtaatggtagcaggatccGGCTG…… 
                                    
      Figure 4.26. Diagrammatic representation of the construction of plasmid pET3aCry41Aa/ORF2ORF3. 
cry41AaORF2ORF3 with BamHI 
overhangs 
BamHI linearised 
pET3a vector 
Ligation 
 pETCry41Aa/ORF2ORF3 
                 9.4kb 
BamHI 
BamHI 
cry41AaORF2ORF3 PCR Product 
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Figure 4.27. Diagrammatic representation of the construction of the plasmid 
pET3aCry41Aa/ORF2. 
 
Ligation 
NdeI+BamHI linearised         
pET3a vector 
cry41AaORF2 with NdeI 
(5’) and BamHI (3’) 
overhangs 
pET3aCry41Aa/ORF2 
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4.2.6.2 Expression of Cry1AcIg by pET3 expression system 
Since several attempts to solubilise Cry1AcIg failed, we attempted an alternative 
expression system for the expression of Cry1AcIg in order to obtain the 
recombinant toxin in the soluble functional form. We designed to express the 
target gene in a tightly regulated T7 RNA polymerase-based pET vector 
expression system in E. coli strain BL21(DE3) as illustrated schematically in 
Figure 4.28. The coding sequence of cry1AcIg before the conserved block 6 was 
subjected to PCR amplification and ligated in frame at the BamHI site of pET3a 
expression vector allowing fusion of the leader peptide for an efficient translation, 
forming the construct, pETCry1AcIg. However, no protein expression was 
apparent on the SDS-PAGE suggesting that T7 bacteriophage promoter is most 
likely unable to drive the expression of the recombinant  pETCry1AcIg. The 
desired 84 kDa recombinant protein was not detected by SDS-PAGE analysis 
(data not shown). 
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Figure 4.28. Diagrammatic representation of construction of pETCry1AcIg. 
Cry1AcIg with BamHI overhangs BamHI linearised pET3a vector 
with T7 promoter 
 
PCR amplicon digested 
with BamHI 
 Ligation 
BamHI  
BamHI  
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4.3 Discussion 
   
E. coli was evaluated as a heterologous host capable of expression of the cry41A 
cytotoxic genes of A1462. cry41Aa1 gene was cloned into pGEM-T vector and 
expressed in E. coli JM109. Attempts to express cry41Aa gene with its own 
promoter and ribosome binding site in E. coli JM109 resulted in expression of 
ORF3 as major protein. Inclusion bodies were formed in E. coli. 
Peptide sequencing by mass spectrometry identified the expressed protein in E. 
coli JM109 as the ORF3 (equivalent to C-terminus in longer Cry1A type proteins). 
The size of ORF3 protein is similar to the size of the ORF2, the desired protein 
which is around 88 kDa. The trypsin treatment resulted in ~64 kDa protein which 
was consistent with the previous report that Cry41Aa is cleaved to 64 kDa protein. 
Toxicity bioassays revealed that these proteins were non-toxic to cabbage insect 
pest, Plutella xylostella. Dye-exclusion cell viability assay confirmed that the 
ORF3 protein was not cytotoxic to human liver carcinoma, HepG2 cells. The 
protein thus expressed in E. coli JM109 was solubilised and processed efficiently 
by the protease treatment. However, the protein lacked any biological activity 
against insect pest and /or against cancer cells. Furthermore, deleting ORF1 from 
pGEMCry41A did not affect the protein expression. However, deleting ORF3 
resulted in no protein expression. Any mutagenesis in ORF3 interfered with 
protein expression. This further validated that cloning in pGEMCry41Aa resulted 
in overexpression of ORF3. 
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To investigate the role of ricin-like domain in toxicity, the particular domain from 
the plasmid pGEMCry41Aa was fused to the insecticidal pGEMCry1Ac between 
its conserved blocks 5 and 6. The expression of pGEMCry1AcIg in E. coli JM109 
was successful yielding a band of approximately 75 kDa as suggested by SDS-
PAGE analysis. However, solubilisation of the recombinant protein in various 
buffers could not be accomplished. The recombinant protein failed to 
demonstrate the activity defining the insecticidal pGEMCry1Ac toxin suggesting 
the improper folding of the recombinant Cry1AcIg. Hence, it is pertinent to 
conclude that fusion of HA-33 domain from cytotoxic Cry41Aa on to Cry1Ac has 
an adverse impact on its folding and structure resulting in the generation of a non-
functional protein. Altering the relative position of the ricin domain between the 
conserved boxes 5 and 6 of pGEMCry1Ac might aid in expression of functional 
protein. Further, usage of different expression vectors might enable us to get the 
functional protein. 
 
We desired to create a hybrid toxin using domains I and III of the three-domain 
insecticidal Cry1Ac and Domain II of cytotoxic Cry41A gene. Previous studies 
have successfully conducted domain swaps for generating new specificities 
(Widner & Whiteley, 1990, Masson et al., 1994, de Maagd et al., 1996). The 
domain swapping resulted in successful creation of a hybrid that entailed domain 
II of Cry41Ab and domains I and III of Cry1Ac. No recombinant protein was 
however, obtained. This could be due to no protein expression or unstable protein 
due to erroneous folding. Hybrid domains of the construct created have not 
evolved together. Hence, the protein lacks the specific intramolecular interactions 
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that are necessary for a stable protein. de Maagd et al. (2000) suggested that 
Domains I, II and in certain cases Domain III appears to have co-evolved towards 
certain specificities. Domain swapping by homologous recombination or 
restriction-fragment exchange leads to the generation of new specificities in Bt 
toxins. For instance, replacement of domain III in Cry1 toxins (Cry1Ab, Cry1Ac, 
Cry1Ba, Cry1Ea) by that of Cry1Ca conferred the toxins activity against 
Spodoptera exigua (beet armyworm) which they originally lacked (de Maagd et 
al., 2000). Further, studies have demonstrated that hybrids of Cry1Ac and Cry1Fa 
possess wider target spectra than their parent toxins (Malvar & Gilmer, 1998). 
The presence of salt bridges between domain I and domain II could be 
responsible for maintaining the protein in a globular form during solubilisation and 
activation by protease. The residues involved in salt bridges are contained in the 
conserved block 2 in Cry proteins that entails helix 7 of domain I and first β strand 
of domain II. These interactions might play a role in specificity. The last β strand 
of domain II is contained in conserved block 3 and maintains interaction between 
domains I and III. Disruption of these interactions during hybrid creation might 
result in unstable protein (Schnepf et al., 1998). Altering the expression system 
could help us achieve our desired recombinant protein.  Alternative hybrids could 
be attempted with closely related Cry proteins for instance Cry3Aa, Cry3B and 
Cry3C. Thus, disruption of a large domain of the protein could be a factor resulting 
in the incompatibility of the hybrid that we created affecting the overall protein 
folding process. Mutagenesis of a more focussed region of domain II could be 
attempted.  
Further, since Cry41Aa expression using pGEM-T T7 promoter in E. coli 
BL21(DE3) resulted in overexpression of β-galactosidase upon induction with 
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IPTG, we attempted to clone cry41Aa gene in a pET plasmid under control of the 
strong bacteriophage T7 promoter. The cloning of cry41Aa gene into pET 
expression vector was successful, albeit resulting in no protein expression in E. 
coli host BL21(DE3). Similarly, an attempt to express recombinant pETCry1AcIg 
in E. coli host BL21 was met with little success. Varying growth conditions for 
instance temperature, media, concentration of the inducer, IPTG did not aid in 
the expression of the desired protein. Altering the host strain from BL21(DE3) to 
an alternative E. coli host might lead to expression of a functional protein. Usage 
of a different E. coli host strain in conjunction with pET vectors might aid in protein 
expression. Similar effects were observed by Miroux and Walker (1996), who 
were unable to produce recombinant bacterial membrane proteins in BL21(DE3) 
host used en masse with pET3a expression vector owing to bacterial cell death. 
However on switching over to an alternative host E. coli C41(DE3), they were 
able to achieve the desired expression (Miroux & Walker, 1996). The proposed 
mechanism for lethality of over expression of protein was generation of large 
amounts of mRNA from the plasmid by T7 RNA polymerase as compared to E. 
coli RNA polymerase. Hence, translation being outstripped by transcription lead 
to generation of unstable naked RNA stretches. By an unascertained process, 
over expression of β-galactosidase from LacZ gene or an inactive form of 
elongation factor Tu leads to the degradation of ribosomal RNAs (Iost & Dreyfus, 
1995). Hence, it is imperative to opt for a strain where the transcripts are 
synthesised slowly by either the affected activity of T7RNA polymerase or due to 
the reduced amount of polymerase produced, thereby procrastinating the onset 
of transcription further preventing uncoupling of transcription and translation 
(Dong et al., 1995; Miroux & Walker, 1996). However, eliminating the lethality of 
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protein expression does not guarantee over expression of protein. Additionally, 
numerous other parameters need to be considered for instance preventing the 
degradation of mRNA and ensuring that undesirable features in the coding 
sequence for instance rare or low-usage codons which lead to misincorporation 
of amino acids do not impede the translation (Kane, 1995; Miroux & Walker, 
1996). 
 
Since attempts to obtain the desired functional protein in E. coli met with little 
success, we aimed at devising strategies to establish a stable homologous 
expression system for Cry41A and its mutants. 
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5. Homologous expression, characterisation and mutagenesis of 
Parasporin-3 genes 
 
5.1 Introduction 
Heterologous expression efforts in E. coli resulted in either expression of ORF3 
or lack of expression of the desired recombinant protein. Similar results were 
obtained by Yamashita et al. when attempting expression of PS-3 genes in E. coli 
(personal communication). The plasmids pCG-I and pCG-III  harbouring the 
genes of parasporin-3 viz., cry41Aa and cry41Ab respectively in an E. coli-Bt 
shuttle vector pHT3101  were transferred to us by Yamashita (Yamashita et al., 
2005). However, our attempts to express cry41Aa and cry41Ab genes from pCG-
I and pCG-III respectively proved unsuccessful (data not shown). Since the 
expression of recombinant cry41Aa gene could not be repeated using 
Yamashita’s previous established expression system (Yamashita et al., 2005), 
we demonstrate here the successful homologous expression of cry41Aa gene in 
B. thuringiensis under a strong promoter and further characterisation of the 
genes. We further elucidate the roles of the ORF2 and ORF3 of the split toxin in 
protein stability and function. 
 
Similarly, since preliminary screening of B. thuringiensis isolate Sbt021 
demonstrated activity against HepG2 (Figure 3.10A, p. 97), we intended to study 
its molecular organisation and further clone and express the relevant gene / 
genes involved in the cytotoxicity of the strain. Two major proteins of molecular 
masses 140 kDa and 80 kDa were obtained on 7.5% SDS-PAGE from the native 
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strain Sbt021 as shown previously in Figure 3.2, Chapter 3. Since an 80 kDa 
protein similar in size to the cytotoxic protein from A1462 was detected on SDS-
PAGE, we decided to assess the cytotoxicity of the gene expressing the 80 kDa 
protein. The 80 kDa protein from Sbt021 has been classed as Cry41Ba1 
(Crickmore et al., 2013) and had been identified following sequencing of the 
strain. However, in the absence of any published upstream and downstream 
regions, the sequence of Cry41Ba from Sbt021 was deduced from the reference 
sequence of closely related Bt serovar andalousiensis BGSC4AW1 producing 
Cry41Ba2. Nucleotide analysis of cry41Ba revealed three open reading frames 
in close proximity to each other in the same orientation with short intergenic 
regions between them. Cry41Ba was found to be a split toxin bearing semblance 
to Cry41Aa with conserved blocks 1-5 contained in ORF2 and conserved blocks 
6-8 being present in ORF3. The upstream flanking region of all the ORF’s 
contained the putative translational signals, ribosome binding sites. The 
presumed translational start site for the ORF2 is 
5’aaaaaggaggtttatacATGAATCCA 3’ with a ribosome binding site indicated in 
bold red letters. The ORF2 yields a polypeptide of 840 amino acids with a 
predicted molecular mass of 95 kDa. Upstream of ORF2 is located ORF1 that 
encodes a protein of 120 amino acids. An intergenic, non-coding region was 
located between ORF1 and ORF2. Downstream of ORF2 is another open reading 
frame, ORF3 separated by short intergenic sequence, with its own ribosome 
binding site. The ORF3 yields a polypeptide of 607 amino acids with a calculated 
molecular mass of 68 kDa.  
 
 
 
Page 156 of 260 
 
Conserved domain analysis in the protein sequence of Cry41Ba1ORF2 by 
Conserved Domain search, NCBI (Marchler-Bauer & Bryant, 2004; Marchler-
Bauer et al., 2009; Marchler-Bauer et al., 2011), detected the presence of a ricin-
like lectin domain [pfam 00652] in its carboxy terminus, referred to as ricin domain 
(RD) as in previous chapters. The amino acid sequence of Cry41Ba ORF2 
contained the signature Q-X-W/F motifs which form the defining characteristics 
of a member of the “Ricin Superfamily” [cd00161]. This was analogous to the 
domain present in Cry41AaORF2 derived from Bt strain A1462 (Figure 5.1). The 
absence of this domain from insecticidal Cry1Ac prompted us to further create 
mutants of the Cry41Aa and Cry41Ba toxins as done previously. However, since 
no expression could be achieved in E. coli, we illustrate here, the cloning and 
expression of Cry41Aa and Cry41Ba without the ricin domain assigned as 
Cry41AaΔRD and Cry41BaΔRD respectively, in Bacillus thuringiensis. We further 
investigate the contribution of this domain to the biological activity of the two 
proteins. 
 
 
Figure 5.1. Diagrammatic representation of Cry41Ba, Cry41Aa and insecticidal 
Cry1Ac. RD (red box) denotes the ricin-like domain found at the end of ORF2 in Cry41Aa 
and Cry41Ba which most closely resembles HA-33 from Clostridium botulinum. 
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5.2 Results 
 
5.2.1 Expression of cry41Aa and cry41Ba genes in Bacillus thuringiensis 
Since attempts to express the cry41 gene in E. coli were met with little success, 
a strategy to express the target gene in B. thuringiensis was devised. The E. coli 
/ B. thuringiensis shuttle vector pSVP27 with the cyt1A promoter upstream of the 
cloned target gene was employed (Crickmore & Ellar, 1992; Crickmore et al., 
1994). The strategy was to individually clone cry41AaORF2ORF3 and 
cry41BaORF2ORF3 genes into the pSVP27 vector to form the recombinant 
plasmids referred to as pSVP27Cry41Aa/ORF2ORF3 (Figure 5.2) and 
pSVP27Cry41Ba/ORF2ORF3 (Figure 5.4) respectively. Further, it was aimed at 
cloning ORF2 without ORF3 of each cry41Aa and cry41Ba operon into pSVP27 
designated as pSVP27Cry41Aa/ORF2 and pSVP27Cry41Ba/ORF2 (Figure 5.3). 
Using PfuUltra Hotstart Master mix from Stratagene, cry41AaORF2 and ORF3 
were amplified by PCR from genomic DNA from the Bt strain A1462. Primers 
were designed to amplify 21 bp upstream of the start codon of ORF2 which 
includes the ribosome binding site. Similarly, genomic Sbt021 DNA was used a 
template for PCR amplification of cry41Ba gene. The primer sets were designed 
from the DNA sequence of Bt serovar andalousiensis BGSC4AW1 and employed 
in PCR to amplify the region encoding cry41BaORF2 and ORF3. Primers were 
designed to amplify 57 bp upstream of the start codon of ORF2 which includes 
the ribosome binding site. Various restriction sites were included in the primers. 
The PCR amplicons were column purified and subjected to restriction digestion 
by the respective enzymes as outlined in Table 5.1.   
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 The vector pSVP27 was subjected to digestion with corresponding restriction 
enzymes as the template DNA and gel purified (Section 2.2.3.2). The genes and 
the vectors were ligated according to the manufacturer’s instructions (Section 
2.2.4) and transformed into E. coli JM109 competent cells by electroporation 
(Section 2.2.5.1). The E. coli transformants were isolated by selection on LB-
agar-ampicillin plates (100 µg/ml) at 37°C. The colonies containing the correct 
inserts were identified by rapid size screen (Section 2.2.6). The single colonies 
with the correct insert obtained were further streaked on to LB-agar-ampicilin 
plates (100 µg/ml) at 37°C for increased plasmid yield. Small -scale plasmid 
preparations were carried using QIAprep Spin Miniprep Kit (Qiagen) and 
extracted plasmids were subjected to restriction analysis (Section 2.2.8) to check 
for colonies harbouring the desired cry41Aa and cry41Ba genes. The correct 
plasmid pSVP27Cry41Aa/ORF2 was corroborated by digesting it with restriction 
enzyme HaeIII and further by NdeI and KpnI (Figure 5.5A & B). Similarly, 
plasmids pSVP27Cry41Aa/ORF2ORF3 (Figure 5.6) and pSVP27Cry41Ba/ORF2 
and pSVP27Cry41Ba/ORF2ORF3 (Figure 5.7) were subjected to HaeIII 
restriction analysis. The colony thus containing the correct inserts was further 
transformed into E. coli GM2163 to obtain unmethylated DNA for ease of 
transformation in B. thuringiensis.  
The colonies thus obtained in GM2163 were confirmed for the correct construct 
by restriction analysis as aforementioned and introduced into various 
acrystalliferous strains of B. thurinigiensis including IPS78/11, 4Q7 and 4D7 by 
electroporation. Different strains of Bt were used as strain-dependent expression 
of other Bt toxin genes had been observed in our lab. The B. thuringiensis 
transformants were isolated by selection on LB-agar-chloramphenicol plates (5 
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µg/ml) at 30°C. Any colony thus obtained in Bt with the desired plasmid was 
purified using QIAprep Spin Miniprep Kit (Qiagen). Additionally, lysozyme (10 
mg/ml) was added to the resuspension buffer to lyse the cell wall (Section 
2.2.7.2). The plasmid was re-transformed back into competent E. coli JM109 cells 
to obtain a clean preparation of the DNA for verification of the final construct by 
restriction analyses as mentioned above. The final construct was further 
ascertained by sequencing. 
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Genomic 
DNA 
Primers Sequence ( 5’->3’) Product 
 
 
 
A1462 
BamrbsF 
 
2BamR 
GAAGAAggatccAAATGGAATGGAGG 
 
TTAGTCAGggatccTTGCACACC 
Cry41Aa/ORF2 
BamrbsF 
 
Cry41Orf3XbaR 
GAAGAAggatccAAATGGAATGGAGG 
 
CGCTtctagaAGCCTGCTACCATTAC 
 
Cry41Aa/ORF2ORF3 
 
 
 
Sbt021 
41BaF 
 
41BaOrf2R 
 
41BaF 
 
41BaOrf2+3R 
 
GTTCgtcgacTATAAAAGTGAACACAC 
 
CATTCgcatgcGAATACATATTTTTAC 
 
GTTCgtcgacTATAAAAGTGAACACAC 
 
GAATCgcatgcAGACTCCCTAC 
 
Cry41Ba/ORF2 
 
 
 
 
Cry41Ba/ORF2ORF3 
 
Table 5.1. PCR primers used for amplification of cry41 genes. Restriction sites 
introduced in the amplified fragments are indicated by lower-case letters. BamHI: ggatcc; 
XbaI: tctaga; SalI: gtcgac; SphI: gcatgc 
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Figure 5.2. Schematic illustration of the construction of plasmid 
pSVP27Cry41Aa/ORF2ORF3. Location of BamHI and XbaI sites are indicated on the 
plasmid. 
 
 
 
cry41AaORF2ORF3 with 
BamHI (5’ end) and XbaI 
(3’end) overhangs 
          Ligation 
BamHI and XbaI linearised 
pSVP27 with cyt1A 
promoter 
pSVP27Cry41Aa/ORF2ORF3 
                  10.4 kb 
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Figure 5.3. Schematic representation of the construction of plasmid 
pSVP27Cry41Aa/ORF2. Location of BamHI sites are indicated on the plasmid. 
 
 
cry41AaORF2 with 
BamHI overhangs. 
BamHI linearised 
pSVP27 with cyt1A 
promoter 
 
         Ligation 
pSVP27Cry41Aa/ORF2 
                   or 
pSVP27Cry41Ba/ORF2 
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Figure 5.4. Schematic representation of the construction of plasmid 
pSVP27Cry41Ba/ORF2ORF3. Location of restriction sites SalI and SphI are indicated 
on the plasmid. 
 
pSVP27Cry41Ba/ORF2ORF3 
cry41BaORF2ORF3 with SalI 
(5’ end) and SphI (3’end) 
overhangs 
 
SalI and SphI linearised 
pSVP27 with cyt1A 
promoter 
 
             Ligation 
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A                                                                B 
                                                
 
Figure 5.5. 1% Agarose gel depicting restriction patterns for recombinant 
pSVP24Cry41Aa/ORF2.  
(A) Lane 1, HaeIII restriction profile. (B) Lane 1, NdeI and KpnI digestion fragments.  
Lane M is the 1 kb DNA ladder. The fragment sizes predicted by NEB cutter are shown 
to the sides. 
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Figure 5.6. 1% Agarose gel illustrating the results of HaeIII restriction 
analysis of the construct pSVP27Cry41Aa/ORF2ORF3. Lane 1 is the HaeIII 
fragments of the recombinant pSVP27Cry41Aa/ORF2ORF3 and lane M is the 1 
kb molecular mass marker. The corresponding base pair length values of each 
DNA fragment as predicted by NEB cutter are shown to the left. 
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Figure 5.7. HaeIII restriction fragment patterns of recombinant plasmid 
pSVP27 carrying cry41Ba genes. Lane 1, HaeIII fragments of the construct 
pSVP27Cry41Ba/ORF2; lane 2, HaeIII fragments of the construct 
pSVP27Cry41Ba/ORF2ORF3; lane M, 1 kb DNA ladder. The corresponding base 
pair length values of each DNA fragment as predicted by NEB cutter are indicated 
next to the respective bands. 
 
 
 
 
3.0Kb 
 
2.0Kb 
1.5Kb 
 
1.0Kb 
 
 
0.5Kb 
 
 
 
 
2469 
 
 
 
 
1078/1049 
 
843 
720 
686 
 
587/580 
 
458 
434 
 
349 
267 
2469 
1290 
1049 
720 
               587 
M        1          2 
 
 
Page 167 of 260 
 
 
 
 
 
5.2.2 Preparation and characterisation of inclusion proteins from the 
recombinants  
 
The recombinants obtained were grown on nutrient agar plates containing 
chloramphenicol (5 µg/ml) at 30°C for 4 days. Sporulation was checked by 
microscope and the sporulated cells were harvested as described in Section 
2.2.9.3. Different crystal cured (Cry-) B. thuringiensis strains were evaluated for 
production of recombinant proteins. The proteins were analysed on 7.5% SDS-
PAGE gel. 
No parasporal inclusions or expressed proteins were observed in Bt strains 
IPS78/11 or 4Q7 (data not shown). However, the recombinant 
Cry41Aa/ORF2ORF3 yielded major bands with apparent molecular weights of of 
80 kDa and 125 kDa when harvested from the 4D7 strain (Figure 5.8). 
Cry41Aa/ORF2 expressed devoid of ORF3, yielded a major band of 80 kDa 
(Figure 5.8). Hence the 80 kDa band is ORF2 observed in the expression of the 
two components of the split toxin Cry41Aa in Bt 4D7. The predicted molecular 
weight of ORF2 which consists of 825 amino acid residues is 93.7 kDa. The 
protein runs as 80 kDa band in our gel system. ORF3 which is composed of 737 
amino acid residues with a predicted molecular weight of 83 kDa appears to 
migrate slower than its predicted molecular weight at approximately 125 kDa 
(Figure 5.8).  
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A weak expression of recombinant Cry41Ba was detected in 4Q7 (data not 
shown). No expression was obtained in IPS 78/11 and a strong expression was 
obtained in 4D7. Cry41Ba/ORF2ORF3 yielded a major band of 80 kDa in 4D7; 
the predicted molecular weight of ORF2 which consists of 840 amino acid 
residues is 95.6 kDa. ORF3 which is composed of 688 amino acid residues does 
not appear to migrate at its expected molecular weight of 78.5 kDa instead 
yielding a band at 62 kDa (Figure 5.9A). Recombinant Cry41Ba/ORF2 expressed 
without the ORF3 yielded a major band of 80 kDa (Figure 5.9B). Thus, expression 
of the recombinant proteins appeared to be strain-specific in B. thuringiensis. 
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Figure 5.8. SDS-PAGE (7.5%) analysis of protein inclusions extracted from B. 
thuringiensis strain 4D7 expressing recombinant Cry41Aa at 30°C. Lane 1, 
recombinant Cry41Aa/ORF2ORF3; lane 2, recombinant Cry41Aa/ORF2; lane M, protein 
marker. 
 
Figure 5.9. SDS-PAGE (7.5%) analysis of recombinant Cry41Ba inclusions 
extracted from B. thuringiensis strain 4D7 grown at 30°C. (A) Lane1, recombinant 
Cry41Ba/ORF2ORF3 showing ~80 kDa ORF2 and ~62 kDa ORF3. (B) Lane 1, 
recombinant Cry41Ba/ORF2 expressed without ORF3. Lane M is the protein marker. 
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5.2.2.1 Solubilisation and proteolytic processing of the toxins 
In order to study the activity of the expressed recombinant proteins on 
mammalian cancer cells, we aimed at obtaining large quantities of the desired 
proteins in soluble and processed forms. Various buffers at different pH were 
used to solubilise the proteins as mentioned in Section 2.2.12. The protein was 
subjected to proteolytic treatment with trypsin at 1 mg/ml as described in Section 
2.2.12. Attempts were made to solubilise and trypsin-activate the proteins in 
presence or absence of a reducing agent. The solubilisation assays suggested 
that 50 mM sodium carbonate buffer at pH 10.9 solubilised the protein in 
presence of 1 mM DTT. In vitro proteolytic processing of recombinant 
Cry41Aa/ORF2ORF3 by 1 mg/ml trypsin in the presence of DTT resulted in the 
partial digestion of 80 kDa protein band generating bands of about 60 kDa and 
78 kDa (Figure 5.10A). Trypsin treatment of recombinant Cry41Ba/ORF2ORF3 
yielded a major protein band of ~58 kDa (Figure 5.10B). 
 Deleting ORF3 resulted in expression of Cry41Aa/ORF2 which could not be 
obtained in the soluble form. Initial attempts at solubilising the recombinant 
Cry41Aa/ORF2 were not successful. Several buffers at different pH ranging from 
2-11 were employed (data not shown). On the contrary, Cry41Ba/ORF2 could be 
readily solubilised and processed efficiently with trypsin in absence of ORF3 (data 
not shown). The trypsin-treated recombinant Cry41Aa and recombinant Cry41Ba 
protein samples containing DTT were dialysed against 50 mM Tris buffer pH 8 
overnight (Section 2.2.13.2). The dialysed samples were analysed on the 7.5% 
SDS-PAGE. The dialysed fraction of solubilised recombinant 
Cry41Aa/ORF2ORF3 contained bands of ~125 kDa (ORF3) and 80 kDa (ORF2) 
(Figure 5.11, lane 2). The trypsin–treated dialysed fraction of 
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Cry41Aa/ORF2ORF3 contained a band of ~78kDa (Figure 5.11, lane 3). In case 
of Cry41BA/ORF2ORF3, a 80 KDa band was obtained in the dialysed fraction of 
the solubilised protein  (Figure 5.11, lane 5) and a processed fragment of ~58 
kDa was seen in the dialysed fraction of the trypsin-treated protein (Figure 5.11, 
lane 6). Protein quantitation was accomplished through Bradford assay. The 
dialysed samples were stored at -20°C until use in the toxicity assays. 
  A                                                         B 
              
Figure 5.10. Solubilisation and trypsin-treatment of recombinant protein 
inclusions extracted from B. thuringiensis strain 4D7.  
(A) Lane 1; solubilsed recombinant Cry41Aa/ORF2ORF3 in carbonate buffer pH 10.9 in 
presence of DTT; lane 2, trypsin- treated Cry41Aa/ORF2ORF3.  
(B) Lane 1, solubilised recombinant Cry41Ba/ORF2ORF3 in carbonate buffer pH 11.0; 
lane 2, trypsin-treated Cry41Ba/ORF2ORF3; lane 3, untreated Cry41Ba/ORF2ORF3. 
Lane M is the protein marker. 
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Figure 5.11. 7.5% SDS-PAGE analysis of the dialysis of the solubilised and trypsin-
treated samples of recombinant Cry41Aa and Cry41Ba extracted from Bt 4D7. 
Lane1, solubilised recombinant Cry41Aa/ORF2ORF3 in carbonate buffer pH 11.0 in 
presence of DTT; lane 2, dialysed solubilised recombinant Cry41Aa/ORF2ORF3; lane 3, 
dialysed trypsin-treated recombinant Cry41Aa/ORF2ORF3; lane 4, solubilised 
recombinant Cry41Ba/ORF2ORF3 in carbonate buffer pH 11.0 in presence of DTT; lane 
5, dialysed solubilised recombinant Cry41Ba/ORF2ORF3; lane 6, dialysed trypsin-
treated recombinant Cry41Ba/ORF2ORF3; lane M, protein marker. 
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5.2.3 In vitro cytotoxic activity of the recombinant Bt toxins 
 
The solubilised and the trypsin-treated proteins were tested on human cancer cell 
lines, HepG2 and HeLa. Cytotoxicity testing was performed using the Promega 
CellTIter-Blue cell viability assay (Section 2.2.15.2.2). Cytopathic effects were 
observed by phase-contrast microscopy. Since Yamashita et al. (2005) observed 
selective cytocidal effects of the parasporal protein at a final concentration of 10 
μg/ml or 1 μg per well, we aimed at using the desired treatments within similar 
range in each well.  
 
The trypsin-treated recombinant Cry41Aa/ORF2ORF3 protein induced marked 
morphological changes and cytotoxicity in HepG2 cells resulting in spillage of the 
intracellular contents into the extracellular milieu as observed under inverted 
phase contrast microscope (data not shown) and significant reduction in the 
number of viable cells (Figure 5.12) but exhibited no detectable morphological 
changes and only a weak toxicity against HeLa cells as seen by the CellTiter-
blue assay (Figure 5.13B) and inverted phase-contrast microscopy (data not 
shown). The trypsin-treated purified recombinant Cry41Ba/ORF2ORF3 did not 
show any cytotoxic activity (Figure 5.12). No cell-killing activity was observed 
when HepG2 and HeLa cells were treated with a negative control of activated 
Cry8 toxins expressed in 4D7 (Figure 5.12). Cell viabilities of HepG2 and HeLa 
cells when treated with processed recombinant Cry 8, 4D7 and recombinant 
Cry41Ba protein inclusions were not affected (Figure 5.12). The positive control 
etoposide brought about significant cell-killing when used at a concentration of 
0.2 mg/ml (Figure 5.12) or 0.1 mg/ml (Figure 5.13A). However, trypsin-treated 
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recombinant Cry41Aa/ORF2ORF3 was able to induce significantly greater 
cytotoxic effects when used at a two-fold lower concentration of 50 μg/ml than 
the etoposide. No cytopathic effects were observed on treatment with 
recombinant Cry41Ba/ORF2 even when used at higher concentrations (data not 
shown). 
A dose-response study conducted showed that cell viability  was significantly 
reduced in a dose-dependent manner after exposure of HepG2 cells to 
recombinant  Cry41Aa/ORF2ORF3 trypsin- treated proteins using the CellTiter-
Blue assay (Figure  5.13A & B). Dose-dependent cytotoxicity was induced in 
HepG2 cells by the trypsin-treated recombinant Cry41Aa/ORF2ORF3. Four-fold 
dilutions of trypsin-treated recombinant Cry41Aa/ORF2ORF3 exerted greater 
cytotoxic effects than etoposide (0.1 mg/ml) in HepG2 cells (Figure 5.13A). Cell 
death was observed with exposure of HepG2 cells to as low as 10 fold dilution of 
trypsin-treated recombinant Cry41Aa/ORF2ORF3. This dose-response study 
suggests a great variation in the susceptibility between the cell lines HepG2 and 
HeLa with HepG2 being highly susceptible to the trypsin-treated recombinant 
Cry41Aa/ORF2ORF3. Four-fold dilutions of trypsin-treated recombinant 
Cry41Aa/ORF2ORF3 did not exhibit any cytotoxic effects on HeLa cells (Figure 
5.13B).  
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Effect of Bt recombinant proteins on HepG2 cells: 2h incubation with CellTiter- 
Blue 
 
 
 
Figure 5.12. Effect of recombinant Bt proteins on cell viability of HepG2 cells.  
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640 nm. Error bars denote SD of the mean of triplicate wells. Experiments are
 representative of at least five independent assays with each treatment. 
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A. Dose-response effect of trypsin-treated Cry41Aa/ORF2ORF3 on HepG2 cells: 4h 
incubation with CellTiter-Blue  
 
 
 
B. Dose-response effect of trypsin-treated Cry41Aa/ORF2ORF3 on HeLa cells: 4h 
incubation with CellTiter- Blue 
 
Figure 5.13. CellTiter- Blue assay indicating a dose-response analysis of trypsin- 
treated recombinant Cry41Aa/ORF2ORF3 protein on A. HepG2 cells B. HeLa cells. 
Y-axis represents Relative Fluorescence Unit (RFU). Effect of various dilutions of 
proteins were checked on HepG2 and HeLa cells. Error bars denote SD for the data 
derived from the individual wells (triplicates). Experiments are representative of at least 
three independent assays with each treatment. 
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5.2.4 Investigating the role of the ricin domain 
 
Having analysed the cytotoxic activities of recombinants Cry41Aa and Cry41Ba, 
we further intended to investigate the factors that contribute to the cytotoxicity. 
We intended to investigate the role of ricin region contained within the ORF2 of 
the recombinants. Although the recombinant Cry41Ba did not show activity 
against HepG2 cells, since it contained the ricin domain as present in Cry41Aa 
and showed remarkable similarity to Cry41Aa, we decided to investigate the 
significance of the conserved domain. 
 
PCR-mediated deletion of the ricin domain from ORF2 of 
pSVP27Cry41Aa/ORF2ORF3 and pSVP27Cry41Ba/ORF2ORF3 was carried out 
as schematically represented in Figure 5.14. PfuUltra Hotstart Master mix from 
Stratagene was used for the PCR. Primers were designed to amplify the entire 
toxin encoding plasmid but excluding the ricin domain. The forward primer 
(TAAAGGTGTGCAACTATCCCTTGAC) included the stop codon (red letters) of 
ORF2 at its 5’ end whereas the 5’ end of the reverse primer 
(TCGAGTGGTTAAGCCAATACCC) encoded the 713th codon of ORF2 (Figure 
5.15A). Following amplification the PCR product was self-ligated to give a plasmid 
(pSVP27Cry41AaΔricin) encoding the Cry41Aa toxin with amino acids 714-825 
deleted. Similarly, pSVP27Cry41BaΔRD mutant was created using the primers  
5’ TAAGTCGAGTTAAAAATATGTATTCGC 3’ and  5’ 
AGCTTGTGTTGTTGGAATGAACTCGA 3’ which was intended to delete 453 
base pairs of residues after conserved block 5 to include the  ricin domain. The 
primers were also designed to encode a HindIII restriction site (AAGCTT) at the 
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ligation point thus allowing confirmation of the deletion of ricin domain from the 
parental cry41Ba gene as illustrated schematically in Figure 5.15B. Briefly, the 
reverse primer 41BaDelRR was designed to encode a part of the HindIII 
restriction site viz., AAGCT + 2066 bp downstream of the ORF2 start codon. The 
forward primer contained the missing T from the stop codon at its 5’end. Upon 
excision of the ricin domain, the resultant PCR amplicon thus had an engineered 
HindIII site (Figure 5.15B) to ascertain the successful excision of the ricin domain. 
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Figure 5.14. Schematic representation of the PCR-mediated deletion of the ricin 
domain from ORF2 of pSVP27Cry41Aa/ORF2ORF3 and 
pSVP27Cry41Ba/ORF2ORF3. 
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A 
Forward primer 
41rddelF 5’ TAAAGGTGTGCAACTATCCCTTGAC 3’  
Reverse primer       
41rddelR 5’ TCGAGTGGTTAAGCCAATACCC 3’   
Primers annealing to pSVP27Cry41Aa/ORF2ORF3 
+2116 bases downstream of the ORF2 start site    
                                                      
 ATG GGT ATT GGC TTA ACC ACT CGA TGT GGG-RD-TAA agg tgt gca act atc cct gac taa catatacatttaacaggcatcttaaagcaaagctcatacgaaggaggataatgaATG 
 M    G   I    G   L   T   T    R   C    G 
                                                                                                                                                                          Intergenic region                                                            Start of ORF3 
                                                                                                                                      
 
Ligation of amplified PCR amplicon with deleted ricin domain region  
ATG GGT ATT GGC TTA ACC ACT CGA TAAaggtgtgcaactatccctgactaacatatacatttaacaggcatcttaaagcaaagctcatacgaaggaggataatgaATG 
 M    G   I    G   L   T   T    R    
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B 
 Part of Cry41Ba ORF 2 sequence depicting the intended mutation to insert a HindIII restriction site 
 +2,060 bases downstream of ORF2 start codon  
                                                            AA GCT 
5’--GAG-TTC-ATT-CCA-ACA-ACA-CCA-ACA-CCA-GAA ----ricin domain---TAA-3’ Stop Codon  
         K        F        I        P      T       T      P/Q     T/A      P      E 
                                                                                                Resulting change in the protein sequence 
Reverse primer                                                                                                     Forward primer 
HindIII site 
5’-AGC-TTG-TGT-TGT-TGG-AAT-GAA-CTC-GA-3’                                                  5’-TAA-GTC-GAG-TTA-AAA-ATA-TGT-ATT-CGC-3’ 
Primers annealing to pSVP27Cry41Ba/ORF2                                                                    Stop Codon 
                       Reverse primer 
 3’---GGT-TGT-GTT-CGA-‘5       Excised region 
5’---CCA-ACA-CCA-ACA--CCA-GAA -RD--TAA-3’-intergenic sequence-5’-ORF3-3’ 
                                                               Forward primer                                                                                
 Ligation of amplified PCR amplicon 
                                                                       Engineered HindIII restriction site to allow confirmation of the excised ricin domain 
                                             5'---CCA-ACA-ACA-CAA-GCT-TAA-3' 
Figure 5.15. Ricin domain deletion. (A) Schematic depiction of binding of the primers to pSVP27Cry41Aa/ORF2ORF3 for deletion of the ricin 
domain. (B) Schematic representation of the strategy to excise ricin domain from ORF2 of cry41Ba gene. Ricin domain is denoted by RD and 
the excised region is highlighted in grey.
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PCR amplicons were DpnI digested to remove the template DNA, gel purified, 
self-ligated using T4 DNA ligase and transformed into E. coli GM2163 to obtain 
unmethylated DNA for ease of transformation in B. thuringiensis. Transformants 
obtained were screened for the correct plasmid by restriction digestion. NdeI and 
KpnI restriction digestion profile differentiated the mutant pSVP27Cry41AaΔRD 
which lacked band of 1531 bp from the non-mutant template 
pSVP27Cry41Aa/ORF2ORF3 (Figure 5.16).  
Similarly, pSVP27Cry41BaΔRD was digested with HindIII and HaeIII. The HaeIII 
restriction fragments differentiated the mutant from the non-mutant (Figure 5.17). 
However, further digestion with HindIII yielded bands of sizes 5949 and 
approximately 3000 base pairs instead of 5949, 1949 and 1743 as predicted by 
NEB cutter suggesting possible deletion in the HindIII site (data not shown). The 
construct was sequenced and this revealed the loss of 2 bases TA at 5’ end of 
the forward primer. The deletion thus shifted the reading frame downstream to 
the intended mutation, encountering the further in-frame stop codon in the 
intergenic region between ORF2 and ORF3, thus extending the reading frame by 
further adding 14 amino acids onto the C-terminus of the protein as schematically 
demonstrated in Figure 5.18. Hoping that this wouldn’t have an impact on the 
functionality of the desired mutant protein, as the frameshift caused changes only 
at the C-terminus of the protein; we decided to proceed further with the construct.  
The constructs were transformed into B. thringiensis 4D7 strain for expression. 
The colony thus obtained in Bt with the desired plasmid was purified (Section 
2.2.5.2) and re-transformed back in competent E. coli 109 to verify the 
transformant by restriction analysis. 
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Figure 5.16. Restriction digestion profile confirming the deletion of the ricin 
domain from pSVP27Cry41Aa/ORF2ORF3.  
Template pSVP27Cry41Aa/ORF2ORF3 (Lane 1) and mutant pSVP27Cry41AaΔRD 
(Lane 2) were digested with NdeI and KpnI. The mutant lacks the 1531 bp band 
(indicated by black arrow) as seen in the template DNA. Instead the mutant possesses 
the 1195 bp band (indicated by green arrow). Lane M is the 1 kb marker. The 
corresponding base pair length values of each DNA fragment as predicted by NEB cutter 
are shown to the left. 
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A                                           B 
 
  
Figure 5.17. HaeIII restriction digestion profile confirming the deletion of the ricin 
domain from pSVP27Cry41Ba.  
(A) pSVP27Cry41BaΔRD HaeIII fragments (Lane 1) (B) pSVP27Cry41Ba/ORF2ORF3 
HaeIII fragments. The mutant has a band of 625 bp (black arrow) which is lacking from 
the template. The template has a band of 1078 bp (underlined) which is lacking from the 
mutant. Lane M is the 1 kb marker. The corresponding base pair length values of each 
DNA fragment as predicted by NEB cutter are shown to the right.
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Intended pSVP27Cry41BaΔRD                                                                                      
+2042 bases downstream of ORF2 start codon 
 E        F          I        P      T       T        Q       A     *                       Intergenic region 
GAG TTC ATT CCA ACA ACA CAA gCt TAA gtc gag tta aaa ata tgt att cgc aaaccgaatgttatctaaaaggagagtgttcaATG 
                                                                                             Start codon ORF3 
pSVP27Cry41BaΔRD after sequencing 
 
  E        F          I        P      T       T       Q   A   S   R   V   K   N   M   Y   S   Q   T   N   V   I   *                                              
 GAG TTC ATT CCA ACA ACA CAA gCt Agt cga gtt aaa aat atg tat tcg caa acg aat gtt atc taa 
 
 
 
 
 
 
Figure 5.18. Frameshift mutation in pSVP27Cry41BaΔRD. Deletion of ricin domain resulted in frameshift mutation in ORF2 in recombinant 
Cry41Ba encountering the further in-frame stop codon in the intergenic region before ORF3 thus extending the reading frame. 
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5.2.5 Preparation and characterisation of recombinant mutant proteins, 
Cry41AaΔRD and Cry41BaΔRD for activity on human cancer cells 
 
The recombinants obtained were grown on nutrient agar plates containing 
chloramphenicol (5 µg/ml) at 30°C for 4 days. Sporulation was checked under the 
microscope and the sporulated cells were harvested as described in Section 
2.2.9.3. The proteins were analysed on 7.5% SDS-PAGE gel.  
 
Parasporal inclusions of the mutant Cry41AaΔRD yielded major bands of 
approximately 70 kDa and 125 kDa when harvested from 4D7 (Figure 5.19, lane 
4). 70 kDa is the modified ORF2. 125 kDa band which is also seen in the 
recombinant Cry41Aa/ORF2ORF3 is ORF3 migrating slower than its predicted 
molecular weight at 125 kDa. The mutant Cry41BaΔRD yielded a major protein 
band of ~75 kDa (Figure 5.19, lane 7). 
 
In order to study the activity of the recombinant mutant proteins thus expressed 
on mammalian cancer cells, we aimed at obtaining large quantities of the desired 
proteins in soluble and processed forms. Various buffers at different pH were 
used to solubilise the proteins. The proteins were processed with trypsin at 1 
mg/ml as described in Section 2.2.12. Attempts were made to solubilise and 
trypsin activate the proteins in presence or absence of a reducing agent. The 
solubilisation assays suggested that 50 mM carbonate buffer at pH 11 solubilised 
the proteins efficiently in presence of 1 mM DTT. Trypsin in the presence of DTT 
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resulted in the partial digestion of 70 kDa protein band of mutant Cry41AaΔRD 
generating a band of about ~68 kDa (Figure 5.20, lane 2). Trypsin-treatment of 
mutant Cry41BaΔRD yielded a band of ~40 kDa (Figure 5.21, lane 6).  
The solubilised and the trypsin-treated samples containing DTT were dialysed 
against 50 mM Tris buffer pH 8.0 overnight (Section 2.2.13.2). The dialysed 
solubilised protein samples when subjected to trypsin treatment at 1 mg/ml 
without DTT yielded the same results as above. Bradford method was employed 
to estimate the concentration of the protein samples (Section 2.2.11). The 
dialysed samples were frozen at -20 °C for further cell assays. 
 
 
Figure 5.19. Solubilisation of the recombinant mutants of Cry41Aa and Cry41Ba 
toxins extracted from B. thuringiensis strain 4D7. Lane1; the total protein sample of 
Cry41Aa/ORF2ORF3 at pH 11; lane 2, the soluble fraction of Cry41Aa/ORF2ORF3 at 
pH 11; lane 3, the total protein sample of Cry41Aa/ORF2; lane 4, the soluble fraction of 
mutant Cry41AaΔRD; lane 5, the soluble fraction of Cry41Ba/ORF2ORF3; lane 6, the 
total protein sample of Cry41Ba/ORF2; lane 7, the soluble fraction of the mutant 
Cry41BaΔRD; lane M, protein marker. 
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Figure 5.20. Solubilisation and proteolytic processing of Bt 4D7 expressed 
recombinant proteins Cry41Aa and mutant Cry41AaΔRD in a reducing 
environment. Lane1, solubilisation of the mutant Cry41AaΔRD in carbonate buffer, pH 
11.0 (supernatant fraction); lane 2, trypsin-treatment of the mutant Cry41AaΔRD; lane 3; 
solubilisation of Cry41Aa/ORF2ORF3 in carbonate buffer, pH 11.0; lane 4; trypsin- 
treatment of Cry41Aa/ORF2ORF3. Note for the sake of clarity, data for recombinant 
Cry41Aa/ORF2ORF3 is presented again from Figure 5.10A. 
 
Figure 5.21. Solubilisation and proteolytic processing of the Bt 4D7 expressed 
mutant Cry41BaΔRD protein inclusions. Sodium carbonate buffers at various pH were 
used to solubilise and process the proteins. Lanes 1-3 are tryptic fragments of 
Cry41BaΔRD. Lane 1, trypsin-treatment overnight, pH 10; lane 2, trypsin-treatment 
overnight at pH 11; lane 3, trypsin-treatment for 1 h, pH 11; lane 4, soluble fraction  of 
Cry41BaΔRD at pH 11; lane 5, soluble fraction of Cry41BaΔRD at pH 10; lane 6, trypsin-
treatment at pH 10.5; lane  M, protein marker; lane 7, trypsin treatment of the non-mutant 
recombinant Cry41Ba/ORF2ORF3  at  pH 11; lane 8, trypsin treatment of the 
recombinant Cry41Ba/ORF2ORF3  at  pH 10. 
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5.2.6 In vitro cytotoxic activity of the recombinant mutant Bt toxins 
 
The solubilised and the trypsin-treated Cry41AaΔRD and Cry41BaΔRD proteins 
were tested on human cancer cell lines, HepG2 and HeLa. Effect on cell viability 
was assessed using the CellTIter-Blue cell viability assay kit (Section 2.2.15.2.2). 
Cytopathic effects were observed by phase-contrast microscopy.  
The mutant trypsin-treated recombinant Cry41AaΔRD when used at a total 
protein concentration of 40 μg/ml exhibited cytotoxicity significantly reducing 
viability of HepG2 cells (Figure 5.22). This indicates lack of change of toxicity of 
Cry41Aa/ORF2ORF3 even when the ricin domain is deleted. The recombinant 
trypsin-treated Cry41AaΔRD induced cytotoxicity in HepG2 cells as seen in 
Figure 5.22 which shows the cell viability graphs for trypsin-treated Cry41AaΔRD 
and Cry41Aa/ORF2ORF3 used at concentrations of 40 and 50 μg/ml respectively 
on HepG2 cells with CellTiter-Blue assay. The trypsin-treated Cry41AaΔRD 
exhibited greater reduction in cell viability as compared to the soluble 
Cry41AaΔRD (Figure 5.22) indicating that N-terminal processing is required for 
enhanced cytocidal activity. Only a weak toxicity against HeLa cells were 
observed on treatment with trypsin-treated Cry41AaΔRD (Figure 5.23B) and 
inverted phase-contrast microscopy (data not shown). The trypsin-treated 
recombinant Cry41BaΔRD did not show any cytotoxic activity against HepG2 or 
HeLa cells (data not shown).  
A dose-response study conducted showed that cell viability was significantly 
reduced in a dose-dependent manner after exposure of HepG2 cells to varying 
concentrations of recombinant mutant Cry41AaΔRD trypsin-treated proteins 
using the CellTiter-Blue assay as seen in case of Cry41Aa/ORF2ORF3 (Figure 
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5.23A). The dose response study further suggests a great variation in the 
susceptibility between the cell lines HepG2 and HeLa with HepG2 being highly 
susceptible to the trypsin-treated mutant Cry41AaΔRD. Four-fold dilutions of 
trypsin-treated recombinant Cry41AaΔRD did not exhibit any cytotoxic effects on 
HeLa cells (Figure 5.23B).  
Dose-dependent cytotoxicity was induced in HepG2 cells by the trypsin-treated 
recombinant Cry41AaΔRD which was comparable to trypsin-treated 
Cry41Aa/ORF2ORF3. Trypsin-treated recombinant Cry41AaΔRD and 
Cry41Aa/ORF2ORF3 at concentrations of 1 µg per well each exerted comparable 
cytotoxic effects to etoposide (100 μg/ml) in HepG2 cells (Figure 5.24). Toxicity 
decreased with decreasing concentration of the trypsin-treated proteins. Two-fold 
dilution of trypsin-treated recombinant Cry41AaΔRD and Cry41Aa/ORF2ORF3 
exerted lesser degree of cytotoxicity in HepG2. The cytotoxic effects effects were 
comparable to etoposide in HepG2 cells at two-fold dilution. Cell death was 
observed with exposure of HepG2 cells to as low as four-fold dilution of trypsin-
treated recombinant proteins, Cry41AaΔRD and Cry41Aa/ORF2ORF3 (Figure 
5.24).   
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Effect of Bt recombinant proteins on HepG2 cells: 2h incubation with CellTiter- 
Blue 
 
 
 
 
Figure 5.22. Effect of recombinant Cry41Aa protein and the mutant Cry41AaΔRD 
on viability of HepG2 cells. Y-axis represents Relative Fluorescence Unit (RFU). Error 
bars denote SD of the mean of triplicate wells. Experiments are representative of at least 
five independent assays with each treatment. 
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A. Dose-response effect of trypsin-treated recombinant mutant protein 
Cry41AaΔRD on HepG2 cells: 2h incubation with CellTiter- Blue 
 
B. Dose-response effect of trypsin-treated recombinant mutant protein 
Cry41AaΔRD on HeLa cells: 2h incubation with CellTiter-Blue 
 
Figure 5.23. Dose-response curves of cytocidal activity associated with varying 
concentrations of trypsin-treated mutant Cry41AaΔRD on A. HepG2 cells & B. 
HeLa cells. Y-axis represents Relative Fluorescence Unit (RFU). Error bars denote SD 
for the data derived from the individual wells (triplicates). Experiments are representative 
of at least three independent assays with each treatment. 
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Comparison of dose-response effects of trypsin-treated recombinant 
Cry41Aa/ORF2ORF3 with mutant protein Cry41AaΔRD on HepG2 cells: 2h 
incubation with CellTiter-Blue 
 
Figure 5.24. Dose-response curves of cytocidal activity associated with varying 
concentrations of trypsin-treated Cry41Aa and mutant Cry41AaΔRD on HepG2 
cells. Y-axis represents Relative Fluorescence Unit (RFU). Error bars denote SD for the 
data derived from the individual wells (triplicates). Experiments are representative of at 
least three independent assays with each treatment. 
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5.3 Discussion 
 
Successful overexpression of cry41Aa and cry41Ba genes were obtained in 
acrystalliferous B. thuringiensis strain 4D7 when cloned downstream of the Cyt 
promoter of the expression vector pSVP27. The recombinant protein 
Cry41Aa/ORF2ORF3 when treated with trypsin was cytotoxic to mammalian 
cancer cells. However no cytotoxicity was obtained in case of Cry41Ba which 
possesses significant similarity in overall sequence and in gene-organisation to 
Cry41Aa. 
The recombinant protein Cry41Aa/ORF2ORF3 expressed in acrystalliferous Bt 
4D7 was able to solubilise and be processed efficiently to a protease-resistant 
core by the proteolytic treatment in a reducing environment. Deleting ORF3 
resulted in expression of Cry41Aa/ORF2 which could not be solubilised. Hence, 
suggesting that ORF3 is required for solubility. The solubility assays carried out 
are congruent with the assumed function of C-terminal ends of longer Cry δ-
endotoxins. Proteolytic activation of Bt protoxins cleaves the C-terminal ends 
containing the conserved homology blocks 6-8 (Lightwood et al., 2000; Bravo et 
al., 2002). The C-terminal ends are implicated in crystal formation and efficient 
solubilisation by ensuring a high pH environment for certain protoxins (Park et al., 
2000; Naimov et al., 2006; Barboza-Corona et al., 2012). However, Lenane et al. 
(2008) suggested that Orf2-5Ad derived from B. thuringiensis strain L366, being 
the primary component of the protein crystals, could still accomplish all the 
functions ascribed to the C-terminus. The Cry5A proteins are nematocidal 
proteins. Albeit E. coli expressed Cry5Ad and Orf2-5Ad proteins lack such 
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activity. To be noted is that Cry5Ad and Orf2-5Ad are produced as two separate 
proteins and hence is a split toxin similar to Cry41Aa and Cry41Ba. Vazquez-
Padron et al. (2004) further reported that C-terminus  containing variants of 
homology blocks 6-8 of Cry1Ab lacking the toxic core exhibits strong toxicity to 
Bt , E. coli and Agrobacterium tumefaciens when cloned and expressed in these 
bacteria. However, the ORF3 of Cry41Aa that was obtained in E. coli JM109 was 
devoid of any biological activity. 
 
Rosso & Delecluse (1997) observed that just Orf2 of the otherwise toxic Cry19Aa 
to Culex pipens and Anopheles stephensilarvae exhibited no larvicidal activity. A 
combination of both proteins synergised the toxic effect of the split toxin Cry19Aa. 
In order to assess if ORF3 contributed to the cytotoxity of recombinant 
Cry41Aa/ORF2ORF3, the protein was expressed without ORF3. However, the 
solubility of ORF2 was severely affected when expressed without ORF3. Thus 
Cry41Aa/ORF2 could not be obtained in soluble form. On the contrary, 
Cry41Ba/ORF2 could be readily solubilised and processed efficiently with trypsin 
in absence of ORF3. It is pertinent to conclude that S-S linkages and cysteine 
residues present in the open reading frames imparts biological function to the C-
terminus and hence varies between the various Cry proteins. 
 
The present results demonstrate that the soluble recombinant Cry41Aa did not 
exhibit toxicity to the HepG2 cells. Trypsin-treatment was essential for the 
required cytocidal activity. This is in congruent with reports of activity of other 
parasporin toxins’ against mammalian cell lines. For instance, Ito et al. (2004) 
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observed that the full length Cry46Aa protoxin from Bt strain A1547 demonstrated 
no apparent cytotoxic activity. However, the N-terminal truncated protein 
generated proteolytic processing with a relative molecular mass of 31 kDa 
exhibited cytocidal activity against MOLT-4 cells. The protease resistant core of 
approximately 78 kDa of recombinant Cry41Aa generated by trypsin treatment 
showed preferential activity against HepG2 cells. The solubilised form of the toxin 
lacked such activity. This is in accordance with previous studies  conducted on 
M. sexta which  suggested  that presence of N-terminal peptide might preclude 
binding of the toxin to non-target membranes (Martens et al., 1995)  inkling that 
pore forming  ability of domain I is achieved only after proteolytic removal of the 
N-terminal peptide (Bravo et al., 2002). Similar studies ascribe the reduced 
toxicity of mutant insecticidal Cry1Ac protoxin in which N-terminal tryptic cleavage 
site has been removed by site-directed mutagenesis to the reduced rate of N-
terminal activation (Bravo et al., 2002). In the homologous Cry1Ab protoxins, a 
mutation preventing N-terminal processing also demonstrated low toxicity to M. 
sexta larvae (Martens et al., 1995). Cry41Aa protoxins that bears a striking 
similarity to the insecticidal Bt Cry1A toxins might function in a similar manner.  
This is further validated by the fact that the  solubilised mutant Cry41AaΔRD in 
which  the ricin domain has been deleted from the C-terminus of ORF2 exhibits 
a moderate cytotoxicity as compared to the trypsin treated Cry41AaΔRD and the 
non-mutant trypsin-treated recombinant Cry41Aa/ORF2ORF3 toxin. This 
suggests that N-terminal activation is essential for the enhanced cytotoxic activity 
of the toxin Cry41Aa/ORF2ORF3. 
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The result of this study however differs with the previous study conducted by 
Yamashita et al. (2005) who found that solubilised Cry41Aa was not toxic to 
HepG2 cells whereas toxin treated with proteinase K / trypsin (yielding a 64 kDa 
fragment) was. The 64 kDa toxin derived from 88-kDa on protease treatment, is 
the cytocidal toxin in their case. However, when we treated our recombinant 
Cry41Aa toxin with trypsin we did not get a 64 kDa fragment but instead one that 
was only marginally smaller than the unprocessed toxin. We did though find that 
whilst the trypsin-activated toxin showed activity against HepG2 even a large 
excess of unprocessed toxin had no activity. 
 
Evolutionary process has repeatedly coalesced (QxW)3 scaffolds with proteins of 
diverse functionality imparting them with novel attributes thus evolving new 
proteins (Hazes, 1996). This domain has been observed in many unrelated 
proteins and it has been proposed that it adds carbohydrate binding functionality 
to these proteins and hence can confer specificity to proteins (Hazes, 1996). In 
an effort to further elucidate the role of the ricin domain, the domain was deleted 
from the recombinant Cry41Aa and Cry41Ba. The present results demonstrate 
that   Cry41Aa retains / preserves its cytotoxic activity when expressed without 
the ricin domain. Ricin domain is not pre-requisite for cytotoxic activity of the 
inclusion proteins. Unlike Cry41Aa, the ricin domain-containing, and apoptotic-
inducing, toxin pierisin is capable of killing HeLa cells (Matsushima‐Hibiya et al., 
2003). Mutagenesis studies suggested that the conserved QxW sequences in 
this domain were essential for toxicity, and most likely involved in binding to 
glycosphingolipid receptors on the cell surface. However our data indicate that 
this domain is not responsible for the HepG2 specificity. Although the non-toxic 
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components of botulinum neurotoxin that entails HA-33 comprising of two (QxW)3  
-like domains are presumed to have the role of protecting the neurotoxin against 
acidity and protease in the digestive tract thus facilitating transport of the toxin 
complex across the intestinal epithelium (Fujinaga et al., 2004). Whether the ricin 
domain possesses such protective role in case of cytocidal Cry41Aa needs to be 
ascertained.  
 
Dose-dependent activity was observed in case of recombinant 
Cry41Aa/ORF2ORF3 and mutant Cry41AaΔRD. Amongst the cell lines assayed, 
the proteins were highly cytotoxic to HepG2 cells, which were more sensitive to 
the proteins than HeLa cells. This result is in accordance with other studies on 
parasporins that demonstrate a preferential activity against certain mammalian 
cancer cells. No defined rule for specificity of the parasporin toxins and no 
common features for resistant or sensitive cells to these toxins have been 
deduced so far. 
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6. The quest for new cytotoxic genes from B. thuringiensis 
 
6.1 Introduction 
 
In pursuit of new cytocidal toxins from Bt, we illustrate in this chapter the 
screening of novel recombinant Bt toxins isolated from collaborators in China. 
Recombinant Cry51Aa1 was delivered from Ming Sun’s lab, Huazhong 
Agricultural University, Wuhan, China for the evaluation of its toxicity against 
cancer cell lines and insects. The gene (GenBank accession number DQ836184) 
was isolated from the B. thuringiensis strain F14-1. The gene was cloned into the 
shuttle vector, pHT304 and expressed in the acrystalliferous B. thuringiensis 
strain BMB171 (Huang et al., 2007). The protein showed toxicity to Bombyx mori 
(Sun et al., unpublished data). The cry51Aa gene is 930 bp in length yielding a 
polypeptide of 309 amino acid residues. Analysis of the protein sequence of 
Cry51Aa by Conserved Domain (CD) search (NCBI) (Marchler-Bauer & Bryant, 
2004; Marchler-Bauer et al., 2009; Marchler-Bauer et al., 2011) revealed the 
presence of a putative ETX_MTX2 [pfam03318] domain.  Cry51 shows a low 
sequence similarity to the known existing Bt Cry toxins with 21% identity to 
Cry15Aa being the highest and only 11% was shown to parasporin-2 and 
parasporin-4.  
 
Cry65Aa1 was isolated from B. thuringiensis strain SBt003 by Sun et al., 2010 
(unpublished). A Bt clone expressing Cry65 was obtained from China to evaluate 
its toxicity against human cancer cells and against insect pests. Cry65Aa1 is a 
three-domain toxin. The 118 kDa Cry65 protein occurs in crystals with a 54 kDa 
accompanying protein encoded in the same operon as Cry65. A 5.3 kb PCR 
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product containing Cry65 and a gene encoding 54 kDa poplypeptide was cloned 
and expressed in the Bt recombinant strain BMB1281. The recombinant 
BMB1281 co-expresses both the polypeptides from the native toxin operon. 
Blast search by NCBI indicates 100% identity to the protein annotated as cancer-
cell killing Cry protein from Bt serovar Pakistani strain T13001. Cry65Aa1 shows 
29% identity to parasporin-3 and 24% identity to Cry1Ac. Since no known 
insecticidal activity of Cry65 against crop pests was identified, its activity against 
cancer cell lines was assessed. 
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6.2 Results 
 
6.2.1 Preparation of Cry51Aa δ-endotoxin inclusion proteins, solubilisation 
and proteolytic processing of the toxins 
Acrystalliferous Bt strain BMB171 harbouring recombinant pHT3101Cry51Aa1 
was grown on nutrient agar plates containing erythromycin at 5 μg/ml at 30°C for 
2 days. Sporulation was checked under the microscope and the sporulated cells 
were harvested as described in Section 2.2.9.3. Crystals were observed under 
the microscope. The proteins were analysed on 12.5% SDS-PAGE gel. A major 
band of 34 kDa was observed which was in accordance with the predicted 
theoretical molecular weight of the protein calculated using ProtParam tool of 
ExPASy (http://web.expasy.org/protparam/) (Bjellqvist et al., 1993; Bjeallqvist et 
al., 1994; Gasteiger et al., 2005) (Figure 6.1). 
Cry51Aa crystals were purified by sucrose density gradient (Section 2.2.13.1).  
Various buffer solutions over a broad pH range of 2.0-11.0 were used to solubilise 
the crystals. Solubility of the purified recombinant Cry51 tended to be higher in 
both alkaline and acidic solutions but low at pH 8.3 (Figure 6.2). Solubilisation of 
the purified Cry51Aa was  most efficiently accomplished by treatment with 50 mM 
sodium carbonate pH 10.9 for 1 h at 37°C and also by treatment with 10 mM HCl 
pH 3 as observed in case of Cry45Aa (parasporin-4) (Okumura et al., 2006). 
However, since in most studies the inclusion bodies of Bt are solubilised in 
alkaline conditions mimicking the alkaline midgut of insects, further experiments 
were carried out in alkaline conditions. The toxin was processed by trypsin (2 
mg/ml) prepared in 50 mM sodium carbonate pH 10.9 to a lower molecular weight 
approximately 28 kDa protein as expected (Figure 6.2). The solubilised and the 
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trypsin-treated Cry51Aa toxin were applied to an anion-exchange column, 
Resource Q (Amersham Pharmacia Biotech, UK) at a flow rate of 1 ml/min at 
4°C. The yield of the purified protein was determined by Bradford method by 
using BSA as the standard (Section 2.2.11). The concentration of purified 
solubilised sample was found to be 1.0 mg/ml. The concentration of the purified 
trypsin-treated sample which showed two bands of approximate sizes of 28 kDa 
and 26 kDa (Figure 6.3) was found to be 0.5 mg/ml. The samples were frozen at 
-20 °C for toxicity assays. 
 
 
 
              
Figure 6.1. 12.5% SDS-PAGE profile of recombinant Cry51Aa expressed in 
acrystalliferous B. thuringiensis strain BMB171. Lane 1, Cry51Aa protein 
inclusions; lane M, protein marker.                                                                                               
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Figure 6.2. 12.5% SDS-PAGE depicting solubility profile and proteolytic 
processing of recombinant Cry51Aa. Recombinant Cry51Aa solubilised with 10 mM 
hydrochloric acid, supernatant fraction (Lane 1); sodium hydrogen carbonate pH 8.3, 
total sample (Lane 2); soluble fraction (Lane 3); sodium carbonate pH 10.9 total sample 
(Lane 4); soluble fraction (Lane 5). Lane M is the protein marker in kDa. Lane T is the 
trypsin- treated sample. 
 
 
Figure 6.3. 12.5% SDS-PAGE analysis of resource Q purified Cry 51 used for 
toxicity assays. Lane 1, solubilised Cry51; lane 2, trypsin-treated Cry51; lane M, protein 
marker. 
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6.2.2 Preparation of Cry65Aa δ-endotoxin inclusion proteins, solubilisation 
and proteolytic processing of the toxin 
Acrystalliferous Bt strain BMB1281 harbouring recombinant Cry65Aa1 was 
grown on sterile nutrient agar plates containing chloramphenicol at 5 μg/ml at 
30°C for 2 days. Sporulation was checked under the microscope and the 
sporulated cells were harvested as described in Section 2.2.9.3. Crystals were 
observed under the microscope. The proteins were analysed on 7.5% SDS-
PAGE gel. Two major bands of expected sizes of 118 kDa and 54 kDa were 
observed (Figure 6.4). Both the polypeptides were co-expressed from the native 
toxin operon. The 118 kDa protein represents Cry65Aa1. 
 
Figure 6.4. 7.5% SDS-PAGE profile of recombinant Cry65Aa1 expressed in Bt 
strain BMB1281. Lanes 1-5, various dilutions of the recombinant Cry65Aa1 protein viz., 
5, 4, 3, 2 and 1 μl of the protein samples were run on the gel. The samples were diluted 
with sterile distilled water to make up to a total volume of 5 μl. Lane M is the protein 
marker. 
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Attempts were made to solubilise and trypsin activate the proteins in the presence 
as well as absence of a reducing agent. The solubilisation assays suggested that 
50 mM Carbonate buffer at pH 10.9 solubilised the proteins in the presence of 1 
mM DTT. Trypsin in presence of DTT resulted in the generation of two 
conspicuous bands with estimated sizes of 60 and 45 kDa (Figure 6.5).  The 
solubilised and the trypsin treated samples containing DTT were dialysed against 
50 mM sodium carbonate buffer, pH 10.9 (Section 2.2.13.2). Bradford method 
was employed to estimate the total protein concentration (Section 2.2.11). The 
total protein concentration was found to be approximately 5 mg/ml. The dialysed 
samples were frozen at -20°C for further cell assays. 
 
Figure 6.5. 7.5% SDS-PAGE analysis of the dialysed Cry65 samples. Lane 1, soluble 
fraction of Cry65; lane 2, tryptic fragments of Cry65; lane M, protein marker. 
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6.2.3 Toxicity evaluation of B. thuringiensis proteins 
 
6.2.3.1 Assessment of insecticidal activity against Plutella xylostella 
The toxicity of recombinant proteins Cry51Aa and Cry65Aa was tested against 
insecticidal Cry1Ac susceptible G88 and resistant NO-QA populations using leaf 
–dip and diet based assays according to the protocol described in Section 
2.2.15.1. No mortality was observed in the case of either population treated with 
crystals, solubilised or trypsin-treated recombinant Cry51 and Cry65 toxins at a 
concentration of 1 mg/ml.   
 
6.2.3.2 In vitro cytocidal activity of the B. thuringiensis toxins 
 
The solubilised and the trypsin-treated proteins were tested on human cancer cell 
line, HepG2. Cytocidal activities of Cry51 and Cry65 were evaluated using the 
CellTiter- Blue assay (Section 2.2.15.2.2). Cytopathic effects were observed 
under a phase-contrast microscopy. The degree of cytotoxicity was further 
verified by CellTiter-Glo luminescent cell viability assays kit (Promega). The 
experiments were set up in 96-well opaque white flat-bottomed microplates 
(Costar) (Section 2.2.15.2.3). No cytotoxicity was observed in case of solubilised 
at 100 µg/ml or trypsin treated Cry51 at 50 µg/ml (Figure 6.6). The positive control 
etoposide at 100 µg/ml brought about significant cell killing. The trypsin-treated 
Bt protein from A1462, the parasporin-3 producer bought about significant cell 
killing when used at 50 µg/ml (Figure 6.6). Trypsin-treated recombinant Cry51 did 
not induce any morphological changes to HepG2 cells as observed using a 
phase-contrast microscope (data not shown). Cytotoxic activity of trypsin-treated 
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Cry51 was further assessed by CellTiter-Glo luminescent cell viability assay. 
However, no cytotoxicity was observed with Cry51 (Figure 6.7). 
 
Phase contrast microscopy (data not shown) coupled with the CellTiter Blue 
assay revealed that recombinant solubilised Cry65 and the trypsin-treated Cry65 
did not exhibit any cytocidal effects on HepG2 cells when used at a concentration 
of 1 mg/ml (Figure 6.8). A lower concentration of etoposide at 0.01 mg/ml was 
used to predict any equivalent activity by the recombinant Cry65. The positive 
control, etoposide brought about significant cell-killing (Figure 6.8). 
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Effect of solubilised and trypsin-treated recombinant Cry51 on HepG2 cells: 2h 
incubation with CellTiter- Blue 
 
Figure 6.6. Effect of recombinant Cry51 on viability of HepG2 cells. X-axis 
represents the cell number and Y- axis represents Relative Fluorescence Unit (RFU). 
Fluorescence was measured using a green filter with an excitation wavelength at 525nm 
and emission wavelength 580-640nm. Error bars denote SD of the mean of triplicate 
wells. 
 
Effect of trypsin-treated recombinant Cry 51 on HepG2 cells: CellTiter- Glo assay 
 
Figure 6.7. Cytotoxicity of trypsin treated Cry51 was further assessed by 
bioluminescent detection of ATP. X-axis represents the cell number and Y- axis 
represents Relative Luminescence Unit (RLU). Error bars denote SD for the data derived 
from the individual wells (triplicates). An integration time of 0.5 s was used.  
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Effect of solubilised and trypsin-treated recombinant Cry65 on HepG2 cells: 2h 
incubation with CellTiter- Blue 
 
 
 
Figure 6.8. Effect of recombinant Cry65 proteins on viability of HepG2 cells. X-axis 
represents the cell number and Y-axis represents Relative Fluorescence Unit (RFU). 
Error bars denote SD of the mean of triplicate wells. 
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6.3 Discussion 
 
 
We hereby present efficient solubilisation and proteolytic processing of 
recombinants Cry51Aa and Cry65Aa with unknown toxicity profiles. The 34 kDa 
recombinant Cry51Aa was obtained in soluble forms in both alkaline and acidic 
solutions. The protein dissolved well in buffers above pH 10 and below pH 4. It 
remained in the crystal form at pH 8.5. The solubility profile of the recombinant 
Cry51Aa demonstrated pH dependence similar to that of the recombinant 
parasporin-4, Cry45Aa precursor (Okumura et al., 2006) and to the native crystals 
of B. thuringiensis var san diego, a coleopteran specific δ-endotoxin (Koller et al., 
1992). Koller et al. (1992) observed that the native crystals from the B. 
thuringiensis var san diego dissolved well in the universal buffers at above pH 10 
and below pH 4 but remained in crystal form between pH 5.0 and pH 9.5. The 
recombinant Cry51 toxin was processed by trypsin (2 mg/ml) to a lower molecular 
weight protein approximately 28 kDa protein. Recombinant Cry65Aa1 was 
efficiently solubilised by treatment with sodium carbonate, pH 10.9 yielding bands 
of 117 kDa and 60 kDa in the supernatant fraction. Trypsin-treatment generated 
two major bands at circa 60 kDa and 45 kDa which need further investigation. 
 
Initial screens performed here suggested that the recombinant Cry51A and Cry65 
are not cytotoxic to the human cancer cell line, HepG2.  The trypsin- treated 
Cry51Aa and Cry65Aa proteins showed no cytopathic effects as observed using 
phase-contrast microscopy and further corroborated by CellTiter-Blue and 
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CellTiter-Glo assays. The recombinant proteins were not toxic to the cabbage 
pest, Plutella xylostella. Whether they exert toxicity on other insects or cell lines, 
need to be further ascertained. 
 
In order to harness the potency of Bt proteins possessing cytocidal activity 
against human cancer cells and  in order to evaluate the ecological risk 
assessment Bt proteins exerting undesirable effects  in non-target organisms , a 
wide toxicity  screening of the Bt isolates are required. It is imperative that proper 
in vitro toxicity assays are carried out to avoid misleading results. Screening 
would also lead to understanding of the diversity of the parasporin genes, their 
occurrence, distribution and frequency. The toxicity screening would also further 
evaluate the safety of B. thuringiensis δ-endotoxins used in agriculture in 
transgenic plants or as biopesticides. Hence, for maximal utilisation of these 
toxins, it is vital that cytotoxic activities are properly assessed. 
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7. Discussion 
The present work has implications not only for the ecological risk assessment of 
B. thuringiensis toxins used in agricultural products but also for the development 
of anti-cancer drugs. 
A variety of insect resistant genetically modified crops, particularly cotton and 
maize, in which B. thuringiensis toxins are expressed are cultivated globally 
particularly in Africa, Asia and America (Gatehouse, 2008; Sanahuja et al., 2011). 
The knowledge that some of the B. thuringiensis toxins exhibit cytocidal activity 
against mammalian cells is of natural concern. This not only threatens the usage 
of new toxins in agricultural products but also requires risk assessment of food 
derived from genetically engineered plants. Recently, there has been a report of 
a modified B. thuringiensis toxin affecting non-target human cells.  In vitro 
cytotoxic effects of modified Cry1Ab toxins were observed on a human embryonic 
kidney 259 cell line. The modified Cry1Ab toxin extracted from GM plants caused 
plasma membrane disruption, thus inducing necrotic effects at 100 ppm 
(Mesnage et al., 2011). 
In nature, plants and bacteria protect themselves with potent toxins that can kill 
mammalian cells non-specifically (Goodsell, 2001). Several pharmaceutical 
drugs are based upon secondary metabolites produced by such plants and 
bacteria. Understanding the interaction of the Bt cancer killing toxins with their 
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host may help in deriving useful products and pharmaceuticals. Since the 
ecological role of the cytocidal toxins from Bt is unclear, it would be intriguing to 
study the interactions that lead to production of the cytotoxic proteins from B. 
thuringiensis. Understanding the diversity and distribution pattern of the 
parasporin producing B. thuringiensis like that of other microbes would be a vital 
tool in bioprospecting (the quest for novel biological samples for use in medicine 
and industry). 
The present research evaluated the cytotoxic activity of several native B. 
thuringiensis strains, and further examined the cytotoxicity of several δ-
endotoxins from B. thuringiensis. Cytotoxic activity was not found in all the crystal 
proteins investigated thus suggesting that the unique activity is present in only a 
few. These cytocidal toxins were found to be nontoxic to the crucifer pest, Plutella 
xylostella. 
The present study resulted in establishment of an expression system for the 
overproduction of recombinant Cry41Aa protein that belongs to parasporin-3 
family. The cry41Aa gene was cloned and homologously expressed in the host 
bacterium Bt. The cry41Ba gene from SBt021 with 49% identity to cry41Aa gene 
was cloned and expressed for comparative studies. Successful overexpression 
of the cry41Aa and cry41Ba genes were obtained in the acrystalliferous B. 
thuringiensis strain 4D7 when cloned downstream of the cyt1A promoter. The 
recombinant Cry41Aa/ORF2ORF3 when treated with trypsin was cytotoxic to 
hepatic cell line, HepG2. However no cytotoxicity was obtained in case of 
recombinant Cry41Ba which possess a similar gene organisation to Cry41Aa. 
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The recombinant Cry41Aa toxin when treated with trypsin exhibited preferential 
cytotoxic activity resulting in significant killing of HepG2 cells whilst HeLa cells 
were unaffected, by the same concentration of toxin. No cytotoxic activity was 
demonstrated by the solubilised but non- proteolytically treated protein. Further, 
our studies demonstrated that it is not the 64 kDa band resulting from proteolytic 
degradation of 88 kDa band that is cytotoxic to the cells as reported by Yamashita 
et al., 2005. But the cytotoxic activity is demonstrated by the protease resistant 
core of approximately 78 kDa resulting from the trypsin treatment of 80 kDa 
Cry41Aa toxin. This is in congruence with reports of activity of other parasporin 
toxins against mammalian cell lines. For instance, Ito et al. (2004) observed that 
the full length Cry46Aa protoxin from Bt strain A1547 demonstrated no apparent 
cytotoxic activity. However, the N-terminal truncated protein generated by 
proteolytic processing, and with a relative molecular mass of 31kDa exhibited 
cytocidal activity against MOLT-4 cells (Ito et al., 2004). A similar phenomenon 
was also observed in the case of insecticidal Cry1 toxins. The crystalline 
inclusions ingested by the susceptible insect pests are dissolved in the alkaline 
milieu of the insect gut and the solubilised protoxins are inactive until cleaved by 
midgut proteases to yield a protease- resistant core of 60-70 kDa (Schnepf et al., 
1998). Bravo et al. (2002) suggested that N-terminal activation is essential for the 
mechanism of Bt Cry1Ac insecticidal toxin. This is in accordance with previous 
studies  conducted on crop pest M. sexta which  suggested  that presence of N-
terminal peptide might preclude binding of the toxin to non-target membranes 
(Martens et al., 1995) suggesting that pore forming  ability of domain I is achieved 
only after proteolytic removal of the N-terminal peptide (Bravo et al., 2002). The 
studies ascribed the reduced toxicity of mutant insecticidal Cry1Ac protoxin in 
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which N-terminal tryptic cleavage site has been removed by site-directed 
mutagenesis to the reduced rate of N-terminal activation (Bravo et al., 2002). In 
the homologous Cry1Ab protoxins, a similar mutation preventing N-terminal 
processing also demonstrated low toxicity to M. sexta larvae (Martens et al., 
1995). It can be inferred from the results that the cytotoxic activity is modulated 
by N-terminal activation during proteolysis as suggested in case of Bt Cry1Ac 
insecticidal toxins in which the N-terminus of the toxin modulates the activity of 
the toxin (Kouskoura et al., 2001). Cry41Aa protoxins which bear a striking 
sequence similarity to the insecticidal Bt Cry1A toxin might function in a similar 
manner.  This is further substantiated by our result that the solubilised mutant 
Cry41AaΔRD in which the ricin domain has been deleted from the C-terminal of 
ORF2 also only exhibits a moderate cytotoxicity as compared to the trypsin 
treated Cry41AaΔRD and the non-mutant trypsin-treated recombinant Cry41Aa 
toxin. This suggests that N-terminal activation is essential for the enhanced 
cytotoxic activity of the toxin Cry41Aa. 
Since these toxins exhibit cytotoxic effects against cancer cells, they could 
potentially be particularly useful as cancer drugs as modifications that alter a 
healthy cell into cancerous ones are extremely subtle. Since parasporins studied 
thus far are endowed with ability to identify unique cancer cell attributes that 
distinguishes them from healthy cells, these toxins can potentially be used in 
anticancer therapy facilitating selective eradication of cancer whilst minimizing 
side effects to normal cells. There have been reports of usage of bacterial 
proteins for cancer therapy. In late 1800’s vaccines comprised of two attenuated 
bacterial species Streptococcus pyogenes and Serratia marcescents were used 
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to successfully treat carcinomas, lymphomas, melanomas and sarcomas 
(Richardson et al., 1999; Zacharski & Sukhatme, 2005). Bacterial endotoxins for 
instance lipopolysaccharides have also been tested for cancer treatment. 
Pathogenic species of anaerobic Clostridia were shown to proliferate 
preferentially within the necrotic tumour regions in animals resulting in tumour 
regression. However, it was accompanied by acute systemic side effects resulting 
in the death of the subject (Malmgren & Flanigan, 1955; Minton, 2003). The non-
pathogenic strain of Clostridia for instance M55, however did not result in 
significant tumour regression (Carey et al., 1967). Bacterial toxins per se or in 
conjunction with anticancer drugs or irradiation could possibly result in effective 
cancer treatment (Carswell et al., 1975). The bacterial spores of the genetically 
modified strain C. novyi-NT that lacks lethal toxin have demonstrated specific 
target activity without causing any toxic side effects. Mice injected intravenously 
with spores of Clostridium sporogene or C. histolyticum resulted in marked lysis 
of tumour tissues. Additionally, Clostridium was undetected in the normal tissues 
of the injected mice (Thiele et al., 1963). Bacterial spores have been engineered 
to deliver anticancer agents, cytotoxic peptides and therapeutic proteins and as 
vectors for gene therapy (Patyar et al., 2010). Since Cry41Aa toxins demonstrate 
selective activity against hepatic carcinoma, it has potential to be developed as a 
promising drug. Further, there are reports that parasporin-2 proteins have limited 
toxicity to normal tissues and are able to discriminate between leukemic and 
normal T cells (Ito et al., 2004). Hence, the cancer-killing proteins from B. 
thuringiensis can potentially be used in cancer treatment. 
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The present work expands our understanding of various open reading frames of 
the cry41Aa and cry41Ba genes. The recombinant Cry41Aa/ORF2ORF3 
expressed in acrystalliferous Bt 4D7 was solubilised and processed efficiently to 
a protease-resistant core by the proteolytic treatment in a reducing environment. 
Deleting ORF3 resulted in expression of Cry41Aa/ORF2 with an altered solubility. 
Hence, suggesting that ORF3 is required for solubility. The solubility assays 
carried out are congruent with the assumed function of C-terminal ends of longer 
Cry δ-endotoxins. Proteolytic activation of B. thuringiensis protoxins cleaves the 
C-terminal ends containing the conserved homology blocks 6-8 (Schnepf et al., 
1998). The C-terminal ends are implicated in crystal formation and efficient 
solubilisation (Park et al., 2000). However, Lenane et al. (2008) suggested that 
Orf2-5Ad derived from B. thuringiensis strain L366, being the primary component 
of the protein crystals could still accomplish all the functions ascribed to the C-
terminus. Vazquez-Padron et al. (2004) reported that the C-terminus containing 
homology blocks 6-8 of Cry41Ab lacking the toxic core exhibits strong toxicity to 
Bt, E. coli and Agrobacterium tumefaciens when cloned and expressed in these 
bacteria. However, we found that the ORF3 of Cry41Aa that was obtained in E. 
coli JM109 was devoid of any biological activity. 
The present study assessed if ORF3 synergised the cytotoxicity of recombinant 
Cry41Aa as it was observed by Ross & Delecuse (1997) that a combination of 
Cry19Aa and its non-toxic component Orf2 synergised the toxic effect of the split 
toxin Cry19Aa against Culex pipens and Anopheles stephensilarvae. In order to 
assess if ORF3 contributed to the cytotoxity of recombinant Cry41Aa, the protein 
was expressed without the C-terminus. However, the solubility of ORF2 was 
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severely affected when expressed without ORF3. Thus Cry41Aa/ORF2 could not 
be obtained in soluble form. On the contrary, Cry41Ba/ORF2 could be readily 
solubilised and processed efficiently with trypsin in absence of ORF3.  
In this study we investigated the role of the (QxW)3 scaffold, that belongs to the 
ricin superfamily, in imparting cytotoxic properties to recombinant Cry41Aa. 
Evolutionary process has repeatedly coalesced (QxW)3 scaffolds with proteins of 
diverse functionality imparting them with novel attributes thus evolving new 
proteins (Hazes, 1996). In an attempt to further elucidate the role of the ricin 
domain, the domain was deleted from the recombinant pSVP27Cry41Aa and 
pSVP27Cry41Ba. The present results demonstrate that Cry41Aa retains / 
preserves its cytotoxic activity when expressed without the ricin domain. Ricin 
domain is not pre-requisite for cytotoxic activity of the crystal proteins. Though 
the non-toxic components of C. botulinum neurotoxin that entails HA-33 
comprising of two (QxW)3  like domains are presumed to have the role of protecting 
the neurotoxin against acidity and protease in the digestive tract (Fujinaga et al., 
2004). Whether ricin domain possesses such protective role in case of cytocidal 
Cry41Aa needs to be ascertained.  
The research attempted various domain swaps and mutations in the domain II 
loop regions in order to evaluate their role in cytotoxicity. Domain swaps have 
been used for generating new specificities in Bt toxins (de Maagd et al., 2001). 
Liu & Dean (2006) redesigned Cry1A domain II loop regions to resemble that of 
Cry4Ba resulting in a Cry1Aa mutant with moderate insecticidal activity against 
C. pipiens. Abdullah et al. (2003) carried out mutagenesis of the loop 3 region of 
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Cry4Ba to mimic that of Cry4Aa introducing toxicity against Culex species. Similar 
research needs to be carried out with the Bt parasporins which might lead to 
generation of new specificities as in case of insecticidal Bt toxins. 
Our investigation has opened several avenues for future research which would 
look into the mechanism of the cytotoxicity, assess in vitro cytotoxicity and 
conduct structural studies. Further, identification and isolation of the receptors 
involved in the cytotoxicity of these toxins would lead to a better understanding 
of the mode of action. An in depth understanding of parasporin diversity and 
mechanism of action would aid in their effective utilization. Thus, the possibility 
of mimicking molecules based on the architecture of parasporins to be used as a 
novel chemotherapy drug in cancer treatments cannot be ruled out. 
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Appendix 
Appendix 1. Alignment of Cry1Ac with homologous Cry1Aa whose three-
dimensional structure has been resolved by x-ray crystallography to predict the 
secondary structure elements. 
                                                                  
                                                 α1                               α2a 
Cry1Aa          MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGL 60 
Cry1Ac          MDNNPNINECIPYNCLSNPEVEVLGGERIETGYTPIDISLSLTQFLLSEFVPGAGFVLGL 60 
                ************************************************************ 
                               α2b                                                 α3 
Cry1Aa          VDIIWGIFGPSQWDAFPVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEAD 120 
Cry1Ac          VDIIWGIFGPSQWDAFLVQIEQLINQRIEEFARNQAISRLEGLSNLYQIYAESFREWEAD 120 
                **************** ******************************************* 
                           α4                                                                    α5 
Cry1Aa          PTNPALREEMRIQFNDMNSALTTAIPLLAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQ 180 
Cry1Ac          PTNPALREEMRIQFNDMNSALTTAIPLFAVQNYQVPLLSVYVQAANLHLSVLRDVSVFGQ 180 
                ***************************:******************************** 
                                  α 6                                                               α7 
Cry1Aa          RWGFDAATINSRYNDLTRLIGNYTDYAVRWYNTGLERVWGPDSRDWVRYNQFRRELTLTV 240 
Cry1Ac          RWGFDAATINSRYNDLTRLIGNYTDYAVRWYNTGLERVWGPDSRDWVRYNQFRRELTLTV 240 
                ************************************************************ 
                                  β1a         β1b       α8a                       α8          
Cry1Aa          LDIVALFSNYDSRRYPIRTVSQLTREIYTNPVLENFDGSFRGMAQRIEQNIRQPHLMDIL 300 
Cry1Ac          LDIVALFPNYDSRRYPIRTVSQLTREIYTNPVLENFDGSFRGSAQGIERSIRSPHLMDIL 300 
                *******.********************************** ** **:.**.******* 
                   β2                 β3r       β3                        β4                                  β5 
Cry1Aa          NSITIYTDVHRGFNYWSGHQITASPVGFSGPEFAFPLFGNAGNAAPP-VLVSLTGLGIFR 359 
Cry1Ac          NSITIYTDAHRGYYYWSGHQIMASPVGFSGPEFTFPLYGTMGNAAPQQRIVAQLGQGVYR 360 
                ********.***: ******* ***********:***:*. *****   :*:  * *::* 
                   β6                               β7r           β7                       β8              β9 
Cry1Aa          TLSSPLYRRIILGSGPNNQELFVLDGTEFSFASLTTNLPSTIYRQRGTVDSLDVIPPQDN 419 
Cry1Ac          TLSSTLYRRPFN-IGINNQQLSVLDGTEFAYG-TSSNLPSAVYRKSGTVDSLDEIPPQNN 418 
                ****.**** :   * ***:* *******::.  ::****::**: ******* ****:* 
                               β10              β11                  β12     β13 
Cry1Aa          SVPPRAGFSHRLSHVTMLSQAAG--AVYTLRAPTFSWQHRSAEFNNIIPSSQITQIPLTK 477 
Cry1Ac          NVPPRQGFSHRLSHVSMFRSGFSNSSVSIIRAPMFSWIHRSAEFNNIIASDSITQIPAVK 478 
                .**** *********:*: .. .  :*  :*** *** **********.*..***** .* 
                 β13b         β14                    β15                 β16                                        β17 
Cry1Aa          STNLGSGTSVVKGPGFTGGDILRRTSPGQISTLRVNITAPL-----SQRYRVRIRYASTT 532 
Cry1Ac          GNFLFNG-SVISGPGFTGGDLVRLNSSGNNIQNRGYIEVPIHFPSTSTRYRVRVRYASVT 537 
                .. * .* **:.********::* .*.*:    *  * .*:     * *****:****.* 
                   Β18        β19                β20     β21       β22 
Cry1Aa          NLQFHTSIDGRPINQGNFSATMSSGSNLQSGSFRTVGFTTPFNFSNGSSVFTLSAHVFNS 592 
Cry1Ac          PIHLNVNWGNSSIFSNTVPATATSLDNLQSSDFGYFESANAFTSSLGN---IVGVRNFSG 594 
                 ::::.. .. .* .....** :* .****..*  .  :..*. * *.    :..: *.. 
                     β23 
Cry1Aa          GNEVYIDRIEFVPAEVTFEAEYDLERAQKAVNELFTSSNQIGLKTDVTDYHIDQVSNLVE 652 
Cry1Ac          TAGVIIDRFEFIPVTATLEAEYNLERAQKAVNALFTSTNQLGLKTNVTDYHIDQVSNLVT 654 
                   * ***:**:*. .*:****:********* ****:**:****:*************  
 
Cry1Aa          CLSDEFCLDEKQELSEKVKHAKRLSDERNLLQDPNFRGINRQLDRGWRGSTDITIQGGDD 712 
Cry1Ac          YLSDEFCLDEKRELSEKVKHAKRLSDERNLLQDSNFKDINRQPERGWGGSTGITIQGGDD 714 
                 **********:*********************.**:.**** :*** ***.******** 
 
Cry1Aa          VFKENYVTLLGTFDECYPTYLYQKIDESKLKAYTRYQLRGYIEDSQDLEIYLIRYNAKHE 772 
Cry1Ac          VFKENYVTLSGTFDECYPTYLYQKIDESKLKAFTRYQLRGYIEDSQDLEIYLIRYNAKHE 774 
                ********* **********************:*************************** 
 
Cry1Aa          TVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDID 832 
Cry1Ac          TVNVPGTGSLWPLSAQSPIGKCGEPNRCAPHLEWNPDLDCSCRDGEKCAHHSHHFSLDID 834 
                ************************************************************ 
 
Cry1Aa          VGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKL 892 
Cry1Ac          VGCTDLNEDLGVWVIFKIKTQDGHARLGNLEFLEEKPLVGEALARVKRAEKKWRDKREKL 894 
                ************************************************************ 
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Cry1Aa          EWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGV 952 
Cry1Ac          EWETNIVYKEAKESVDALFVNSQYDQLQADTNIAMIHAADKRVHSIREAYLPELSVIPGV 954 
                ************************************************************ 
 
 
Cry1Aa          NAAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVLPEW 1012 
Cry1Ac          NAAIFEELEGRIFTAFSLYDARNVIKNGDFNNGLSCWNVKGHVDVEEQNNQRSVLVVPEW 1014 
                ********************************************************:*** 
 
Cry1Aa          EAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTV 1072 
Cry1Ac          EAEVSQEVRVCPGRGYILRVTAYKEGYGEGCVTIHEIENNTDELKFSNCVEEEIYPNNTV 1074 
                ************************************************************ 
 
Cry1Aa          TCNDYTVNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCEFNRGYRDY 1132 
Cry1Ac          TCNDYTVNQEEYGGAYTSRNRGYNEAPSVPADYASVYEEKSYTDGRRENPCEFNRGYRDY 1134 
                ************************************************************ 
 
Cry1Aa          TPLPVGYVTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE 1176 
Cry1Ac          TPLPVGYVTKELEYFPETDKVWIEIGETEGTFIVDSVELLLMEE 1178 
                ******************************************** 
Amino acid residues of Cry1Aa and Cry1Ac in red letters and highlighted in yellow 
represent the α-helices of domain I (α1-7) and those in green letters and highlighted in 
yellow represent the α-helices of domain II (α8a and 8) and those highlighted in pink 
represent the β-strands of domain II (β1a-β11) and the ones highlighted in turquoise 
represent domain III (β12-23). 
 
 
 
 
 
  
